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Abstract 
 
Identification of pathways that regulate longevity in an evolutionarily conserved manner 
is a major focus of modern biogerontology. Interest in the sirtuin family of 
deacetylases/ADP-ribosyltransferases/deacylases began with the observation that 
increased expression of SIR2 extends replicative lifespan in budding yeast. The seven 
mammalian sirtuin homologs have been the focus of intense investigation for their 
potential impacts on health- and lifespan. My thesis work focuses specifically on the 
mammalian sirtuin SIRT6. SIRT6 plays multiple roles in metabolic homeostasis and 
genome integrity through modification of histones and other protein targets; 
consequently SIRT6 suppresses many age-associated pathologies such as neoplasia, 
cardiac hypertrophy, and glucose intolerance. SIRT6 overexpression results in 
extended lifespan in male mice, suggesting that SIRT6 may represent a true functional 
ortholog of yeast SIR2, and supporting an evolutionarily conserved role for sirtuins in 
longevity. In this work, we identified a protective role for SIRT6 in suppressing 
tumorigenesis. First, SIRT6 suppresses aerobic glycolysis, the preferred form of 
energy metabolism in cancer cells, by inhibiting the expression of various glycolytic 
proteins. Second, SIRT6 regulates cell growth by reducing ribosomal biogenesis via 
the proto-oncogene c-MYC. Additionally, we identified H3K56ac, a histone mark 
involved in DNA repair which is often elevated in cancer, as a novel target for SIRT6 
	   xvi	  
and we identified an increased incidence of aneuploidy in SIRT6-deficient cells. Thus, 
SIRT6’s role in maintaining genomic integrity could possibly provide a third means 
through which SIRT6 suppresses tumor development. Conversely, examination of 
established cancer cell lines and tissues, revealed high SIRT6 protein expression and 
cytoplasmic localization. However, SIRT6 activity appears to be compromised as 
SIRT6 no longer acts upon its target H3K56. Overall, the identified tumor suppressive 
properties of SIRT6 are possibly the underlying mechanism through which SIRT6 
extends mammalian lifespan, and provides therapeutic potential for the treatment of 
various malignancies. 
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Chapter 1 
Introduction: The Diverse Roles of SIRT6 in Mammalian 
Healthspan 
 
Introduction to SIRT6 
Aging is a conserved phenomenon, which is associated with loss of function and 
impaired stress resistance in invertebrate and mammalian model organisms. In 
humans, most common health conditions – type 2 diabetes (T2D), cardiovascular 
disease, cancer, and neurodegeneration, among many others – are strongly 
associated with advancing age.  Conversely, genetic and environmental interventions 
that promote increased longevity typically also delay or even prevent many age-
associated pathologies. Therefore, an understanding of molecular mechanisms of 
aging offers the possibility of improved treatments for many common diseases. This 
realization has led to a hunt for pathways that regulate health- and lifespan, at least 
some of which function in a conserved manner across different phyla. 
 
The sirtuins are a conserved NAD+-dependent enzyme family regulating many cellular 
functions, in particular stress responses. The SIR2 (Silent Information Regulator 2) 
gene in budding yeast was the first sirtuin to be identified and functionally 
characterized. Increased dosage of SIR2 or its homologs promotes increased lifespan 
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in budding yeast, worms and flies (Belenky et al., 2007; Berdichevsky et al., 2006; 
Hoffmann et al., 2013; Kaeberlein et al., 1999; Rogina and Helfand, 2004; Salvi et al., 
2013; Tissenbaum and Guarente, 2001; Viswanathan et al., 2005; Whitaker et al., 
2013). As an aside, it should be noted that one prominent study did not reproduce 
these pro-longevity effects of sirtuins in worms or flies (Burnett et al., 2011), and 
aspects of the roles of sirtuins in yeast longevity are also still hotly debated (Longo and 
Kennedy, 2006). The discrepant results obtained by different laboratories likely result 
from variations in experimental protocols, strain background and/or husbandry 
conditions. Notwithstanding these controversies, the apparently conserved pro-
longevity effect of sirtuins has led to intensive efforts to characterize functions of the 
seven mammalian sirtuins, termed SIRT1-7 (Figure 1.1). Each of these proteins 
possesses a fairly conserved catalytic domain; however sirtuins differ at their N- and C-
termini, and are a divergent family in terms of sub-cellular localization, targets and 
functions (Canto et al., 2013). Overexpression of at least two mammalian sirtuins, 
SIRT1 (in the hypothalamus) or SIRT6 (globally) extends mouse lifespan (Kanfi et al., 
2012; Satoh et al., 2013).  
 
In addition to lifespan per se, a large body of evidence has revealed major roles for 
individual sirtuins in suppressing age-associated pathologies (Morris, 2013). 
Biochemically, mammalian sirtuins function as NAD+-dependent lysine deacetylases, 
with varied catalytic efficiencies and substrates. Several mammalian sirtuins have been 
shown to possess ADP-ribosyltransferase activity (Ahuja et al., 2007; Frye, 1999; 
Haigis et al., 2006; Liszt et al., 2005), and some sirtuins remove non-canonical lysine  
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Figure 1.1: Mammalian Sirtuin family 
A schematic representation of yeast SIR2 and its mammalian homologs (SIRT1-7). 
The sirtuins share a conserved catalytic domain but differ in their N and C-termini, 
resulting in diversity in intracellular localization and function. N, nucleus; C, cytoplasm; 
MT, mitochondria; Nucl., nucleolus. Yellow depicts mitochondrial localization 
sequence. 
 
post-translational modifications such as succinyl, malonyl, and acyl groups (Du et al., 
2011; Feldman et al., 2013; Jiang et al., 2013; Peng et al., 2011). Through these 
activities, mammalian sirtuins modulate a diverse array of biological processes such as 
transcriptional regulation, metabolism, genomic stability, cell cycle control and 
inflammation (Morris, 2013). 
 
SIRT6, the focus of my dissertation work, has been implicated in suppressing many 
age-associated pathologies: obesity and metabolic syndrome (Kanfi et al., 2010; Kim et 
al., 2010; Schwer et al., 2010), inflammation (Lappas, 2012; Lee et al., 2013b; Lee et 
al., 2013c; Xiao et al., 2012), cardiac hypertrophy (Sundaresan et al., 2012; Yu et al., 
2013), neurodegeneration (Jin et al., 2013), cellular senescence (Cardus et al., 2013; 
Kawahara et al., 2009; Shen et al., 2013; Xie et al., 2012) and cancer (Bauer et al., 
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2012; Han et al., 2014; Khongkow et al., 2013b; Lefort et al., 2013; Marquardt et al., 
2013b; Min et al., 2012; Sebastian et al., 2012; Thirumurthi et al., 2014; Van Meter et 
al., 2011). 
 
SIRT6 is a nuclear protein that associates with heterochromatin (Liszt et al., 2005; 
Michishita et al., 2005; Mostoslavsky et al., 2006; Xiao et al., 2010). Biochemically, 
SIRT6 functions as a lysine deacetylase, a mono-ADP-ribosyltransferase, and a long-
 
Figure 1.2: SIRT6 biochemical functions 
SIRT6 possess three known biochemical functions: deacetylation, ADP-ribosylation 
and fatty chain deacylation. Each one of these reactions is dependent on the presence 
of NAD+. Ac, acetyl group; NAM, nicotinamide; ADPr, ADP-ribose group; NAD, 
nicotinamide adenine dinucleotide. 
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chain fatty acid deacylase (Jiang et al., 2013; Liszt et al., 2005; Mao et al., 2011; 
Michishita et al., 2008) (Figure 1.2). In vitro studies suggest that SIRT6 possesses very 
modest deacetylase activity (Pan et al., 2011). However, a recent study suggested that 
SIRT6 is more active when interacting with nucleosomes as it is reconfigured there into 
a more active form (Gil et al., 2013) and that physiological concentrations of various 
free fatty acids drastically induce SIRT6 catalytic efficiency (Feldman et al., 2013). 
Nevertheless, as described in depth below, recent work has revealed that SIRT6 
functionally deacetylates at least three targets: one histone site (H3K9) (Michishita et 
al., 2008), and two non-histone proteins (CtIP and GCN5) (Dominy et al., 2012; Kaidi et 
al., 2010). Initial insights into SIRT6 function came from studies of SIRT6-deficient 
mice (Mostoslavsky et al., 2006). These animals show severe pleiotropic defects, 
suggesting that SIRT6 likely impacts multiple processes important for organismal 
health.  
 
Sirt6-deficient fibroblasts and ES cells grow slowly and show genome instability. Sirt6 
knockout (KO) mice appear normal at birth but soon manifest growth retardation due to 
very low serum IGF-1 levels. They are frail, with a hunched posture (lordokyphosis) 
and lose most of their white adipose tissue (WAT), including the subcutaneous fat. At 
approximately two weeks of age, blood glucose levels begin to decline steeply in Sirt6 
KO animals. These mice also show rapid depletion of lymphocytes via a massive wave 
of apoptosis. The latter phenotype is most likely a systemic rather than a cell-
autonomous defect, as Sirt6-deficient bone marrow cells are able to repopulate the 
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lymphocyte compartment of irradiated recipient mice as efficiently as wild-type bone 
marrow (Mostoslavsky et al., 2006). Clearly, SIRT6 plays crucial roles in cellular and 
organismal homeostasis. 
 
As described below, there has been significant recent progress in elucidating molecular 
functions of SIRT6. A common theme that has emerged is that SIRT6 negatively 
regulates the transcriptional output of key cellular signaling pathways by deacetylating 
histones at their target promoters. This is in contrast to SIRT1; though SIRT1 can also 
deacetylate histones, it exerts many of its functions by directly deacetylating 
transcription factors and other non-histone targets themselves (Guarente, 2011). Much 
of the newer functional analysis of SIRT6 has been carried out using tissue-specific 
Sirt6 KO animals, avoiding the lethality associated with global Sirt6 deficiency, and 
permitting a finer dissection of SIRT6’s roles.  
 
SIRT6 is a master metabolic regulator 
As noted above, SIRT6 is required for glucose homeostasis, a role that is critical for 
organismal survival. Two different Sirt6 germline KO mouse strains have been 
described (Mostoslavsky et al., 2006; Xiao et al., 2010). Both show severe 
hypoglycemia and greatly reduced serum IGF-1 levels. On a pure 129SvJ strain 
background, SIRT6 deficiency results in completely penetrant postnatal lethality by one 
month of age (Mostoslavsky et al., 2006). However, in an outbred background, a 
minority of Sirt6-deficient mice survives this hypoglycemia and lives into adulthood 
(Xiao et al., 2010).  
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Figure 1.3: SIRT6 as a master regulator of glucose metabolism 
SIRT6 regulates glucose metabolism through at least two distinct mechanisms. (1) 
SIRT6 deacetylates histone H3, thereby attenuating transcriptional output of HIF-1α 
and c-JUN, which normally enhance glucose uptake and induce glycolysis or activate 
the insulin-IGF-1-like signaling (IIS) pathway. (2) SIRT6 deacetylates the histone 
acetyltransferase GCN5 (KAT2A), which in turn acetylates and activates the 
transcriptional regulator PPARγ coactivator-1α (PGC-1α), reducing de novo production 
of glucose (gluconeogenesis) in the liver. Ac, acetyl group; HAT, histone 
acetyltransferase; H3, histone H3; TF, transcription factor. 
 
 
Glucose supplementation of these Sirt6-deficient mice further improves their survival, 
proving that hypoglycemia is a major cause of death in the absence of SIRT6 during 
postnatal development (Xiao et al., 2010). Reduced NF-κB signaling can also partially 
rescue the lethality of SIRT6 deficiency (Kawahara et al., 2009). As described more 
fully below, NF-κB family transcription factors are implicated in inflammation, apoptosis, 
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and cellular senescence. SIRT6 attenuates NF-κB mediated gene expression by 
deacetylating histone H3 lysine K9 (H3K9) at the promoters of NF-κB target genes 
(Kawahara et al., 2009). Therefore, other factors besides hypoglycemia contribute to 
the lethality of SIRT6 deficiency.  
 
Recent work has revealed multiple roles for SIRT6 in glucose homeostasis. SIRT6 
controls blood glucose levels by regulating at least three distinct pathways: HIF-1α 
signaling, insulin/IGF-like signaling (IIS), and gluconeogenesis (Dominy et al., 2012; 
Xiao et al., 2010; Zhong et al., 2010) (Figure 1.3). HIF-1α is a master metabolic 
regulator; under conditions of low oxygen or glucose, HIF-1α promotes a shift from 
oxidative metabolism to glycolysis (Koh and Powis, 2012) (Figure 1.4). HIF-1α 
promotes expression of multiple genes encoding proteins in the glycolytic cascade; 
conversely, HIF-1α drives increased expression of PDK1, in turn inhibiting carbon flow 
into mitochondria (see also Figure 3.2). The glucose transporter GLUT1 is another key 
HIF-1α target. SIRT6 functions as a repressor of HIF-1α transcriptional output by 
deacetylating H3K9 at the promoters of HIF-1α target genes, and also by reducing 
overall HIF-1α levels. Hence, in the absence of SIRT6, uncontrolled HIF-1α activity 
results in increased glycolysis and glucose uptake from the circulation, most evident in 
skeletal muscle and brown adipose tissue, culminating in hypoglycemia (Zhong et al., 
2010). Increased glycolytic gene expression has also been found in the livers of 
hepatic-specific Sirt6 KOs (Kim et al., 2010).  
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Figure 1.4: SIRT6 regulates glycolysis 
Under normal oxygen tension and high glucose conditions, SIRT6 deacetylates histone 
H3K9ac at the promoter region of HIF-1 target genes and represses HIF-1 activity, 
thereby suppressing glycolysis and promoting oxidative phosphorylation. When oxygen 
or glucose levels are low, the removal of SIRT6 allows transcription of glycolytic genes 
by HIF-1. Figure adapted from (Zhong et al., 2010) 
 
In addition to GLUT1, Sirt6-deficient mice show higher levels of the glucose transporter 
GLUT4 at the cell membrane (Xiao et al., 2010). Unlike GLUT1, GLUT4 translocation is 
promoted by IIS. Despite lower serum insulin and IGF-1 levels in Sirt6 mutant mice, IIS 
is actually much more active in these animals (Sundaresan et al., 2012; Xiao et al., 
2010). This may reflect the role for SIRT6 as a co-repressor of c-JUN, as c-JUN 
promotes expression of many genes involved in IIS (Sundaresan et al., 2012). c-JUN is 
a component of the activator protein 1 (AP-1) transcription factor, which is involved in 
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various processes such as apoptosis, cell proliferation and development (Dunn et al., 
2002).  
 
SIRT6 also suppresses hepatic gluconeogenesis by deacetylating the 
acetyltransferase GCN5, activating it to acetylate PGC-1α (Dominy et al., 2012) (Figure 
1.3). PGC-1α is a transcriptional co-activator that is a master regulator of mitochondrial 
biogenesis and other metabolic processes (Puigserver and Spiegelman, 2003). In the 
liver, PGC-1α promotes gluconeogenesis by coactivation of FoxO1 and Hnf4 
(Puigserver et al., 2003; Rhee et al., 2003). Acetylation of PGC-1α inhibits PGC-1α 
transcriptional activity (Rodgers et al., 2005); hence, via activation of GCN5, SIRT6 
inhibits hepatic glucose production (Dominy et al., 2012). The twin roles of SIRT6 in 
suppressing glycolysis while simultaneously inhibiting hepatic glucose output might 
superficially seem at odds with one another. These functions might be rationalized as a 
means to avoid futile cycling of glucose production and breakdown (Dominy et al., 
2012).  
 
The relationship between SIRT1 and SIRT6 in the context of PGC-1α acetylation is 
also intriguing. SIRT1 deacetylates PGC-1α to activate its transcriptional function, thus 
opposing the activity of SIRT6/GCN5 (Rodgers et al., 2005). Consistent with 
antagonistic functions of these sirtuins, protein kinase A (PKA) suppresses SIRT6 
activity while stimulating SIRT1 function (Dominy et al., 2010; Gerhart-Hines et al., 
2007; Nin et al., 2012). However, these findings seem inconsistent with the published 
role of SIRT1 in stimulating SIRT6 expression (Kim et al., 2010). Further studies are 
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required to elucidate the precise interplay between SIRT1 and SIRT6 in response to 
varied dietary conditions. 
 
In addition to its role in glucose homeostasis, SIRT6 also controls hepatic fatty acid 
metabolism by regulating expression of genes involved in this process via promoter 
H3K9 deacetylation.  SIRT6 suppresses accumulation of triglycerides in hepatocytes 
by inhibiting fatty acid uptake and synthesis, while promoting their breakdown via β-
oxidation (Kim et al., 2010). A number of genes involved in these processes are 
regulated by the nuclear receptor PPARγ. PPARγ induces expression of genes that 
regulate lipid metabolism and adipocyte differentiation (Zhang et al., 2013a), including 
angiopoietin-like protein 4 (ANGPTL4) and adipocyte fatty acid binding protein (A-
FABP). ANGPTL4 negatively regulates lipoprotein lipase, which hydrolyzes serum 
triglycerides into free fatty acids, and thus mediates triglyceride clearance from the 
blood (Kim et al., 2010). A-FABP is a chaperone for cytosolic fatty acids, elevated 
levels of which are associated with obesity and metabolic syndrome (Xu et al., 2006). 
Furthermore, SIRT6 binds to the promoter of DGAT1, a key enzyme in triglyceride 
synthesis, repressing its expression (Kim et al., 2010). Through this mechanism, SIRT6 
protects against fatty liver formation in response to a high fat diet (HFD). SIRT6 also 
inhibits pancreatic inflammation under these dietary conditions (Kanfi et al., 2010). 
Human fatty livers exhibit lower levels of SIRT6, and liver-specific Sirt6 knockout mice 
develop fatty liver and hypercholesterolemia, in particular LDL cholesterol (Tao et al., 
2013a, b). Overexpression of SIRT6 protects the liver from excessive lipid 
accumulation (Kanfi et al., 2010) and lowers LDL cholesterol in response to HFD by 
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recruiting FOXO3 and repressing transcription of Pcks9 and Srebp1/ 2, major 
regulators of cholesterol homeostasis (Elhanati et al., 2013; Tao et al., 2013a, b). The 
SREBPs, or sterol regulatory element binding proteins, are transcription factors that 
bind the sterol regulatory element DNA sequence and are required for cholesterol and 
fatty acid biosynthesis (Tao et al., 2013a, b). In addition to suppressing their 
expression, SIRT6 suppresses SREBP1/2 cleavage into their active forms and SIRT6 
inactivates SREBP1 through its phosphorylation (Elhanati et al., 2013).  
 
Given the roles of SIRT6 in glucose and lipid homeostasis, it is perhaps not surprising 
that it plays protective roles against obesity and T2D, both common age-associated 
pathologies (Dominy et al., 2012; Schwer et al., 2010). Brain-specific Sirt6 KO mice 
become obese in adulthood, which is associated with reduced levels of pituitary growth 
hormone and the hypothalamic factors proopiomelanocortin (POMC), single-minded 
homolog 1 (SIM1) and brain-derived neurotrophic factor (BDNF). These factors have 
all been linked to obesity in humans. SIRT6 deficiency in the brain causes 
hyperacetylation of H3K9 and H3K56, possibly leading to dysregulation of these and 
potentially numerous other genes (Schwer et al., 2010). Furthermore, ectopic 
expression of SIRT6 in a mouse model of diabetes reduces hepatic glucose output and 
normalizes serum glucose levels (Dominy et al., 2012). Thus, roles of SIRT6 in 
regulating obesity-associated gene expression and glucose and lipid metabolism might 
eventually be exploited therapeutically. It will be of great interest to assess roles for 
SIRT6 in other metabolically critical tissues such as skeletal muscle, adipose tissue, 
and pancreatic β-cells. Similarly, it remains an outstanding question whether the 
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depletion of WAT observed in global Sirt6 KOs indicates a primary role for SIRT6 in 
maintaining WAT, or a secondary consequence of hypoglycemia and overall 
disordered metabolism in these animals. 
 
Regulation of SIRT6 
Despite its central role in metabolic homeostasis, relatively little is known regarding 
how SIRT6 levels and activity are regulated. Like other sirtuins, SIRT6 requires the 
metabolic cofactor NAD+ for activity. In response to fasting or long term calorie 
restriction, SIRT6 protein levels are elevated in brain, heart and WAT (Kanfi et al., 
2008; Kim et al., 2010), promoting a metabolic switch from glycolysis to oxidative 
phosphorylation (Dominy et al., 2012; Kim et al., 2010; Xiao et al., 2010; Zhong et al., 
2010). However, there is conflicting evidence about the underlying mechanism of 
altered Sirt6 expression. SIRT6 levels are decreased in livers of obese and diabetic 
mice (Dominy et al., 2012). Conversely, SIRT6 mRNA rises in liver and subcutaneous 
fat in response to severe weight loss; possibly due to decreased inflammation as TNFα 
can suppress SIRT6 expression (Moschen et al., 2013). Likewise, SIRT6 protein levels 
increase in response to caloric restriction. Kanfi and colleagues showed that SIRT6 
protein levels, but not mRNA levels, rise in response to fasting, due to stabilization of 
the SIRT6 protein (Kanfi et al., 2008). However, Kim and coworkers found that 
induction of Sirt6 during fasting occurs transcriptionally and requires SIRT1 (Kim et al., 
2010). They found that SIRT1 deacetylates FOXO3a to allow FOXO3a to form a 
complex with NRF1 and induce Sirt6 gene expression (Kim et al., 2010). As noted 
above, PKA also inhibits SIRT6 expression, while simultaneously increasing SIRT1  
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Figure 1.5: Mechanisms of SIRT6 regulation 
SIRT6 is regulated through numerous factors that mediate SIRT6 protein expression, 
SIRT6 binding to the chromatin and SIRT6 stability or activity. CR, calorie restriction; 
HCC, hepatocellular carcinoma; TNFα, tumor necrosis factor α; USP10, ubiquitin-
specific peptidase 10; CHIP, carboxyl terminus of Hsp70-interacting protein; FFA, free 
fatty acids; PTM, post-translational modification; TF, transcription factor.  	  	  
levels (Dominy et al., 2010; Gerhart-Hines et al., 2007; Nin et al., 2012). SIRT1 is 
regulated by a complex network of interactors and post-translational modifications 
(PTM) (Revollo and Li, 2013); analogously SIRT6 activity is regulated by means other 
than expression levels. Physiological concentration of free fatty acids induces catalytic 
efficiency of SIRT6, thereby increasing SIRT6 activity. In addition, the ubiquitin ligase 
CHIP (carboxyl terminus of Hsp70-interacting protein) ubiquitinates and consequently 
stabilizes SIRT6 by preventing SIRT6’s interaction with other ubiquitin ligases 
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(Ronnebaum et al., 2013). Likewise, SIRT6 is protected from proteasomal degradation 
by the ubiquitin-specific peptidase USP10 (Figure 1.5) (Lin et al., 2013). 
 
Other studies, discussed in detail later, report dysregulation of SIRT6 levels under 
various pathological conditions; however it remains unclear for the most part how this 
occurs mechanistically. In one case, recent data (discussed below) suggest that 
altered c-JUN and c-FOS signaling reduce Sirt6 expression during the initiation of 
hepatocellular carcinoma (Min et al., 2012). SIRT6 associates with nuclear chromatin 
and upon stress induction, e.g. TNFα treatment, SIRT6 relocalizes dynamically to 
different promoters (Kawahara et al., 2011). Similarly, SIRT6 relocalizes to sites of 
DNA damage, perhaps via interaction with DNA repair machinery (McCord et al., 
2009). The interaction of SIRT6 with the chromatin appears to be mediated at least in 
part by transcription factors. Kawahara and coworkers demonstrated that SIRT6 and 
RELA bind to a large panel of common promoter sites of genes involved in processes 
such as cell cycle progression, immune system development, anti-apoptosis and 
glycolysis. For a large fraction of these promoter sites, binding of SIRT6 was 
dependent on RELA (Kawahara et al., 2011). Other common binding sites in SIRT6 
occupied gene promoters are SP1, STAT1/3 and FOXO1/4 (Kawahara et al., 2011) 
and thus it is reasonable to hypothesize that those transcription factors may also be 
necessary to recruit SIRT6 to these specific promoters in response to stimuli. 
Conversely numerous other post-translational modifications present on SIRT6 that 
have been identified by mass spectrometry (cf. www.phosphosite.org), whose functions 
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have not yet been elucidated, could regulate the interaction of SIRT6 with specific 
transcriptional activators and/or repressors (Figure 1.5).  
 
SIRT6 regulates inflammation 
Increased inflammation is a common feature of aging in many mammalian tissue types 
(Agrawal et al., 2009; Agrawal et al., 2010). Evidence from global and tissue-specific 
Sirt6 KOs suggests that SIRT6 has important roles in limiting the inflammatory 
response. As part of their overall degenerative syndrome, SIRT6-deficient mice 
develop severe colitis with erosion of the intestinal mucosa (Mostoslavsky et al., 2006). 
In outbred SIRT6-deficient mice that survive hypoglycemic crisis, inflammation also 
develops in the liver, where it eventually leads to fibrosis, and, to lesser extent, in the 
kidneys, pancreas and lung (Xiao et al., 2012). In the context of hepatic inflammation, 
using tissue-specific knockouts, it was shown that SIRT6 in lymphocytes and 
macrophages, and not in hepatocytes, is required to suppress this phenotype. Liver 
inflammation coincides with increased expression of numerous pro-inflammatory 
genes, including Mcp-1 and Il-6, in Kuppfer cells and T-cells. Mechanistically, SIRT6 
binds the transcription factor c-JUN at the promoters of these pro-inflammatory genes, 
where it deacetylates H3K9ac and inhibits c-JUN transcriptional output (Figure 1.6) 
(Xiao et al., 2012).  
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Figure 1.6: SIRT6’s regulation of inflammation 
Through its deacetylation of H3K9, SIRT6 inhibits at least 3 transcription factors that 
support an inflammatory response: c-JUN, RELA and HIF-1α. Thereby, SIRT6 
aleviates chronic tissue inflammation and arthritis, and prevents the activation of 
lymphocytes and macrophages. Ac, acetyl group; Acyl, acyl group; TNFα, tumor 
necrosis factor α; Mcp-1, monocyte chemoattractant protein 1; Il-6, interleukin-6. 
 
In addition to c-JUN, SIRT6 also inhibits the transcriptional output of NF-κB signaling 
resulting in decreased expression of genes involved in aging (Kawahara et al., 2009). 
NF-κB is a family of transcription factors implicated in multiple processes such as 
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inflammation, cell death and proliferation, and development. The NF-κB protein family 
consists of five members: RELA (p65), RELB, c-REL, p50 and p52, among which 
RELA interacts with SIRT6. Under basal conditions, they are retained in the cytoplasm 
by an inhibitor of NF-κB (IκB) family member. In response to diverse stimuli, such as 
the inflammatory cytokine TNFα, NF-κB is released and consequently moves to the 
nucleus where it can activate expression of its target genes. The transcriptional output 
of NF-κB is dependent on various co-regulators and chromatin modulators, including 
SIRT6 (Kawahara et al., 2009; Wan and Lenardo, 2010). Overexpression of SIRT6 can 
reduce arthritis in a collagen-induced arthritis mouse model by blocking NF-κB 
transcriptional output and consequently diminishes secretion of pro-inflammatory 
cytokines (Figure 1.6) (Lee et al., 2013a). SIRT6 may also mediate the inflammatory 
response through the pro-inflammatory cytokine TNFα, however their interplay is 
somewhat complex. Xiao and coworkers showed that TNFα protein levels are elevated 
in SIRT6-deficient macrophages under both basal and lipopolysaccharide stimulated 
conditions (Xiao et al., 2012). Conversely, Van Gool and colleagues reported that 
SIRT6 promotes elevated TNFα protein levels at a post-transcriptional level, indicating 
that under some conditions, SIRT6 may actually promote secretion of pro-inflammatory 
cytokines (Van Gool et al., 2009; Xiao et al., 2012). A recent study revealed that SIRT6 
stimulates TNFα secretion by removing long-chain fatty acyl groups of lysine 19 and 20 
in this protein (Jiang et al., 2013). Conversely, treatment of HeLa cells with TNFα 
increases SIRT6 translocation to NF-κB/RELA target promoters (Kawahara et al., 
2009). Further studies are needed to clarify interactions between TNFα and SIRT6; it is 
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possible that a negative feedback loop exists in which SIRT6 inhibits TNFα by 
suppressing NF-κB mediated transcription of pro-inflammatory genes.  
 
In addition to roles for SIRT6 in modulating c-JUN and NF-κB function, the function of 
SIRT6 in metabolism may be relevant in its suppression of inflammation. Both 
lymphocytes and macrophages shift their metabolism from respiration to aerobic 
glycolysis upon activation (Ardawi and Newsholme, 1982; Garedew and Moncada, 
2008). Conversely, cells that limit inflammation, such as regulatory T-cells, show 
relatively low levels of glycolysis (O'Neill and Hardie, 2013). Therefore, it is possible 
that increased glycolysis occurring in the absence of SIRT6 preferentially drives 
activation of pro-inflammatory cells.  
 
Overall, most studies have identified roles for SIRT6 in suppressing inflammation. 
Based on known functions of SIRT6, it is possible that SIRT6 activators might be useful 
in treating age-associated chronic inflammatory diseases such as diabetes, and 
cardiovascular and autoimmune diseases characterized by ongoing, chronic 
inflammation.  
 
SIRT6 promotes genomic stability via diverse mechanisms 
Initial studies of SIRT6-deficient cells revealed that SIRT6 plays a major role in 
genome integrity (Mostoslavsky et al., 2006). Sirt6 KO cells show reduced proliferation, 
an elevated incidence of chromosomal abnormalities, and increased sensitivity to DNA 
damaging agents. Originally it was hypothesized that SIRT6 might play a role in base 
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excision repair (BER), pathways that repair small DNA lesions, including those induced 
by oxidative insult (Parsons and Dianov, 2013). This hypothesis was based on the 
spectrum of sensitivities of SIRT6-deficient cells, as well as the ability of the catalytic 
domain of Polβ, the major polymerase involved in BER, to rescue cellular phenotypes 
of SIRT6 deficiency (Mostoslavsky et al., 2006). In support of an involvement of SIRT6 
in BER, overexpression of SIRT6 can suppress oxidative DNA damage in porcine fetal 
fibroblasts, possibly by enhancing BER (Xie et al., 2012). However, there is currently 
no mechanistic insight into how SIRT6 might facilitate BER. In contrast, there has been 
significant progress in understanding how SIRT6 promotes DNA double strand break 
(DSB) repair.  
 
DNA DSBs represent a severe threat to cell viability. They are repaired via three major 
pathways: classical non-homologous end-joining (C-NHEJ), homologous 
recombination (HR), and alternative end-joining (A-EJ) (Boboila et al., 2012). 
Overexpression of SIRT6 increases the clearance of γH2AX foci and accelerates 
overall DSB repair (Mao et al., 2011). A recent study showed that, in response to DNA 
insult, SIRT6 is recruited to the breakage site where it interacts with the helicase 
SNF2H. This complex remodels the nucleosome and consequently attracts various 
DNA repair factors such as BRCA1 and 53BP1 (Toiber et al., 2013). In support of this 
idea, SIRT6 stimulates both C-NHEJ and HR by mono-ADP-ribosylating poly (ADP-
ribose) polymerase 1, PARP-1 (Mao et al., 2011). PARP-1 binds and stabilizes broken 
DNA ends and mediates the recruitment of other DNA repair factors. In this context, 
ectopic SIRT6 expression can rescue the decline of HR capacity associated with 
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replicative exhaustion (Mao et al., 2012). SIRT6 is required for optimal recruitment of 
the C-NHEJ factor DNA-PKcs to DNA DSBs, an effect potentially occurring via 
modulation of local chromatin structure by SIRT6 (McCord et al., 2009).  SIRT6 
promotes HR by deacetylating and activating CtIP, a factor required for DNA end 
resection to generate ssDNA for initiation of HR (Kaidi et al., 2010).  
 
In addition to these roles for SIRT6 in promoting global genome stability, SIRT6 in 
human cells plays a role in stabilizing telomeres specifically. In normal human cells, 
SIRT6 deacetylates H3K9 at telomeres to promote telomeric heterochromatinization 
and association of telomeric binding proteins (Michishita et al., 2008; Tennen et al., 
2011). Hyperacetylation of telomeric chromatin in the absence of SIRT6 disrupts the 
interaction of telomeric regions with WRN, a protein involved in telomere maintenance, 
which is mutated in the premature aging disorder Werner Syndrome. Telomeric attrition 
is a major cause of replicative senescence in human cells; indeed SIRT6 KD in human 
fibroblasts causes premature cellular senescence (Michishita et al., 2008; Tennen et 
al., 2011). Furthermore, SIRT6 is essential for maintaining telomere position effect 
(TPE), a phenomenon in which telomere-proximal genes are epigenetically silenced 
(Aparicio et al., 1991; Ng et al., 2002). TPE is lost with replicative aging in yeast (Dang 
et al., 2009b). This role of SIRT6 is reminiscent of the function of yeast SIR2 in 
promoting heterochromatinization of the rDNA array to suppress recombination and 
promote increased replicative lifespan (Ha and Huh, 2011).  In contrast, despite the 
fact that SIRT6 also deacetylates H3K9 at telomeres in mouse cells, telomeres are 
much longer in mice than humans, and thus do not apparently display dysfunction 
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upon SIRT6 deletion (Michishita et al., 2008). It would be of interest to determine 
whether SIRT6 has roles in stabilizing other heterochromatic loci in mammalian cells 
besides telomeres. Overall, SIRT6 plays many roles through which it can maintain the 
genomic integrity of the cell.  
 
SIRT6 suppresses cardiac hypertrophy and promotes cardiac stress resistance 
Cardiac hypertrophy is a condition characterized by cardiac enlargement, occurring 
either physiologically in response to normal stimuli such as pregnancy or exercise, or 
as a consequence of disease states (pathological hypertrophy).  Even in the absence 
of overt stress stimuli, thickening of the ventricular wall occurs with age. In humans, 
hypertension is a frequent cause of pathological cardiac hypertrophy. Age-associated 
cardiac hypertrophy is characterized by loss of cardiomyocytes, interstitial fibrosis, and 
hypertrophy of the remaining cells. Pathological cardiac hypertrophy and consequent 
ventricular dysfunction is thought to be a mostly irreversible process, which can 
eventually result in cardiac failure (Dai et al., 2012; Olivetti et al., 2000).  
 
Mice induced to develop cardiac hypertrophy have elevated NF-κB activity in 
cardiomyocytes, and inhibition of RELA in these mice can revert this phenotype (Gupta 
et al., 2008). Likewise, overexpression of SIRT6 ameliorates hypertrophy in vitro and 
inhibits the increase in hypertrophic marker genes in cardiomyocytes by repressing NF-
κB gene expression (Yu et al., 2013). Sundaresan and colleagues showed a strong 
reduction in SIRT6 levels in cardiac hypertrophy in both human and mouse hearts 
(Sundaresan et al., 2012). In contrast, Yu and coworkers reported that SIRT6 levels 
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are elevated in cardiac hypertrophy in rats, but that this coincides with decreased 
SIRT6 activity due to decreased NAD+ levels (Yu et al., 2013). Whole-body Sirt6 KO 
and cardiomyocyte-specific Sirt6 KO mice spontaneously develop cardiac hypertrophy 
as early as two months after birth, characterized by increased cardiomyocyte size, 
cellular degenerative changes, and increased expression of aging-associated 
cytoskeletal proteins, as well as fibrotic and apoptotic markers. Conversely, SIRT6 
overexpression protects animals against induction of cardiac hypertrophy (Sundaresan 
et al., 2012). In the absence of SIRT6, both c-JUN and NF-κB are hyperactive, and 
silencing either of these transcription factors can prevent hypertrophy in vitro (Gupta et 
al., 2008; Sundaresan et al., 2012; Yu et al., 2013). 
 
The underlying mechanism through which SIRT6 promotes cardiac health is not fully 
understood. Sundaresan and colleagues reported that SIRT6 protects against cardiac 
hypertrophy by inhibiting IIS, as Sirt6 KO hearts showed elevated expression of 
proteins involved in this pathway. Furthermore, pharmacological inhibition of IGF-1 
signaling was able to protect Sirt6 KO mice from development of cardiac hypertrophy 
(Sundaresan et al., 2012). Conversely, SIRT6 overexpression was able to decrease 
the expression of these proteins in vivo.  
	   24	  
 
Figure 1.7: Schematic overview of SIRT6 functions 
Through its deacetylase and mono-ADP-ribosyltransferase activities, SIRT6 affects 
activities of transcription factors and other proteins, causing alterations in key cellular 
processes (black boxes). Through these activities, SIRT6 suppresses multiple 
metabolic and age-associated pathologies (ovals). 
 
Likewise, both mouse and human hypertrophic hearts showed increased 
phosphorylated AKT and IGFR expression in comparison to controls, indicative of 
hyperactivity of the IIS pathway. Indeed, suppression of IIS in Drosophila can prevent 
the age-associated decline in cardiac performance. However, the role of IIS in cardiac 
health may be at odds with this mechanism, as previous studies have reported that 
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age-dependent heart failure is associated with low serum IGF-1 levels in elderly with 
no history of heart disease (Dai et al., 2012), and treatment of cardiomyocytes with a 
locally-produced IGF-1 isoform can protect these cells from hypertrophy in a SIRT1 
dependent manner (Vinciguerra et al., 2010). Therefore, the hypertrophy observed in 
Sirt6 KO mice might not mimic age-related cardiac hypertrophy, and possibly other 
age-associated changes in elderly hearts could contribute to the opposing effects of IIS 
on cardiac health. Conversely, this discrepancy could be explained by a bimodal effect 
of IIS on heart health in which both inactive and excessive IIS are harmful and an 
intermediate level would be desirable for optimal cardiac health. 
 
SIRT6 prolongs mammalian lifespan 
Interest in the sirtuin protein family in the context of the biology of aging began with the 
observation that SIR2 overexpression in budding yeast extends longevity in this 
organism (Kaeberlein et al., 1999). Therefore, the finding that SIRT6 overexpression 
increases median and maximal lifespan in male (but not in female mice; C57BL6/J and 
BALB/cOlaHsd mixed background) represents an extremely significant milestone in 
sirtuin biology (Kanfi et al., 2012). The mechanisms underlying this effect are not 
entirely clear. Sahin and colleagues observed an age-dependent increase in 
methylation of Sirt6 promoter, meaning that Sirt6 expression decreases with age 
(Sahin et al., 2014). Lower IGF-1 levels are observed in male SIRT6 overexpressors; 
genetic reduction of IIS is associated with increased lifespan in mice as well as 
invertebrates (Holzenberger et al., 2003; Kenyon, 2010). However, this effect is 
typically more pronounced in female animals, whereas the impact of SIRT6 
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overexpression on lifespan is seen in male mice only. While the gender-specific effect 
on SIRT6-mediated lifespan could be mouse strain specific, it is likely that other 
functions of SIRT6 may be relevant for its pro-longevity role. A higher incidence of 
spontaneous tumors is observed in male mice than in females (Kanfi et al., 2012); thus, 
a tumor suppressor role for SIRT6 might explain why lifespan extension is only 
observed in male SIRT6-overexpressors (Lombard and Miller, 2012).  
 
Other roles of SIRT6 may also be relevant for its pro-longevity effects. The roles of 
SIRT6 in DNA repair, maintenance of genomic integrity and epigenetic silencing could 
contribute to increased longevity of SIRT6-overexpressing male mice. As described 
above, through its histone deacetylase activity, SIRT6 impacts activities of HIF-1α and 
NF-κB. Both these factors have been implicated in regulating aging. HIF-1α appears to 
play a role in longevity; however the data on this topic are somewhat controversial. 
Deletion of HIF-1α can extend lifespan in C. elegans by inhibiting IIS (Zhang et al., 
2009). However, others have reported that overexpression of HIF-1α causes lifespan 
extension, possible by reducing mitochondrial respiration and thus reactive oxygen 
species (ROS) production, and/or by acting as a stress response factor (Mehta et al., 
2009). Hence, both deletion and overexpression of HIF-1α may have beneficial effects 
depending on context, and it is possible that increased levels of SIRT6 could cause 
lifespan extension by inhibiting HIF-1α activity. Moreover, pharmacological inhibition of 
NF-κB can extend lifespan in both male and female Drosophila (Moskalev and 
Shaposhnikov, 2011).  NF-κB activity increases with age, promoting increased tissue 
inflammation (Baker et al., 2011), and blocking the age-associated increase in NF-κB 
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levels in the skin of aged mice reverts the gene expression profile to that seen in young 
animals (Adler et al., 2007). In support of this, suppression of NF-κB activity in the 
hypothalamus extends mouse median and maximal lifespan (Zhang et al., 2013b). 
Therefore it is possible that SIRT6 overexpression might attenuate age-associated NF-
κB mediated inflammation, helping to preserve tissue function.  
 
 
Figure 1.8: Implications of SIRT6 in diseases 
SIRT6 improves overall healthspan by impacting diverse physiological processes. The 
function of SIRT6 as a tumor suppressor protein is the focus of my thesis work (grey). 
SIRT6 crystal structure was obtained from RCSB Protein Data Bank (Pan et al., 2011). 
Figure was produced using images from Servier Medical Art (www.servier.com). 
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Finally, SIRT6 has been implicated in stress responses, which are essential for cellular 
survival. Mechanistically, SIRT6 translocates to the cytoplasm where it promotes the  
dephosphorylation of G3BP (Ras GTPase-activating protein-binding protein) and 
thereby influences stress granule formation and enhances cell viability (Jedrusik-Bode 
et al., 2013). Overall, SIRT6 is implicated in many processes that could contribute to 
the longevity phenotype seen in male SIRT6 overexpressing mice. 
 
Rationale 
It has been widely accepted that numerous cellular processes need to be disrupted in 
order for a normal cell to become cancerous. Hanahan and Weinberg originally divided 
up these processes into the six hallmarks of cancer: continued proliferation, resistance 
to cell death, avoiding growth suppression, initiating angiogenesis, allowing 
immortalization, and activating invasion and metastasis (Hanahan and Weinberg, 
2000). Based on recent advancements in the field of tumorigenesis, Hanahan and 
Weinberg revisited their original cancer hallmarks and have added two emerging and 
two enabling traits: metabolic reprogramming, immune avoidance, tumor-promoting 
inflammation, and genome instability and mutation (Figure 1.9) (Hanahan and 
Weinberg, 2011).  
 
Based on these cancer hallmarks and the biological processes regulated by SIRT6, we 
postulated that SIRT6 has protective properties against tumor formation. The 
acquisition of the above mentioned hallmarks is in large part dependent on the  
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Figure 1.9: The revised hallmarks of cancer 
The newly described hallmarks of cancer as described by Hanahan and Weinberg: 
Resistance to cell death, deregulating cellular energetics, sustaining proliferative 
signaling, evading growth suppressors, avoiding immune destruction, enabling 
replicative immortality, tumor promoting inflammation, activating invasion and 
metastasis, inducing angiogenesis, and genome instability and mutation. Figure was 
adapted from (Hanahan and Weinberg, 2011) 
 
 
accumulation of alterations in the genome (= enabling hallmark). As SIRT6 protects 
against DNA damage by interacting with the double strand DNA repair proteins CtIP 
and PARP1 (Kaidi et al., 2010; Mao et al., 2012), it is possible that the ablation of 
SIRT6 can lead to genetic mutations and consequently the acquisition of tumorigenic 
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properties. Likewise, SIRT6 protects against telomere dysfunction by deacetylating 
H3K9 and by recruiting WRN to regulate telomere processing during S-phase 
(Michishita et al., 2008). Patients with a mutation in the Wrn gene age prematurely, 
with cancer and cardiovascular disease being their main causes of death. Furthermore, 
cancer cells alter their metabolism such that their ATP generation is largely derived 
from glycolysis. With SIRT6 being an essential regulator of this pathway, SIRT6 
deficiency may aid in tumor progression by supporting the preferred form of 
metabolism in cancer. Therefore, in my thesis work we aimed to elucidate a role for 
SIRT6 in cancer.
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Chapter 2 
 
Identification of novel SIRT6 targets 
 
 
Abstract 
Post-translational modifications of histones drive many important cellular 
processes such as DNA repair, DNA replication and transcriptional regulation. 
The latter is generally activated by histone hyperacetylation. Therefore, knowing 
the acetylation state of histones can provide great insight in the activity of 
downstream signaling pathways. The histone deacetylase SIRT6 deacetylates 
H3K9 at various promoter regions, resulting in repression of various 
transcription factors such as NF-κB, HIF-1 and c-JUN. In doing so, SIRT6 
regulates many important cellular processes and is implicated in a wide array of 
pathologic conditions. In this study we aimed to identify additional histone 
targets for SIRT6 to further our understanding of SIRT6’s molecular functions. 
Here we report that SIRT6 has three additional histone targets: H3K18ac, 
H3K23ac and H3K56ac. Misregulation of each of these residues has been shown 
to impact organismal health.  
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Introduction 
 
Our genetic information is tightly packaged into chromatin, a complex structure 
composed of DNA, proteins and RNA. The main functions of chromatin are to regulate 
gene expression, protect against DNA damage, mediate DNA replication and compact 
DNA into a smaller volume. The basic unit of chromatin is the nucleosome, which 
consists of 146bp wrapped around a histone core complex. This complex is an octamer 
made up of two copies of each of the four core histones: H2A, H2B, H3 and H4. 
Histones are small proteins that consist of a globular core structure and N- and C- 
termini called histone tails. Histones are subjected to many different post-translational 
modifications (PTMs), such as phosphorylation, ubiquitination, methylation and 
acetylation. Each of these modifications is controlled by enzymes. For example 
acetylation of lysine residues is carried out by histone acetyltransferases (HATs), which 
use acetyl-coenzyme A as a cofactor to catalyze the transfer of an acetyl group to a 
lysine residue resulting in charge reduction. Deacetylation, on the other hand, is 
mediated by histone deacetylases (HDACs), which cleave off the acetyl groups from 
lysine residues. Histone acetylation reduces the affinity between histones and DNA, 
allowing the chromatin to adopt a more relaxed structure, and permits the binding of 
transcription factors. Because HDACs counteract this action, deacetylation is generally 
associated with transcriptional repression. Despite their names, HATs and HDACs can 
also target non-histone proteins (Kouzarides, 2000; Shahbazian and Grunstein, 2007).  
 
The first identified target for SIRT6 was histone H3 acetylated at Lysine 9 (H3K9ac) 
(Michishita et al., 2008). The interaction of SIRT6 with the chromatin, and its 
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subsequent deacetylation of H3K9, generates a hypoacetylated region that is 
associated with compacted chromatin and gene silencing. SIRT6 binds telomeric 
regions specifically where it deacetylates H3K9. Hypoacetylated telomeres allow for 
the binding of WRN, the protein that is mutated in the premature aging disease 
Werner’s Syndrome and that is responsible for proper regulation of telomere ends. In 
SIRT6 deficient cells, hyperacetylation, and subsequently the absence of WRN, results 
in telomere dysfunction with an increased risk for end-to-end chromosomal fusions, 
telomere loss and premature cellular senescence (Michishita et al., 2008). In a similar 
fashion, a number of transcription factors have been described to interact with SIRT6 
at the promoter regions of their target genes. By deacetylating H3K9 at these regions, 
SIRT6 suppresses transcriptional output and thus regulates a wide range of cellular 
processes. One such transcription factor is NF-κB, which plays an important role in 
regulating the inflammatory response, immunity, apoptosis and cellular senescence 
(Kawahara et al., 2009). SIRT6 deficient cells show apoptotic resistance and cellular 
senescence due to hyperactivity of NF-κB. Strikingly, reduction of NF-κB activity in 
Sirt6 germline knockout mice partially rescues their early lethality (Kawahara et al., 
2009). Likewise, SIRT6 inhibits HIF-1 and c-JUN transcriptional output, resulting in 
hypoglycemia (Zhong et al., 2010), cardiac hypertrophy (Sundaresan et al., 2012), and 
liver inflammation and fibrosis (Xiao et al., 2012).  
 
In addition to the above-mentioned functions, SIRT6 also plays a role in DNA repair as 
SIRT6 deficiency leads to chromosomal aberrations (Mostoslavsky et al., 2006). 
Various studies have indicated that SIRT6 enhances base excision repair (BER) and 
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DNA double strand break repair (Kaidi et al., 2010; Mao et al., 2012; McCord et al., 
2009; Mostoslavsky et al., 2006; Toiber et al., 2013). Two modifications that are rapidly 
and reversible deacetylated in response to DNA damage are H3K9ac and H3K56ac 
(Tjeertes et al., 2009). H3K56ac is acetylated by the HATs CBP and p300, and 
deacetylated by the HDACs SIRT1 and SIRT2 (Das et al., 2009; Yuan et al., 2009). 
Acetylation of H3K56 is critical for chromatin assembly after DNA replication, chromatin 
disassembly during gene transcription and cell survival (Chen et al., 2008; Li et al., 
2008; Williams et al., 2008). Furthermore, proper H3K56ac regulation is crucial for 
genomic stability and accurate DNA damage response as mutated H3K56 results in 
spontaneous DNA breaks (Yuan et al., 2009). Due to the importance of H3K56ac in 
maintaining genomic integrity, a feature shared by SIRT6, we investigated if SIRT6, in 
addition to H3K9ac, deacetylates H3K56ac or any other histone H3 residues. The 
subsequent studies were done in collaboration with Dr. B. Yang. 
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Materials and Methods 
	  
Site-directed mutagenesis 
The H133Y mutation was introduced into mouse 1xFlag-SIRT6 in pBABE-puro and 
3xFlag-SIRT6 in pCMV 7.1 (Sigma) by site-directed mutagenesis using Pfu turbo 
(Stratagene) per the manufacturer’s instructions using the following mutagenesis 
oligonucleotides: Forward: 5’ TGGCAGAGCTGTACGGAAACATGTTTGTAGAGGA 3’, 
Reverse: 5’ TCCTCTACAAACATGTTTCCGTACAGCTCTGCCA 3’.  
 
Cells and mice 
In our studies we used mouse embryonic fibroblasts (MEFs), isolated from C57/BL6 
WT and Sirt6 KO embryos (E13.5) according to standard conditions (Mostoslavsky et 
al., 2006). MEFs were grown in DMEM supplemented with 15% fetal bovine serum, 1% 
L-Glutamine, 1% pen/strep, 1% sodium pyruvate, 1% non-essential amino acids, 2% 
HEPES and 115 µM beta-mercaptoethanol. MEFs were grown at low oxygen 
conditions, split 1:3 with each passage and maintained in culture up to passage 8. 
SIRT6-deficient ES cells and mice were as previously described (Mostoslavsky et al., 
2006). For rescue experiments, a SIRT6-deficient MEF line immortalized by serial 
passage was incubated with retroviral supernatants for 48 hours in the presence of 4 
µg/ml polybrene, after which they were selected in media containing 2.5 µg/ml 
puromycin for 72 hours. 
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Mass spectrometry analysis 
Mass spectrometry was used to identify acetylation sites on histone H3 after incubation 
with p300 acetyltransferase +/- SIRT6 and was performed in collaboration with Dr. G 
Cavey. Non-acetylated lysines of histone H3 were propionylated prior to trypsin 
digestion to restrict enzyme digest to arginine amino acids. Histone H3 has several 
acetylated and non-acetylated lysine amino acids in close proximity. Without restricting 
trypsin digestion to arginine amino acids trypsin cleavage at non-acetylated lysines 
would result in very short peptides or single acetylated lysine that would not bind 
sufficiently to C18 reverse phase columns during LC-MS analysis and subsequently be 
missed in the analysis (Garcia et al., 2007). Data was collected with a Waters 
quadrupole time-of-flight mass spectrometer in data independent MS^E mode that 
collects accurate mass data for all detectable peptides and also generates fragment 
ions that are diagnostic of acetylated peptides (Geromanos et al., 2009; Niggeweg et 
al., 2006). 
 
Immunoblot analysis 
For analysis of histone acetylation in cell lines and in mouse tissues, 50 µg of total 
protein was fractionated on 4-20% gradient gels (Bio-Rad), transferred to PVDF 
membranes, and probed with the following antibodies in TBST/5% milk at the dilutions 
indicated: rabbit anti-H3K56ac (Epitomics, catalog number 2134-1), 1:1000; rabbit anti-
H3K9ac (Abcam), 1:1000; rabbit anti-H3K18ac (Abcam), 1:2000; rabbit anti-H3K23ac 
(Millipore), 1:2000; rabbit anti-H3 (Abcam), 1:20,000; rabbit anti-mouse SIRT6 (Novus), 
1:1000.  
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Immunocytochemistry 
For H3K56ac analysis, MEFs were grown on multi-chamber slides (Fisher Scientific) 
and fixed in 100% methanol at -20°C for 10 minutes. All subsequent steps, unless 
indicated, took place at room temperature. Slides were rehydrated in PBS for 20 
minutes and subsequently washed for 20 minutes in PBS/0.1% Tween-20 (PBST). 
Slides were blocked in PBS/1% BSA/10% goat serum for 1 hour, and then incubated 
with primary antibody (1:500; Abcam) in blocking buffer for 1 hour, followed by 3 
washes (10 minutes each) in PBST. Slides were then incubated with Alexa Fluor-
conjugated goat-anti-rabbit (Invitrogen) (1:500) for 1 hour in blocking buffer, washed as 
above, and mounted in Vectashield with DAPI (Vector Labs). For H3K18ac and 
H3K23ac staining, MEFs were grown on multi-chamber slides, fixed in 4% PFA for 10 
minutes, permeabilized in 100% MeOH for 10 minutes at -20°C and rehydrated in PBS 
for an additional 10 minutes. Slides were blocked for 30 minutes in 5% goat serum in 
PBS containing 0.3% triton and subsequently incubated with primary antibody (1:100; 
H3K18ac, abcam; H3K23ac, Millipore) in blocking buffer 1 hour, followed by 3 washes 
in PBST. Slides were then incubated with secondary antibody and mounted as 
described above. Images were captured on an Olympus BX-51 scope with an Olympus 
DP-70 high-resolution digital camera (University of Michigan Microscopy & Image 
Analysis lab); images shown were taken at equal exposure times. For quantification, 
two random fields on each of 3 separate slides were imaged (~100 cells/field) per cell 
line. 
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Immunohistochemistry 
Immunohistochemistry (IHC) for H3K18ac was performed on brain tissue of WT and 
Sirt6 KO mice by the University of Michigan histology core. In brief, slides were 
deparaffinized and rehydrated through a series of xylene and alcohol washes. Antigen 
retrieval was performed by heating the slides for 10 minutes in citrate buffer (10mM 
Citric Acid, 0.05% Tween 20, pH 6.0), followed by a 10 minutes cool down at room 
temperature. Endogenous peroxide was blocked by incubation in 3% hydrogen 
peroxide (H2O2) for 10 minutes. Additional blocking was performed by incubating the 
slides in 5% normal goat serum in PBS for one hour. Tissues were incubated with 
rabbit anti-H3K18ac antibody (Abcam) overnight at 4°C. Signal was visualized using 
3,3’-diaminobenzidine (DAB; Vector Laboratories) and slides were mounted using 
permanent mounting medium (Vector Laboratories). Slides were imaged with an 
Olympus BX-51 scope with an Olympus DP-70 high-resolution digital camera 
(University of Michigan Microscopy & Image Analysis lab). 
 
In vitro deacetylation 
3xFlag-tagged SIRT6 and 3xFlag-tagged SIRT6-H133Y were generated in 293T cells, 
and purified in 500mM NaCl using anti-FLAG M2 agarose (Sigma). Histone H3 was 
acetylated in vitro by incubating 10 µg of recombinant histone H3 (New England 
Biolabs) for 2 hours at 30°C with 150 ng FLAG-tagged p300 acetyltransferase (kindly 
provided by Yali Dou, University of Michigan) in HAT buffer (50 mM Tris pH 8.0, 0.1 
mM EDTA, 1 mM DTT and 10% glycerol). Subsequently, p300 was isolated using 5 ml 
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of M2-agarose beads (Sigma) for 30 minutes. Histone H3 was deacetylated by 
incubating acetylated histone H3 with purified SIRT6 or SIRT6-H133Y (1:1 ratio) in 
HDAC buffer (10 mM Tris pH 8.0, 150 mM NaCl and 0.5 mM NAD+) for 2 hours at 
30oC. Deacetylation of histone H3K9 (Abcam), H3K18 (Abcam), H3K23 (Millipore) and 
H3K56 (Millipore) was monitored by immunoblot using site-specific antibodies. 
 
 
 
Figure 2.1: Illustration of in vitro deacetylation assay 
Recombinant histone H3 protein was acetylated by the acetyltransferase p300 and 
subsequently deacetylated with SIRT6 to identify SIRT6 specific targets on H3. 
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Results 
SIRT6 deacetylates Histone H3 Lysine 56. 
To test a potential role for SIRT6 in deacetylating H3K56, levels of this modification 
were assessed in SIRT6-deficient MEFs and littermate controls. Levels of H3K56ac 
were dramatically increased in Sirt6 KO cells (Figure 2.2A, left panel). H3K56ac levels 
were also elevated in two independent SIRT6-deficient ES cell lines compared with a 
WT control (Figure 2.2A, middle panel). Reintroduction of wild-type SIRT6, but not a 
catalytically inactive SIRT6 allele (SIRT6HY), rescued H3K56 hyperacetylation in 
MEFs (Figure 2.2A, right panel), indicating that H3K56 hyperacetylation in these cells 
is a direct consequence of loss of SIRT6 function. Interestingly, overall H3K9ac levels 
were unaltered in SIRT6-deficient MEFs (Figure 2.2A, left panel), although they were 
modestly elevated in ES cells lacking SIRT6 (Figure 2.2A, middle panel). Thus, SIRT6 
plays a critical role in deacetylating H3K56 in MEFs and ES cells; SIRT6 regulates 
global H3K9 acetylation levels in ES cells but is dispensable for this function in MEFs. 
To assess H3K56ac levels on a single cell level, immunofluorescence analysis was 
performed on SIRT6-deficient MEFs and littermate controls. H3K56ac staining was 
markedly brighter in SIRT6-deficient MEFs, and also present in a much greater fraction 
of cells (Figure 2.2B, left panel). H3K56ac was detectable in 96.6% of SIRT6-deficient 
cells, whereas H3K56ac was only detectable in 21.5% of control MEFs. Thus SIRT6 
deficiency leads to both higher levels of H3K56ac on a per-cell basis, as well as an 
increased fraction of cells with detectable acetylated H3K56.  
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Figure 2.2: SIRT6 deacetylates Histone H3 Lysine 56                               
(A) H3K56 is hyperacetylated in the absence of SIRT6 in both MEFs (left) and ES cells 
(middle). Reconstitution of a SIRT6 deficient immortalized MEF cell line with SIRT6, 
but not the catalytic inactive mutant, reduces H3K56ac levels (right). (B) 
Immunofluorescence analysis for H3K56Ac in SIRT6-deficient MEFs and littermate 
controls. (C) Recombinant SIRT6, but not catalytic null SIRT6, deacetylates H3K56 in 
vitro. (D) H3K56 is hyperacetylated in thymus and brain tissue from SIRT6-null mice 
compared to littermate controls. Figures A, C and D were generated by Dr. B. Yang 
(Yang et al., 2009). 
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To rule out the possibility that hyperacetylation of H3K56 in SIRT6-deficient cells might 
be an indirect result of genomic instability associated with SIRT6 deficiency, the ability 
of SIRT6 to deacetylate this site was assessed. Acetylated H3 was incubated with 
catalytically active SIRT6 or the SIRT6 catalytic mutant SIRT6-H133Y. WT SIRT6 
robustly deacetylated both H3K56ac and H3K9ac, whereas this activity was completely 
abrogated in the mutant (Figure 2.2C). We conclude that SIRT6 directly deacetylates 
H3K56 to regulate global H3K56Ac levels. 
To test the role of SIRT6 in deacetylating H3K56ac in vivo, H3K56 acetylation was 
assessed in tissues from SIRT6-deficient mice and littermate controls. We focused on 
thymus and brain, tissues where SIRT6 is highly expressed (Mostoslavsky et al., 
2006). SIRT6 deficiency was associated with dramatically higher levels of H3K56ac in 
both tissues (Figure 2.2D). Thus SIRT6 is a critical H3K56ac deacetylase in vivo. 
 
 
SIRT6 targets Histone H3 Lysine 18 and 23. 
 
The identification of SIRT6 as a potent deacetylase of H3K56, prompted us to test if 
SIRT6 had additional histone H3 targets. Therefore, we performed an in vitro 
deacetylation assay in which we incubated recombinant histone H3, acetylated by the 
acetyltransferase p300, with SIRT6. Following this deacetylation reaction we looked for 
lysine residues that were no longer acetylated after SIRT6 treatment using mass 
spectrometry analysis (in collaboration with Dr. Cavey, van Andel Institute). When 
comparing histone H3, H3ac, and H3ac treated with SIRT6, we found a peak that 
appeared after acetylation of H3 but disappeared after SIRT6 treatment (Figure 2.3A, 
purple star).  
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Figure 2.3: In vitro deacetylation of Histone H3 residues by SIRT6 
(A) MS/MS spectrum of H3 peptide KQLATKAAR acetylated at K18 and K23. The 
1070.62 M+H mass is consistent with two acetylated lysine amino acids (purple star).  
(B) After acetylation of H3 with the acetyltransferase p300, H3 is deacetylated by 
SIRT6, but not the catalytic mutant SIRT6HY, at the indicated lysine residues. Figure A 
was generated by Dr. G. Cavey, Figure B was generated by Dr. B. Yang.  
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Figure 2.4: Immunocytochemistry of histone marks in Sirt6 MEFs 
Immunofluorescence staining of Sirt6 WT and Sirt6 KO MEFs for (A) H3K23ac and (B) 
H3K18ac. Fluorescence intensity was measured with ImageJ and represented in bar 
graph. 
 
 
This peak corresponds with a protein sequence containing the lysine residues K18 and 
K23. To test if either histone H3 residues were targets for SIRT6, we repeated the in 
vitro deacetylation and ran the reactions on a western blot. When probing with 
antibodies specific for either modification, we confirmed that, under in vitro conditions, 
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SIRT6, but not the catalytic inactive mutant SIRT6HY, was able to deacetylate 
H3K18ac and H3K23ac (Figure 2.3B). As positive controls for the deacetylation 
reaction we confirmed the deacetylation of the previously described targets H3K9ac 
and H3K56ac. 
Next, we investigated if SIRT6 was able to deacetylate H3K18 and H3K23 in living 
cells. Thus we isolated MEFs from 13.5 days old embryos from our Sirt6 germline 
knockout strain and performed immunocytochemistry for both histone modifications. As 
predicted, we observed an increase in fluorescence intensity for H3K23ac in the 
absence of SIRT6 (Figure 2.4A). However, H3K18ac does not appear to be different 
between WT and Sirt6KO MEFs (Figure 2.4B). Even more so, it appears SIRT6 
deficient cells show a slight decline in H3K18ac levels compared to control cells.  
Since histone modifications can be cell type specific, we performed IHC on Sirt6 WT 
and KO brain sections for H3K18ac, and detected a marked increase in this 
modification with SIRT6 ablation (Figure 2.5). To strengthen this finding, we tested the 
levels of H3K18/23ac in various tissues derived from germline Sirt6 KO and littermate 
control mice by western blot analysis, in conjunction with the previously described 
histone H3 targets of SIRT6, H3K9 and H3K56. In both brain and thymus, two high 
Sirt6 expressing organs, H3K18 and H3K23 acetylation levels appear to be elevated in 
the absence of SIRT6 (Figure 2.6). Although less apparent, this finding holds up for 
H3K23ac in heart, kidney and spleen. H3K18ac, on the other hand, is mildly elevated 
in Sirt6 KO hearts, but does not appear to be different in kidney or spleen tissues 
(Figure 2.6). As for the previously described SIRT6 histone targets, global H3K56ac 
are elevated in each tissue analyzed, while H3K9ac is only different in thymus and  
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Figure 2.5: SIRT6 deacetylates H3K18ac in the brain 
Brain sections of germline Sirt6 KO and control mice were stained for H3K18ac. 
Arrows point at representative neuronal nuclei in WT and KO tissue indicating higher 
H3K18ac staining in Sirt6 KO brains. 
 
 
 
Figure 2.6: SIRT6 deacetylates histone H3 in vivo 
50 µg of tissue extract was loaded per lane and probed for the indicated proteins and 
histone marks. Total H3 is visible (arrow) on ponceau staining of immunoblot. Figure 
was generated in collaboration with Mary Skinner. 
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spleen. Overall, these findings suggest that SIRT6 globally deacetylates H3K23, similar 
to H3K56, while overall H3K18 deacetylation by SIRT6 appears to be more tissue 
specific as seen for H3K9ac.  
 
 
 
Discussion 
 
In our study we identified three novel targets for SIRT6 in vivo: H3K18ac, H3K23ac and 
H3K56ac. H3K56 acetylation levels are normally very low in mammalian cells, but rise 
dramatically in the context of SIRT6 deficiency (Yang et al., 2009). Improper regulation 
of H3K56 acetylation in mammalian cells leads to impaired cell cycle progression, 
sensitivity to genotoxins and spontaneous DNA damage (Michishita et al., 2009; Yang 
et al., 2009; Yuan et al., 2009), phenotypes reminiscent of SIRT6 deficiency. The exact 
mechanism through which deacetylation of H3K56ac by SIRT6 might repress DNA 
damage accumulation is not fully understood. A recent study has demonstrated that, in 
the event of a double strand break, SIRT6 is one of the first factors recruited to the 
damaged locus where it deacetylates H3K56 and consequently recruits the chromatin 
remodeler SNF2H and other DNA repair factors (Toiber et al., 2013). It has been 
hypothesized that H3K56 acetylation is asymmetric around the replication fork during 
S-phase: acetylated behind the fork on newly synthesized DNA, and non-acetylated 
ahead of the replication fork. Thus, H3K56 acetylation may allow newly-replicated DNA 
to be distinguished from unreplicated DNA for proper targeting of HR during S-phase 
(Munoz-Galvan et al., 2013). H3K56 acetylation is also required for chromatin 
reassembly following DSB repair (Chen et al., 2008) and for recovery from post-repair 
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checkpoint arrest following UV irradiation (Battu et al., 2011). In SIRT6-deficient cells, 
which show dramatically elevated levels of H3K56ac, it is possible that any or all of 
these processes may be perturbed. It should be noted however that SIRT6-deficient 
cells are not hypersensitive to UV, despite their dramatic H3K56 hyperacetylation 
(Mostoslavsky et al., 2006). 
 
The global deacetylation of H3K18 and H3K23, like H3K9, appears to show more 
tissue specificity, which would imply that these modifications are involved in 
transcriptional regulation of genes whose expression is dependent on cell type. 
Conversely, SIRT6 mediated regulation of these histone residues could be restricted to 
specific genomic regions, and thus we would not observe any global changes in 
acetylation in the absence of SIRT6. Both modifications are markers of active gene 
expression. Understanding the regulation of these histone modifications is clinically of 
great relevance as both H3K18ac and H3K23ac have been implicated in various 
disease states. High levels of H3K23ac have been reported in advanced diabetic 
kidney disease (Sayyed et al., 2010). Low levels of H3K18ac are associated with poor 
survival in pancreatic adenocarcinoma (Manuyakorn et al., 2010), and a higher risk of 
prostate, lung and kidney cancer recurrence (Seligson et al., 2009). However, thyroid 
tumors appeared to have higher levels of H3K18ac in comparison to normal tissue 
(Puppin et al., 2011). A previous study has identified H3K18ac as a target of SIRT7. 
SIRT7 does not alter global acetylation levels of H3K18, instead it is recruited by the 
cancer-associated transcription factor ELK4 to specific promoter sites where it 
represses downstream transcription. Through H3K18 deacetylation, high levels of 
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SIRT7 in prostate cancer cells stimulate anchorage-independent growth and cellular 
proliferation, and reduce contact inhibition and cell death (Barber et al., 2012). 
However, SIRT7 mediated H3K18 deacetylation is most likely highly region specific 
since SIRT7 promotes rRNA expression, which is under the influence of the MYC 
transcription factor, while on the other hand MYC, like the oncogenes Ras and Braf, 
binding to its target genes has been described to enhance H3K18ac levels (Martinato 
et al., 2008; Puppin et al., 2011). In addition to SIRT6 and SIRT7, H3K18 is also 
deacetylated by SIRT2. In the event of an infection with bacterium Listeria 
monocytogenes, SIRT2 facilitates the infection by translocating to the nucleus where it 
deacetylates H3K18. This deacetylation results in gene repression, of which a subset 
are involved in the immune response. Through this mechanism, SIRT2 supports the 
bacterium in taking over cellular control of the host cell (Eskandarian et al., 2013). 
Our finding that SIRT6 deacetylates histone H3 K18, K23 and K56 is of great 
importance in understanding the cellular functions of SIRT6. SIRT6 suppresses the 
activity of multiple transcription factors by deacetylating H3K9ac (Kawahara et al., 
2009; Sundaresan et al., 2012; Xiao et al., 2012; Zhong et al., 2010). With the 
identification of three additional histone targets for SIRT6, further studies will clarify 
whether SIRT6 deacetylates these novel targets at the same genomic regions as H3K9 
or if this indicates that more chromatin binding sites for SIRT6 are yet to be identified. 
As previously described, SIRT6 plays a role in overall healthspan, thus understanding 
the molecular functions of SIRT6 is essential when considering its therapeutic 
potential.  
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Future directions 
 
In addition to the known SIRT6 target H3K9ac, we have identified three histone H3 
residues that are targeted by SIRT6: H3K18ac, H3K23ac and H3K56ac. By deacetyling 
H3K9ac, SIRT6 silences HIF-1 mediated transcription of glycolytic genes (Zhong et al., 
2010). Furthermore, our recent work (see chapter 3) has identified SIRT6 as a 
transcriptional inhibitor of ribosomal gene expression by targeting H3K56ac at their 
promoter regions (Sebastian et al., 2012). Thus it would be of interest to test H3K18 
and H3K23 acetylation status at these promoter sites. In a pilot experiment we 
performed ChIP for these four acetylated histone H3 lysine residues followed by qPCR 
for glycolytic and ribosomal genes (Figure 2.7). Overall, H3K23 and H3K56 acetylation 
levels were elevated at all four analyzed promoter regions, while surprisingly we did not 
observe a change in H3K9ac. Furthermore, H3K18ac levels appeared to be lower for 
each of the sites tested (Figure 2.7). These results suggest that SIRT6 mainly targets 
K23 and K56 on histone H3 at the tested promoter regions. Our previous results 
indicated an apparent global change of these residues in the absence of SIRT6 across 
all tissues analyzed, while both H3K9ac and H3K18ac appeared to be more tissue 
specific (Figure 2.6). The lack of SIRT6-dependent change in acetylation of K9 and 
K18 might thus reflect tissue specificity. Alternatively, SIRT6 could target H3K9 and 
H3K18 at still unknown regions, which should be clarified through further studies. 
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Figure 2.7: Histone H3 acetylation changes at SIRT6 target promoter regions 
ChIP for indicated acetylated histone H3 residues at promoters of (A) glycolytic and (B) 
ribosomal genes WT and Sirt6 KO MEFs (n=3 technical replicates). Primer sequences 
(Table 3.1) and methods (chapter 3) are described at indicated locations. 
 
 
The three newly identified SIRT6 targets have been shown to be implicated in cancer 
(Barber et al., 2012; Das et al., 2009; Manuyakorn et al., 2010; Puppin et al., 2011; 
Seligson et al., 2009), diabetic kidney disease (Sayyed et al., 2010) and bacterial 
infection (Eskandarian et al., 2013). From a therapeutic perspective, it would be of 
interest to know if SIRT6 plays a role in mediating their acetylation state in these 
pathological conditions and whether SIRT6 modulation could prevent disease onset or 
progression.  
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Chapter 3 
 
 
 
SIRT6 acts as a tumor suppressor through inhibition of 
glycolysis 
 
 
Abstract 
Cancer cells derive much of their energy from aerobic glycolysis, a phenomenon 
called the Warburg Effect. Despite being known for decades, the underlying 
mechanism driving the metabolic switch in cancer cells is largely unknown. Here 
we demonstrate that the histone deacetylase SIRT6 acts as a tumor suppressor 
protein in part by inhibiting aerobic glycolysis. Loss of SIRT6 drives 
tumorigenesis in immortalized cells and supports tumor growth and glycolysis in 
already transformed cells. Furthermore, deletion of Sirt6 in the intestinal 
epithelial cells of mice predisposed to developing intestinal adenomas results in 
an increase in the number, size and aggressiveness of these tumors. In addition, 
SIRT6 also inhibits cell growth by repressing c-MYC driven transcription of 
ribosomal genes. And lastly, SIRT6 protein levels are decreased in human 
colorectal adenomas. Thus our studies strongly support a role for SIRT6 as a 
potent tumor suppressor protein. 
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Introduction 
Warburg effect  
Cells regulate glucose metabolism based on their differentiation and growth state, and 
the availability of oxygen. Differentiated tissues preferentially metabolize glucose to 
pyruvate through glycolysis; pyruvate subsequently enters the mitochondrial 
tricarboxylic acid (TCA) cycle to be fully oxidized to CO2 (oxidative phosphorylation). 
However, oxidative phosphorylation is dependent on the availability of O2. Under 
hypoxic conditions, pyruvate is converted instead into lactate in anaerobic glycolysis 
(Vander Heiden et al., 2009). In 1924, Otto Warburg observed that cancer cells 
preferentially convert glucose into lactate, irrespective of the presence of oxygen 
(aerobic glycolysis) (Warburg, 1956). This phenomenon, termed the Warburg effect, is 
also observed in non-neoplastic proliferating cells, such as lymphocytes (Wu and Zhao, 
2013) and LPS-stimulated macrophages (Tannahill et al., 2013) (Figure 3.1).  
 
It might at first seem surprising that cancer cells carry out a form of metabolism that is 
relatively inefficient at generating ATP. For each molecule of glucose that enters the 
cell, oxidative phosphorylation generates up to 36 molecules of ATP, whereas aerobic 
glycolysis provides only 2 net ATP molecules (Vander Heiden et al., 2009). Thus, 
glycolysis must provide rapidly proliferating cells with benefits that outweigh a lower 
efficiency of ATP production. A large body of recent work indicates that glycolysis and 
lactate production provide cancer cells with a number of advantages that drive 
tumorigenesis. First, in the presence of ample glucose, glycolysis generates ATP more 
rapidly than oxidative phosphorylation (Wu and Zhao, 2013). Second, aerobic  
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Figure 3.1: Illustration of the Warburg Effect 
In the presence of ample oxygen, differentiated tissue preferentially generates energy 
through oxidative phosphorylation, hereby producing 36mol ATP/mol glucose. 
However, under low oxygen condition pyruvate is converted into lactate instead 
(anaerobic glycolysis), hereby providing the cell with a mere 2mol ATP/mol glucose. 
Proliferative or cancerous tissue, independent of oxygen levels, preferentially 
generates ATP through conversion of glucose to pyruvate and lactate, a phenomenon 
referred to as the Warburg Effect. Figure is adapted from (Vander Heiden et al., 2009) 
 
glycolysis provides the cell with increased capacity to generate precursors for 
synthesis of macromolecules (lipids, nucleic acids, and proteins) essential for rapid cell 
division (Soga, 2013; Vander Heiden et al., 2009; Wu and Zhao, 2013). Finally, lactate 
secretion by tumors creates a toxic environment for immune cells, thereby inhibiting 
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immune surveillance, and stimulates endothelial cells to form new blood vessels, 
facilitating tumor metastasis (Hirschhaeuser et al., 2011). Lactate levels are negatively 
correlated with survival in patients with diverse tumor types, including cervical cancer, 
head and neck squamous cell carcinoma, and glioblastoma multiforme (Hirschhaeuser 
et al., 2011). In addition, high blood lactate levels are associated with radioresistance 
(Hirschhaeuser et al., 2011). It is now known that aerobic glycolysis is a part of the 
broader metabolic reprogramming that occurs in cancer cells (Ward and Thompson, 
2012).  
 
SIRT6 plays a particularly crucial physiologic role in maintaining glucose homeostasis. 
The first observation linking SIRT6 and glucose metabolism was made in SIRT6-
deficient mice. Loss of SIRT6 in a 129Sv strain background caused severe 
hypoglycemia that resulted in death by one month post-partum (Mostoslavsky et al., 
2006). Subsequent studies have shown that this hypoglycemia results from elevated 
tissue uptake of blood glucose in SIRT6-deficient mice, despite their lower circulating 
insulin levels. Collectively, these studies have revealed that SIRT6 is a master 
regulator of glucose homeostasis (Dominy et al., 2012; Kim et al., 2010; Xiao et al., 
2010; Zhong et al., 2010). SIRT6 exerts this function through three distinct pathways: 
(1) inhibiting activity of HIF-1α, a transcription factor that drives glycolysis and 
simultaneously inhibits oxidative phosphorylation (Zhong et al., 2010), (2) attenuating 
IIS and glucose uptake by reducing c-JUN transcriptional activity (Sundaresan et al., 
2012; Xiao et al., 2012), and (3) inhibiting hepatic gluconeogenesis by promoting 
acetylation of the transcription factor PGC-1α (Dominy et al., 2012) (Figure 1.3). 
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Highlighting the central role of metabolic reprogramming in neoplasia, mutations in 
genes that encode proteins involved in mitochondrial metabolism can promote 
tumorigenesis (Wu and Zhao, 2013). A number of transcription factors have been 
identified as the drivers of cancer metabolism (Soga, 2013; Ward and Thompson, 
2012). Two such transcription factors are HIF-1α and c-MYC.  
 
HIF-1 is a driver of metabolic reprogramming in cancer 
Hypoxia-inducible factors (HIFs), HIF-1, HIF-2 and HIF-3, are transcription factors that 
drive glycolysis and lactate production when the oxygen supply is limited. HIFs consist 
of an α-subunit whose levels are sensitive to oxygen concentration, and a stable β-
subunit. Under physiological oxygen tension, the α-subunit undergoes hydroxylation by 
prolyl hydroxylase (PHD) and subsequent proteasomal degradation mediated by von 
Hippel-Lindau (VHL) protein and E3 ligase (Keith et al., 2012; Semenza, 2010). 
However, under hypoxic conditions, oxygen shortage and/or the generation of reactive 
oxygen species (ROS) by the mitochondria inhibits the activity of PHD resulting in 
stabilization of the α-subunit, resulting in the HIF complex binding to hypoxia-
responsive elements (HREs) in the promoters of HIF target genes. The ubiquitously 
expressed HIF-1α was first identified in 1995, followed shortly after by the discovery of 
HIF-2α (Ema et al., 1997; Flamme et al., 1997; Hogenesch et al., 1997; Tian et al., 
1997; Wang et al., 1995). HIF-2α was initially thought to be mainly expressed in 
endothelial cells; however, expression of HIF-1α and HIF-2α overlaps in many cell 
types, and they regulate common as well as unique target genes (Hu et al., 2003; Keith 
et al., 2012; Raval et al., 2005; Wiesener et al., 2003).  
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HIF-1 induces expression of a number of glycolytic genes, such as SLC2A1 and 
SLC2A3, hexokinases 1 and 2 (HK1/2), PFK1, LDHA, MCT4, and PDK1 (Figure 3.2).  
SLC2A1 and SLC2A3 encode the glucose transporters GLUT1 and GLUT3 
respectively, which are responsible for basal, non-insulin-responsive glucose uptake.  
 
 
Figure 3.2: HIF-1 transcriptional activity positively regulates glycolysis and 
lactate production 
HIF-1 regulates transcription of a number of glycolytic genes that drive aerobic 
glycolysis (blue arrows) and inhibit oxidative phosphorylation (red arrows). GLUT, 
glucose transporter; HK1/2, hexokinase 1/2, PFK1, phosphofructokinase 1; LDH, 
lactate dehydrogenase; PDC, pyruvate dehydrogenase complex; PDK1, pyruvate 
dehydrogenase kinase 1; PDP1, pyruvate dehydrogenase phospatase 1; MCT4, 
monocarboxylate transporter 4.  
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Once imported into the cell, glucose is converted to glucose-6-phosphate in the initial 
step of glycolysis by hexokinases. Another important enzyme in glycolysis is 
phosphofructokinase 1 (PFK1) which converts fructose-6-phosphate into fructose-1,6-
biphosphate. Pyruvate generated in the final step of glycolysis can either be converted 
into acetyl-CoA by pyruvate dehydrogenase complex (PDC) for further metabolism in 
the TCA cycle, or be converted to lactate. Under hypoxic conditions, HIF-1 upregulates 
expression of glycolytic enzymes and favors lactate production, while inhibiting 
pyruvate entry into the TCA cycle. Two of HIF-1’s major transcriptional targets are 
pyruvate dehydrogenase kinase 1 (PDK1) and lactate dehydrogenase (LDH). PDK1 
phosphorylates the E1α subunit of PDC, thereby inhibiting holoenzyme activity. LDH 
catalyzes conversion of pyruvate into lactate. Once formed, lactate is transported out of 
the cell by the monocarboxylate transporter MCT4 (Keith et al., 2012; Semenza, 2010). 
Increased expression of HIF-1α and HIF-2α has been detected in many different 
cancer types as well as tumor-associated stromal cells, and in both cases high HIF 
levels are associated with a poor clinical outcome (Bonuccelli et al., 2010; Keith et al., 
2012; Pavlides et al., 2010; Semenza, 2010).  
 
Oncogenic c-Myc regulates biomass production in cancer 
c-MYC, l-MYC and n-MYC are the three members of the oncogenic MYC transcription 
factor family. n-MYC and c-MYC possess overlapping functions, though expression of 
n-MYC is more tissue-restricted, being more prevelant in postmitotic cells undergoing 
differentiation (Dang, 2012; Malynn et al., 2000). c-MYC heterodimerizes with its 
partner protein MAX (MYC-associated factor X) to bind specific DNA sequences, 
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termed E-boxes, on promoter regions of 30% of all genes (Dang et al., 2009a). In this 
regard, recent data indicate that MYC functions as an amplifier of the expression of 
essentially all expressed genes, in a cell-type specific manner (Lin et al., 2012; Nie et 
al., 2012). To regulate gene expression, the c-MYC/MAX complex requires interaction 
with other transcription factors such as E2F1 and HIF-1. c-MYC positively regulates 
ribosomal biogenesis, glucose metabolism, and mitochondrial respiration in most cell 
types (Dang et al., 2009a). Ribosomal genes are particularly important c-MYC targets 
in the context of cellular transformation; heterozygosity for a ribosomal gene (L24) is 
sufficient to attenuate MYC-driven oncogenesis in B-lymphocytes (Barna et al., 2008). 
 
With respect to glucose metabolism and mitochondrial function, a complex interplay 
exists between MYC and HIF proteins. Under hypoxic conditions, HIF-1 inhibits MYC 
activity, either through interruption of MYC/MAX binding, or through stimulation of 
proteasomal degradation of MYC (Corn et al., 2005; Gordan et al., 2007b). However, 
oxygen levels tend to fluctuate in cancer cells (Dewhirst, 2007). Therefore, in tumor 
cells, where c-MYC levels are generally elevated, HIF-1α will only inhibit MYC activity 
during short periods of severe hypoxia, while at other times the high c-MYC levels can 
drive cellular proliferation (Gordan et al., 2007b). In contrast to HIF-1, HIF-2 was 
reported to promote MYC/MAX heterodimerization under hypoxic conditions and 
enhance MYC activity (Gordan et al., 2007a). Because HIF-2 is expressed in 
endothelial cells, it has been postulated that, via this mechanism, HIF-2 stimulates 
endothelial proliferation and angiogenesis. However, endothelial-specific deletion of 
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HIF-2α does not affect endothelial proliferation per se; instead it results in defective 
tumor vessel formation and increased tumor hypoxia and apoptosis (Skuli et al., 2009). 
 
Increased c-MYC activity is a feature of many diverse human tumors (Dang et al., 
2008; Dang et al., 2009a). A key function of c-MYC in cancers is regulating the 
absorption and metabolism of the non-essential amino acid glutamine. In 1955, Dr. H. 
Eagle observed that cellular proliferation of normal and malignant cells in culture 
requires exogenous glutamine (Eagle, 1955). Glutamine uptake by cancer cells 
exceeds that of any other amino acid by 10-fold, and glutamine deprivation of 
transformed cells induces apoptosis (Wise et al., 2008; Yuneva et al., 2007). The 
importance of glutamine in cancer cell survival and growth is due largely to its 
involvement in macromolecular synthesis (Dang, 2010; Wise and Thompson, 2010). 
Glutamine is essential for protein translation in cancer cells as it drives the uptake of 
extracellular essential amino acids (EAAs), which in turn activate mTORC1, a master 
regulator of protein translation (Wise and Thompson, 2010). In addition, glutamine and 
glucose are important carbon and nitrogen sources for synthesis of all non-essential 
amino acids except tyrosine (Wise and Thompson, 2010). In addition, through various 
processes, glutamine metabolism generates important substrates for energy 
production (DeBerardinis et al., 2007), carbon and nitrogen to support protein, 
nucleotide, and lipid synthesis (Jones and Thompson, 2009) (Wise and Thompson, 
2010), and high levels of NADPH (Wise and Thompson, 2010).  
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C-MYC can regulate glutamine uptake and metabolism in cancer cells in at least three 
distinct ways. First, c-MYC directly increases the expression of the amino acid 
transporters SLC5A1 and SLC7A1 (Gao et al., 2009). Second, c-MYC stimulates 
glutamine metabolism by indirectly regulating the expression of the enzyme 
glutaminase (GLS) (Gao et al., 2009). Finally, c-MYC promotes the expression of 
several enzymes involved in nucleotide biosynthesis using glutamine (Dang, 2010; 
Wise and Thompson, 2010). 
 
In addition to c-MYC’s regulation of glutamine uptake and metabolism, c-MYC also 
plays an important role in promoting cellular growth, a feature that depends on c-MYCs 
ability to stimulate ribosomal gene expression and ribosomal biogenesis (Arabi et al., 
2005; Grandori et al., 2005; Grewal et al., 2005). Ribosomal biogenesis encompasses 
the synthesis and processing of ribosomal RNA (rRNA), the synthesis and import of 
ribosomal proteins, and the assembly and export of pre-ribosomal subunits. The 
human ribosomal genes are clustered together on various chromosomes. Each one of 
these clusters co-localizes with a nucleolus where rRNA transcription and processing 
takes place and ribosomal proteins are integrated to form the immature ribosome 
(Gonzalez and Sylvester, 1995). The rate at which rRNA is synthesized is essential in 
ribosomal biogenesis and protein synthesis, which in turn are rate-limiting steps for 
cellular proliferation (Dai and Lu, 2008). In mammals, c-MYC regulates the 
transcription of ribosomal genes by recruiting RNA polymerase I to the nucleolus 
(Grandori et al., 2005). As a result, the expression of the majority of genes dedicated to 
ribosomal biogenesis are regulated by c-MYC (Grewal et al., 2005). Cells expressing 
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high levels of c-MYC have an abundance of rRNA, large numbers of ribosomes and 
have dense endoplasmatic reticulum network (Grewal et al., 2005). These features 
coincide with the increased nucleolar size and enhanced rRNA synthesis that is 
commonly seen in transformed cells (Derenzini et al., 1998).  
 
Based on the role of SIRT6 in maintaining genomic stability and glucose homeostasis 
(Cardus et al., 2013; Kaidi et al., 2010; Mao et al., 2012; McCord et al., 2009; 
Mostoslavsky et al., 2006; Toiber et al., 2013; Zhong et al., 2010), we hypothesized 
that SIRT6 could function as a tumor suppressor protein. In this study we confirm that 
the absence of SIRT6 drives tumorigenesis in immortalized cells through at least two 
pathways. First, SIRT6 controls HIF-1 activity, hereby preventing the switch to aerobic 
glycolysis, the main mode of energy production in cancer cells (Warburg Effect). 
Second, SIRT6 regulates cell growth by co-repressing c-MYC transcriptional activity, 
and thereby inhibits ribosomal gene expression. Manipulation of either pathway 
rescues the tumorigenic potential of SIRT6 deficient cells in vitro and in vivo. 
Furthermore, we find that SIRT6 protein levels are decreased in human adenomas in 
comparison to normal colon tissues, consistent with the notion that SIRT6 is a potent 
tumor suppressor. These studies were performed in collaboration with Dr. R. 
Mostoslavsky and Dr. C. Sebastiàn at Massachusetts General Hospital and Harvard 
Medical School. 
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Materials and Methods 
Immortalized and transformed MEFs 
Primary MEFs were isolated from 13.5 day-old embryos as previously described 
(Mostoslavsky et al., 2006). These cells were further immortalized through 3T3 serial 
passaging or transformed by KD of p53 expression. 
 
Cell culture 
MEFs were grown in DMEM supplemented with 15% fetal bovine serum, 1% L-
Glutamine, 1% pen/strep, 1% sodium pyruvate, 1% non-essential amino acids, 2% 
HEPES and 115 µM β-mercaptoethanol. ES cells were grown on gelatinized tissue 
culture dishes in MEF growth media supplemented with 1 ng/ml recombinant mouse 
leukemia inhibitory factor (LIF; Life Technologies). U2OS and 293T cells were grown in 
DMEM with 10% FBS, 2 mM Glutamine and 1% pen/strep. 
  
Xenograft studies 
5 x 106 cells in 100 ul matrigel were injected subcutaneously into the flanks of SCID 
mice (Taconic Farms, Inc., Hudson, NY) or athymic nude (Foxn1nu/Foxn1nu) mice 
(Jackson Laboratories). Mice were checked for the appearance of tumors twice a 
week, and the tumors were harvested and measured after 4 weeks. 
 
Immuno Blot analysis and Immunoprecipitation 
Western analysis was carried out as previously described (Zhong et al., 2010). The 
following primary antibodies were used in 5% milk in TBST: anti-SIRT6 (Abcam, 
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ab62739), anti-FLAG (Sigma, F1804), anti-PDK1 (Cell Signaling), anti-LDHa (Santa 
Cruz), anti-p53, anti-phospho-AKT (Ser473), anti-total-AKT (Cell Signaling), anti-
phospho-ERK (Sigma), anti-ERK (Santa Cruz), anti-phospho-PDH-E1a-Ser293 
(Abcam), anti-MYC (Epitomics), anti-actin (Sigma). To determine the interaction 
between SIRT6 and MYC, Flag-SIRT6, FLAG-SIRT2 or FLAG-SIRT5 were co-
transfected with MYC into U2OS cells and after anti-Flag immunoprecipitation  the 
presence of MYC was evaluated by western blot (according to manufacturers 
instructions). Endogenous immunoprecipitation was performed in mouse ES cells. 
Cells were grown to approximately 70% confluency, then washed twice with 1xPBS 
and collected in CHAPS buffer (25 mM HEPES, 2 mM EGTA, 2.5 mM MgCl2 and 0.3% 
CHAPS). After a 20 min incubation on ice and a 20 min centrifugation at 4°C, the 
supernatants were transferred to fresh tubes. Lysates (1 mg) were pre-cleared with 50 
µl Protein A Agarose beads (Roche) for two hours and supernatants were collected 
after short centrifugation (1 min, 1000 rpm and 4°C). IPs were performed by adding 5 
µg of SIRT6 antibody or IgG control (Abcam) together with 50 µl of protein A Agarose 
beads overnight at 4°C. After three washes in CHAPS buffer containing 150 mM NaCl, 
the immuno-complexes were eluted by boiling the samples for 10 min in 4x SDS 
loading buffer. 
 
Lactate, Glutamine, and Glucose Uptake Assays 
Lactate and glutamine concentration were measured in the media using the Lactate 
Assay Kit and the EnzyChrom Glutamine Assay Kit (BioVision), respectively. In vitro 
glucose uptake was performed as previously described (Zhong et al., 2010). 
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Luciferase Reporter Assays 
MYC transcriptional activity was determined by luciferase experiments as previously 
described (Zhong et al., 2010). In short, 293T cells were co-transfected with 1 µg of 
pCMV-3xFlag-SIRT6 or empty vector, 950 ng of pMYC-luc (Signosis, Inc., Sunnyvale, 
CA) and 50 ng of pGL3-Renilla. Twenty-four hours after transfection, cells were 
harvested and luciferase activity was deteremined using the Dual-Luciferase Reporter 
Assay system (Promega). An aliquot of the same lysates was used to confirm protein 
expression of Flag-SIRT6. 
 
RNA Extraction and Real-Time PCR 
Total RNA was extracted with the TriPure Isolation Reagent (Roche) per 
manufacturers instructions. For cDNA synthesis, 1 µg total RNA was reverse-
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). Real-time PCR 
was carried out using the SYBR green master mix (Roche) as described by the 
manufacturer, with the exception that SYBR green reaction mix was adjusted to a total 
volume of 12.5 µl. The real-time PCR reaction was run on a LightCycler 480 detection 
system (Roche). Data are represented as relative mRNA levels normalized to β-actin 
levels in each sample. The primer sequences are shown in Table 3.1. 
 
	   66	  
Table 3.1: Primer sequences for Real-Time PCR 
 Forward sequence Reverse sequence 
Rpl3 cgtttcgctaagcttgaacc aggagccagtgcaggctat 
Rpl6 gagtcgcaaggctcaaagtc ataagcaatgacgggaggtg 
Rpl23 catcttaagcgcagctttcc gggacactgggatatgaacg 
Rps15a cctcgcattggttgtcctat gatggcacagataccacacg 
LDHA agggggtgtgtgaaaacaag atggcttgccagcttacatc 
LDHB agagagagcgcttcgcatag ggctggatgagacaaagagc 
ALDOC aagtggggcactgttaggtg gttggggattaagcctggtt 
PFKM ttaagacaaagcctggcaca caaccacagcaattgaccac 
Pkd4 ctgtagtcccccttccctgt gagcttttggagcagactgg 
β-actin gaggtatcctgaccctgaagta cacacgcagctcattgtaga 
 
FDG-PET Assays 
Glucose uptake in tumors was measured as previously described (Zhong et al., 2010). 
Briefly, H-RasV12/shp53 cells were injected into the flanks of SCID mice 15 days prior 
to glucose measurement. Prior to imaging with an Inveon (Siemens) small animal 
scanner, animals were fasted for 12 hours and intravenously injected with 
approximately 700 µCi 18FDG 45 minutes prior to PET acquisition (Boiselle et al., 
1998). CT preceded PET, acquiring 360 cone beam projections, and PET data sets 
acquired 600 million counts. During CT acquisition, iodine contrast was infused 
intravenously at a rate of 20 µl/min to enhance intravascular contrast. Data analysis 
consisted of region of interest analysis on standard uptake value (SUV) PET images 
superimposed on anatomic contrast enhanced CT images. Images were analyzed 
using OsiriX software and FDG-PET data were calculated as SUVmax for selected 
regions of interest. 120-days old Apcmin/+ mice were imaged similarly to analyze in vivo 
adenoma glucose uptake. FDG-PET was performed in collaboration with Dr. R. 
Weissleder’s group. 
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Proliferation Assay 
Cells were plated in triplicate in 12-well plates and cultured in complete media. At the 
indicated time points, cells were harvested with trypsin and counted. For colony 
formation assays, 250 cells were plated in 6-well plates and kept in culture for 10-15 
days. 
 
Apoptosis Assay 
Cells were plated in triplicate in 12-well plates and grown in complete media overnight. 
The next day, medium was replaced by DMEM with 10% FBS and 0.3 mM Glutamine 
with or without glucose. After 6 days, cells were collected and stained with Annexin-V 
(BD Bioscience) to analyze cell death.   
 
Anchorage-independent Cell Growth Assay 
7.5 x 103 cells were resuspended in 0.4% agar and plated in triplicate in 6 cm dishes 
containing a 0.8% base agar layer. Colonies were stained with 0.005% Crystal Violet in 
2% methanol and counted. 
 
Viral Infection 
The following plasmids were used to generate viral particles: pBabe-H-RasV12, pLMS-
shp53.1224, pLKO.1-shPDK1 (The MGH RNAi Consortium Library), pLKO.1-shMYC 
(Open biosciences), pMSCV-3xFlag-SIRT6 (generated by subcloning Flag-SIRT6 from 
pCMV-3xFlag-SIRT6 to pMSCV-puro). Viral infection was carried out as previously 
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described (Zhong et al., 2010). These plasmids and viral infections were generated by 
Dr. R. Mostoslavsky’s group. 
 
Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation (ChIP) was performed as previously described 
(Sebastian et al., 2008) with minor modifications. Cells were cross-linked with 1% 
paraformaldehyde for 20 minutes at room temperature. The reaction was quenched for 
10 minutes by adding 0.125 M glycine. After three washes with 1x PBS, cells were 
lysed with lysis buffer (1% SDS, 10 mM EDTA pH 8, 50 mM Tris-HCl pH 8) 
supplemented with protease and deacetylase (TSA) inhibitors. Lysates were sonicated 
on ice using a Bioruptor sonicator (2 pulses of 10 minutes, 0.5 minute soication) to 
obtain 200-1200bp fragments. Soluble chromatin was collected after centrifugation at 
14,000 rpm at 4°C for 10 minutes and 1 mg (for MYC IP) or 0.2 mg (for H3K9ac and 
H3K56ac IP) of protein was diluted to 1:10 in dilution buffer (1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.1) supplemented with protease and 
deacetylase inhibitors. 1-5% of the soluble chromatin was kept as input control. 
The soluble chromatin was pre-cleared with 100 µg/ml of salmon sperm DNA 
(Amersham Biosciences), 2.5 µg/ml of control IgG, and protein-A-Sepharose at 50% 
overnight at 4°C while rotating. After centrifugation at 1000 rpm for 1 minute, 
supernatants were collected and specific antibodies were added: 7.5 µl MYC 
(Epitomics), 3 µl H3K9ac (Millipore), 3 µl H3K56ac (Epitomics) or control IgG (Abcam). 
Mixtures were incubated at 4°C for 6 hours while rotating and subsequently incubated 
overnight at 4°C with 50% protein-A-Sepharose (Roche). Beads were collected and 
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washed sequentially at 4°C for 10 minutes with buffer I (150 mM NaCl, 0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, and 20 mM Tris-HCl (pH 8.1)), buffer II (500 mM NaCl, 
0.1% SDS, 1% Triton X-100, 2 mM EDTA and 20 mM Tris-HCl (pH8.1)), and buffer III 
(0.25 mM LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA and 10 mM Tris-HCl 
(pH 8.1)). After one wash with 1x PBS, the immunoprecipitates were eluted from the 
beads twice for 20 minutes with elution buffer (0.1 M NaHCO3 and 1% SDS). The 
eluates and the input controls were incubated overnight at 65°C to reverse the cross-
linking, and DNA was subsequently purified using the QIAquick spin kit (Qiagen). Real 
time PCR was performed as described above. 
 
Generation of Sirt6 Conditional KO Mice 
To generate mice lacking SIRT6 specifically in the intestinal epithelial cells, we crossed 
previously described homozygous Sirt6f/f mice (Kim et al., 2010) with C57BL6/J mice 
expressing Cre-recombinase under the Villin-1 promoter. Cre-recombinase exposure 
leads to deletion of exon 2 and 3. These crossed mice were consequently interbred 
with C57BL/6J-Apcmin/+ mice (Jackson Laboratories) to generate mice heterozygous for 
Apc in which Sirt6 is specifically deleted in the intestinal epithelial cells (Figure 3.3). 
Mice were euthanized at 120 days, the intestines harvested and analyzed for the 
presence of polyps. Subsequently, the intestines were fixed in 10% formaldehyde and 
processed for H&E staining according to standard procedures by the University of 
Michigan histology core.  
A subset of Sirt6f/f;V-c;Apcmin/+ and control;Apcmin/+ mice were treated just after weaning 
with dichloroacetic acid (DCA; 5 g/l of drinking water) or regular water and euthanized 
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at 108 days of age. Intestines were harvested and processed as described above. Of 
each mouse one polyp was collected for protein extraction to analyze PDH-E1α 
phosphorylation. 
 
 
Figure 3.3: Adenoma-prone mouse model breeding scheme 
Mice containing the Sirt6 allele with loxP sites flanking exons 2 and 3 were crossed 
with mice carrying the cre-recombinase gene driven by the Villin-1 promoter to 
generate intestinal epithelial specific knockouts for Sirt6. These mice were further 
crossed with Apcmin/+ mice that are predisposed to developing intestinal adenomas.  
 
 
Immunohistochemistry 
IHC for SIRT6 was performed on human normal colon and adenomas by the University 
of Michigan histology core. In brief, slides were deparaffinized and rehydrated through 
a series of xylene and alcohol washes. Antigen retrieval was performed by first heating 
the slides for 10 minutes in citrate buffer (10 mM Citric Acid, 0.05% Tween 20, pH 6.0) 
and then slides were allowed to cool down for 10 minutes at room temperature. 
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Endogenous peroxide was blocked by incubation in 3% hydrogen peroxide (H2O2) for 
10 minutes. Additional blocking was performed by incubating the slides in 5% normal 
goat serum in PBS for one hour. Tissues were incubated with anti-SIRT6 antibody (Cell 
Signaling Technology) overnight at 4°C. Signal was visualized using 3,3’-
diaminobenzidine (DAB; Vector Laboratories) and slides were mounted using 
permanent mounting medium (Vector Laboratories). Slides were imaged with an 
Olympus BX-51 scope with an Olympus DP-70 high-resolution digital camera 
(University of Michigan Microscopy & Image Analysis lab). 
 
 
Results 
SIRT6-deficient cells are tumorigenic 
It was previously shown that SIRT6 plays a role in maintaining genomic integrity 
(Mostoslavsky et al., 2006) and in controlling glucose homeostasis in part by regulating 
aerobic glycolysis (Zhong et al., 2010). Both these processes are key features in 
cancer cells, and thus we hypothesized that the absence of SIRT6 might result in 
tumorigenesis. To investigate this hypothesis, we obtained mouse embryonic 
fibroblasts (MEFs) from Sirt6 WT and KO embryos and immortalized them through 
serial passaging according to a standard 3T3 protocol. Sirt6 KO MEFs had a higher 
proliferative rate (Figure 3.4A) and formed larger colonies when plated at very low 
density (Figure 3.4B) than Sirt6 WT MEFs. Subsequently, we injected Sirt6 WT and KO 
cells into the flanks of nude mice to assess tumor growth in vivo. Immortalized MEFs 
normally do not grow in this setting except when transformed with an activated 
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oncogene. However, the SIRT6-deficient MEFs easily formed tumors indicating that the 
absence of SIRT6 is sufficient to drive tumorigenesis in immortalized MEFs (Figure 
3.4C).  
Genomic instability can cause cellular transformation by activating oncogenes or 
inactivating tumor suppressor genes. Since SIRT6 is known to maintain genomic 
integrity through its stimulatory function in various DNA repair pathways (Kaidi et al., 
2010; Mao et al., 2012; McCord et al., 2009; Mostoslavsky et al., 2006), we first wanted 
to verify if the tumorigenesis observed in Sirt6 KO MEFs was due to genomic 
instability. To test this, we reintroduced SIRT6 in KO MEFs and injected these cells into 
nude mice. If cellular transformation were caused by genomic instability due to the 
absence of SIRT6, we would expect tumor growth even when reintroducing SIRT6. We 
observed that these rescued cells were no longer capable to form tumors in vivo 
(Figure 3.4C), indicating that an alternative pathway is responsible for mediating 
SIRT6’s tumor suppressor function. In support of this, KO MEFs reconstituted with the 
catalytic inactive mutant SIRT6-H133Y still formed tumors in vivo (Figure 3.4C), 
suggesting that SIRT6 catalytic activity is required for tumor suppression.  
Finally, we examined whether SIRT6 deficiency influenced tumor growth in the 
presence of activated oncogenes. Therefore, we expressed an activated form of H-Ras 
(H-RasV12) and knocked down p53 expression (shp53) in both WT and Sirt6 KO 
MEFs and found that even in this setting SIRT6 deficiency provided transformed MEFs 
with a growth advantage when subjected to an anchorage-independent soft agar assay 
(Figure 3.4E). Indicating that SIRT6 protects against both tumor initiation and tumor 
progression. 
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Figure 3.4: SIRT6-deficient cells are tumorigenic 
 (A) Sirt6 WT and KO immortalized MEFs (two independent cell lines for each) were 
plated, and cells were counted on indicated days. Error bars indicate SEM. (B) Sirt6 
WT and KO immortalized MEFs were plated at a low density and cultured to assess 
colony formation. (C) Immortalized MEFs were injected into the flanks of nude mice to 
assess their tumorigenic potential. Likewise, Sirt6 KO MEFs were infected with 
lentiviruses encoding Flag-SIRT6 or Flag-SIRT6HY (catalytic inactive mutant) and 
grown in nude mice. (D) SIRT6 protein levels were assessed in the indicated 
immortalized MEFs. (E) Anchorage-independent cell growth assay of Sirt6 WT and KO 
H-RasV12/shp53 transformed cells. (Sebastian et al., 2012) Experiments in figures A, 
B and E were performed by Dr. C. Sebastian. 
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SIRT6 deficient cells and tumors exhibit enhanced aerobic glycolysis 
To identify the underlying mechanism associated with the tumorigenic phenotype of 
SIRT6 deficient cells, we concentrated on SIRT6’s role in regulating glucose 
metabolism. Immortalized MEFs showed increased glucose uptake and lactate 
production in the absence of SIRT6 (Figure 3.5A). Additionally, reintroduction of SIRT6 
in KO MEFs, in addition to decreasing tumor growth in vivo (Figure 3.4C), reduced 
cellular glucose absorption (Figure 3.5B), suggesting that compromising the inhibitory 
role of SIRT6 on aerobic glycolysis could mediate tumorigenesis. To analyze the 
glycolytic phenotype of these cells, we measured the expression levels of various 
glycolytic genes that have previously been shown to be regulated by SIRT6 (Zhong et 
al., 2010). In comparison to WT MEFs, SIRT6-deficient MEFs show higher expression 
of Glut1, Pfk1, Pdk1 and Ldha (Figure 3.5C). Further enhanced expression of these 
genes was observed in Sirt6 KO tumors derived from Sirt6 KO MEFs (Figure 3.5C), 
suggesting a selective advantage within Sirt6 KO tumors for cells with elevated 
glycolytic activity. Enhanced glycolytic activity is indicative of glucose addiction. To test 
this, we measured cellular apoptosis of Sirt6 WT and KO MEFs under high and low 
glucose conditions. Strikingly, almost 50% of SIRT6-deficient cells died after glucose 
withdrawal, while most SIRT6-proficient cells survived (Figure 3.5D). These results 
strongly suggest that SIRT6 acts as a tumor suppressor protein by inhibiting aerobic 
glycolysis and thereby glucose addiction, a hallmark of cancer cells. 
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Figure 3.5: SIRT6 deficient cells and tumors show elevated aerobic glycolysis 
(A) Glucose uptake (left and middle) and lactate production in Sirt6 WT and KO 
immortalized MEFs (two independent cell lines; error bars indicate SEM). (B) Glucose 
uptake in Sirt6 KO immortalized MEFs virally infected with empty vector or WT Sirt6 
(error bars indicate SD). (C) Real-time PCR showing the expression of the indicated 
genes in Sirt6 WT and KO immortalized MEFs (n=20 experiments from two 
independent lines) and for cells derived from Sirt6 KO tumors (n=8 experiments from 
three independent lines) (error bars indicate SEM). (D) Sirt6 WT and KO MEFs were 
cultured with or without glucose. After 6 days cell death was measured using Annexin 
V staining (error bars indicate SEM). Experiments were performed by Dr. C. Sebastián 
(Sebastian et al., 2012) 
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Inhibition of glycolysis suppresses tumorigenesis in Sirt6 KO cells 
The above results suggest that SIRT6 acts as a tumor suppressor protein by mediating 
aerobic glycolysis. In addition to changes at a transcriptional level, both LDHA and 
PDK1 protein levels are elevated in immortalized and transformed Sirt6 KO MEFs, in 
comparison to control cells (Figure 3.6A). To further assess the importance of aerobic 
glycolysis in driving tumorigenesis in the absence of SIRT6, we hypothesized that 
reversing this metabolic switch by stimulating the conversion of pyruvate to Acetyl-CoA 
instead of to lactate, would rescue the tumorigenesity phenotype in SIRT6 deficient 
cells. Therefore, we virally infected immortalized Sirt6 KO MEFs with shPdk1 or vector 
control. This resulted in efficient knockdown of PDK1 and, as a consequence, reduced 
PDH phosphorylation (Figure 3.6B). Furthermore, PDK1 downregulation reversed both 
the proliferative potential and the glucose addiction of Sirt6 KO MEFs (Figure 3.6C). In 
addition, inhibition of PDK1 activity diminished anchorage-independent cell growth in 
soft agar that was previously observed in SIRT6-deficient cells (Figure 3.6D). Overall, 
these results indicate that SIRT6 acts as a tumor suppressor protein by preventing the 
switch from oxidative phosphorylation to aerobic glycolysis and that reactivation of 
oxidative phosphorylation is sufficient to revert this phenotype.  
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Figure 3.6: Inhibition of glycolysis suppresses tumorigenesis in Sirt6 KO cells 
(A) Western blot showing the expression of PDK1 and LDHA in Sirt6 WT and KO 
immortalized and transformed MEFs. (B) Western blot showing PDK1 and phospho-
PDH-E1α (Ser293) protein levels in Sirt6 KO cells infected with shPdk1 and vector 
control. (C) Cell proliferation assay (left) and glucose-starvation-induced cell death 
assay (right) in Sirt6 KO-vector and Sirt6 KO-shPdk1 MEFs (error bars indicate SD). 
(D) Anchorage-independent cell growth of the same cells as in (C) (error bars indicate 
SD). Experiments were performed by Dr. C. Sebastián and members of Mostoslavsky 
laboratory (Sebastian et al., 2012). 
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Table 3.7: SIRT6 inhibits ribosomal gene expression by co-repressing MYC 
transcriptional activity 
(A) IPs of Flag-SIRT6 and cMYC indicating their physical interaction. (B) Luciferase 
activity measured in 293T cells which were co-transfected with a luciferase reporter 
gene under the regulation of a MYC-responsive element and with Flag-SIRT6 or empty 
vector (error bars indicate SEM). (C) Relative expression of the indicated genes in Sirt6 
WT and KO H-RasV12/shp53 tumors (n=4; error bars indicate SEM). (D) ChIP analysis 
of H3K56ac levels at indicated loci for Sirt6 WT and KO H-RasV12/shp53 MEFs (n=4; 
error bars indicate SEM). IP was performed by Dr. E. Guccione and remaining 
experiments were performed by Dr. C. Sebastián (Sebastian et al., 2012). 
 
SIRT6 inhibits ribosomal gene expression by co-repressing MYC 
In general, a metabolic switch to glycolysis alone is not sufficient to provide cells with a 
growth advantage. Therefore we hypothesized that SIRT6 might regulate cellular 
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proliferation in addition to glycolysis. Based on data sets from SIRT6 chromatin 
immunoprecipitation followed by DNA sequencing (ChIP-seq) performed in 
collaboration with Dr. Bernstein and Dr. Regev’s research groups using their newly 
developed method to study chromatin regulator binding (Ram et al., 2011), we found 
that SIRT6 binds ribosomal and ribonucleoprotein genes. Interestingly, these genes 
are under the transcriptional regulation of MYC (Arabi et al., 2005; Grandori et al., 
2005; Grewal et al., 2005), and therefore we hypothesized that SIRT6 might suppress 
MYC transcriptional activity. We first confirmed that SIRT6 and MYC physically interact 
by co-transfecting 293T cells with Flag-SIRT6 and c-MYC followed by 
immunoprecipitation (Figure 3.7A). Since SIRT6 has been previously identified as a 
transcriptional repressor, we verified if SIRT6 could also inhibit MYC activity. Thus, we 
measured the expression of a MYC-dependent luciferase reporter in 293T cells in the 
presence or absence of SIRT6. We found that SIRT6 suppressed the luciferase 
expression significantly (Figure 3.7B), demonstrating that SIRT6 represses MYC 
activity in this setting. To confirm this in vivo, we measured the expression of various 
ribosomal genes in SIRT6-deficient tumors, which were all upregulated in the absence 
of SIRT6 (Figure 3.7C). As it was previously shown that SIRT6 deacetylates multiple 
residues on histone H3 (Michishita et al., 2008; Michishita et al., 2009; Yang et al., 
2009), and that this deacetylation can repress activity of multiple transcription factors 
(Kawahara et al., 2009; Zhong et al., 2010), we performed ChIP to assess if SIRT6 
represses MYC in a similar fashion. We found that SIRT6 specifically deacetylates 
H3K56ac, and not H3K9ac (data not shown), on the promoter regions of ribosomal 
protein genes (Figure 3.7D). In summary, we have shown that SIRT6 physically 
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interacts with MYC on the promoter regions of ribosomal genes and that SIRT6 
functions as a transcriptional repressor of MYC to inhibit ribosomal gene expression. 
Thus we provide another mechanism through which SIRT6 can suppress 
tumorigenesis. 
 
To assess the importance of SIRT6 suppression of MYC activity in preventing 
tumorigenesis, we knocked down MYC in SIRT6-deficient MEFs using a viral short 
hairpin vector (Figure 3.8A). Upon knockdown of Myc, cellular proliferation in culture 
(Figure 3.8B) and in vivo (Figure 3.8C) was reduced in the absence of SIRT6. 
Additionally, MYC knockdown inhibited ribosomal gene expression as well as 
glutaminase (Gls) expression in Sirt6 KO MEFs (Figure 3.8D). However, glucose 
uptake and glycolytic gene expression was unaffected by Myc knockdown (Figure 
3.8E-F), indicating that MYC regulates tumor growth in SIRT6-deficient cells 
specifically by enhancing expression of glutamine and ribosomal genes and that the 
metabolic switch observed in the absence of SIRT6 is likely through hyperactivation of 
HIF-1α. 
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Figure 3.8: MYC regulates growth of SIRT6-deficient cells 
(A) Western blot showing MYC protein levels in Sirt6 KO-shMYC and vector control 
MEFs. (B) Proliferation assay in which 5 x 105 MEFs were plated in triplicate and 
counted at the indicated time points (error bars indicate SD). (C) 5 x 105 MEFs were 
injected into either side of the flanks of SCID mice. The weights of the harvested 
tumors are depicted in the bar graph (error bars indicate SD). (D) Relative expression 
of ribosomal genes and glutaminase (Gls) in Sirt6 KO-shVector and Sirt6 KO-shMYC 
cells (n=9; error bars indicate SEM). (E) Glucose uptake in Sirt6 KO-shVector and Sirt6 
KO-shMYC cells (error bars indicate SD). (F) As in (D) relative expression of glycolytic 
genes (error bars indicate SEM). Experiments were performed by Dr. C. Sebastián 
(Sebastian et al., 2012). 
 
	   82	  
SIRT6 functions as a tumor suppressor in vivo 
Our studies so far strongly suggest a tumor suppressor role for SIRT6. To test whether 
our findings would hold in vivo, we took advantage of a well-described mouse model of 
colorectal adenomatosis in which mice lack a mutation in the Apc gene (Apcmin/+) 
(Moser et al., 1990; Su et al., 1992). To overcome the early lethality of Sirt6 germline 
KO mice, we deleted Sirt6 specifically in the mouse epithelial cells by crossing a 
previously described mouse strain with a floxed Sirt6 allele (Kim et al., 2010) with a 
mouse strain expressing cre-recombinase under the Villin-1 promoter (V-c+) (Madison 
et al., 2002). Mice with intestinal epithelial specific deletion of Sirt6 were further bred 
with Apcmin/+ mice to obtain Apcmin/+; Sirt6f/f; V-c+ (Figure 3.3). Littermate controls were 
Apcmin/+; V-c+ mice either null (Sirt6+/+) or heterozygous (Sirt6f/+) for the floxed Sirt6 
allele. Remarkably, a three-fold increase in polyp number was observed upon deletion 
of Sirt6 (Figure 3.9B-C). Furthermore, the average polyp size was greater than in the 
littermate controls (Figure 3.9D). Finally, as graded by Dr. J. Greenson, a pathologist in 
our department, the SIRT6 deficient adenomas had a higher grade and, in some 
instances, showed invasive properties, a phenotype rarely seen in Apcmin/+ animals 
(Figure 3.9E). In these polyps, glycolytic (Figure 3.10A) and ribosomal (Figure 3.10B) 
gene expression were both elevated in Sirt6f/f; V-c; Apcmin/+ mice in comparison to their 
littermates. Strikingly, treatment of Sirt6f/f; V-c; Apcmin/+ mice and controls with the 
PDK1 inhibitor DCA specifically inhibited tumor formation in the absence of SIRT6 as 
we observed smaller, fewer and lower-grade tumors upon treatment with DCA (Figure 
3.9). Finally, to assess whether SIRT6 levels are altered in human adenomas, we  
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Figure 3.9: Increased tumorigenesis in SIRT6-deficient intestinal mouse model 
(A) PCR showing the floxed Sirt6 allele (left) and the Apc mutant allele (right). (B) 
Representative image of intestines from Sirt6f/f; V-c; Apcmin/+ and littermate controls. (C) 
Adenoma count in intestines of SIRT6-deficient Apcmin/+ mice and littermate controls. 
(D) Adenoma area from indicated mice (left) with representative images from 
hematoxylin and eosin (H&E) stained intestines (right). (E) Quantification of the tumor 
grade in indicated mice (left) with representative images of invasive phenotype in 
Sirt6f/f; V-c; Apcmin/+ mice. Tumor grading in figure E was carried out by Dr. J. Greenson 
(Sebastian et al., 2012). 
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Figure 3.10: Enhanced glycolytic and ribosomal gene expression in mouse 
adenomas 
Expression of various glycolytic (A) and ribosomal (B) genes in Sirt6 proficient and 
deficient adenomas derived from Apcmin/+ mice (n=3) (error bars indicate SEM). 
Experiments were performed by Dr. C. Sebastián (Sebastian et al., 2012). 
 
stained normal human colons and human adenomas for SIRT6 and observed a 
decrease in SIRT6 levels in adenomas in comparison to normal tissue (Figure 3.12).   
Overall our study shows that SIRT6 inhibits the initiation of colorectal cancer in vivo by 
repressing aerobic glycolysis and ribosomal gene expression (Figure 3.13). 
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Figure 3.11: Inhibition of glycolysis decreases tumorigenesis of SIRT6-deficient 
adenomas 
Tumor grade (A) and area (B) of Sirt6f/f; V-c; Apcmin/+ and Control; Apcmin/+ mice 
untreated or treated with DCA (5g/L). Experiments were performed by Dr. C. 
Sebastián, tumor grading was carried out by Dr. J. Greenson (Sebastian et al., 2012). 
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Figure 3.12: SIRT6 expression is decreased in human adenomas 
Immunohistochemistry for human SIRT6 in human normal colon and colorectal 
adenomas. Right column is higher magnification of middle column.  
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Discussion 
An increased incidence of neoplasia is a major feature of aging in mammals. SIRT6’s 
functions in regulating glucose homeostasis, genomic stability and cellular senescence 
have prompted multiple groups to assess roles for SIRT6 in cancer. Our work has 
revealed that SIRT6 functions as a tumor suppressor, at least in part by modulating 
cellular metabolism and c-Myc induced cellular proliferation. SIRT6-deficient mouse 
embryonic fibroblast cell lines, immortalized by a 3T3 serial passage protocol or p53 
knockdown, show increased proliferation relative to controls. In contrast to controls, 
these cells are able to form colonies in vitro and tumors in vivo. These results are 
consistent with a cell-autonomous tumor suppressor role for SIRT6. Furthermore, 
conditional deletion of Sirt6 in intestinal epithelial cells in the Apcmin/+ adenomatosis 
model results in a three-fold increase in the number of tumors, which are larger and of 
higher grade than lesions in littermate controls. Furthermore, SIRT6 protein levels are 
reduced in human adenomas relative to normal tissue. These data support a tumor 
suppressor role for SIRT6 in mice and potentially in humans as well.  
 
Molecularly, SIRT6 deficiency leads to increased levels of glycolytic gene expression. 
Ribosomal biogenesis and glutaminase expression are also elevated in the absence of 
SIRT6; these are regulated by the proto-oncogene c-MYC. Mechanistically, SIRT6 
interacts with c-MYC and deacetylates H3K56 at the promoters of c-MYC target genes, 
attenuating their expression. Inhibition of c-MYC in the absence of SIRT6 reduces 
cellular proliferation and inhibits tumor growth, indicating that SIRT6 acts as a tumor 
suppressor at least in part by inhibiting c-MYC activity. 
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Figure 3.13: Schematic overview of the role of SIRT6 as a tumor suppressor 
A first mutation in cell cycle or growth regulatory genes renders normal cells checkpoint 
defective. Inactivation of SIRT6 in these cells drives tumorigenesis through two distinct 
pathways: (1) enhancing glycolysis and (2) increasing Myc transcriptional activity and 
ribosome biogenesis. Figure adapted from (Sebastian et al., 2012) 
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In addition to targeting c-MYC, SIRT6 inhibits HIF-1α transcriptional activity resulting in 
decreased glycolysis. Cancer cells shift their energy production from mitochondrial 
respiration to glycolysis and lactate production (Warburg effect) (Warburg, 1956). Upon 
SIRT6 ablation, increased HIF-1α activity causes reprogramming of cellular 
metabolism by enhancing glucose uptake and glycolysis, providing SIRT6 deficient 
cells with tumorigenic potential. Conversion of pyruvate to lactate is the rate-limiting 
step in glycolysis, and blocking this step is able to enhance mitochondrial respiration, 
reducing proliferation and inhibiting colony formation of SIRT6-deficient cells. Similarly, 
treating adenoma-prone SIRT6 deficient mice with dichloroacetate (DCA), a small 
molecule that promotes mitochondrial respiration, reverts increased tumorigenesis of 
these mice in vivo. Finally, lower SIRT6 protein levels were observed in human 
adenomas. Consistent with this finding, decreased SIRT6 expression has been 
reported in hepatocellular carcinomas (HCC), and low levels of SIRT6 are associated 
with shortened time to recurrence in patients with this disease. Furthermore, liver-
specific SIRT6 KO mice have elevated levels of HCC biomarkers (e.g. AFP, IGF2 and 
H19) and re-expression of SIRT6 in HCC cell lines sensitizes these cells to 
chemotherapeutic drugs resulting in increased apoptosis (Marquardt et al., 2013a). 
This indicates that decreased SIRT6 expression in some tumors is correlated with 
more aggressive clinical behavior. 
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SIRT6 plays tumor suppressor functions in other contexts as well. Overexpression of 
SIRT6 can induce apoptosis specifically in cancer cells through p53 or p73 (Van Meter 
et al., 2011). P53 is a tumor suppressor that is mutated or inactivated in most human 
cancers. Both p53 and its homolog p73 are involved in cell cycle regulation and 
induction of apoptosis (Murray-Zmijewski et al., 2006). Additionally, SIRT6 can prevent 
tumor formation in liver cells by blocking RELA-mediated expression of survivin to 
promote cell survival (Min et al., 2012). Survivin is a member of the inhibitor of 
apoptosis (IAP) family and inhibits cell death. It is mainly expressed during 
embryogenesis and, with the exception of a few cell types, is not normally expressed in 
adult tissue (Church and Talbot, 2012). In human dysplastic liver nodules, c-JUN 
interferes with c-FOS transcriptional output. As Sirt6 is a target of c-FOS, c-JUN 
thereby inhibits Sirt6 expression. Decreased SIRT6 levels coincide with increased 
acH3K9 levels at the survivin promoter, allowing for increased NF-κB-driven 
expression of this gene (Min et al., 2012). Survivin is only upregulated during the 
initiation phase of liver cancer, as survivin levels were not altered in normal livers or in 
advanced hepatic carcinomas (Min et al., 2012). Furthermore, a recent study showed 
that Sirt6 mRNA levels are decreased in human non-small cell lung cancer (NSCLC) 
and that overexpression of SIRT6 in lung cancer cell lines decreased cellular 
proliferation by inhibiting the expression of Twist1 (Han et al., 2014). Finally, in breast 
cancer cell lines, SIRT6 is phosphorylated by AKT and consequently degraded by 
MDM2. Inhibition of MDM2 mediated degradation of SIRT6 suppresses cellular 
proliferation, and low levels of phosphorylated SIRT6 (Ser 338) is positively correlated 
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with breast cancer patient survival (Thirumurthi et al., 2014). These findings indicate 
that SIRT6 functions as a tumor suppressor in multiple tissues, and suggest that SIRT6 
activators could be useful therapeutic tools for cancer treatment, potentially in both 
early-stage and advanced lesions. 
 
 
Future directions 
Our striking results demonstrating SIRT6 as a potent tumor suppressor, raises the 
question whether SIRT6 activators would provide protection against tumor formation. 
Kanfi and colleagues demonstrated that whole body SIRT6 overexpressing mice have 
an extended lifespan (Kanfi et al., 2012) and it was postulated by others that this could 
be explained by a decrease in cancer incidence (Lombard and Miller, 2012). In a small 
pilot study we crossed Apcmin/+ mice with an inducible SIRT6 overexpressor, in which 
an extra copy of the Sirt6 gene, at the Rosa26 locus driven by a tet inducible promoter, 
was inserted in the genome. At five weeks of age, doxycycline was added to the 
drinking water resulting in whole body SIRT6 overexpression. After 150 days, mice 
were sacrificed and polyps were counted (Figure 3.14). We observed no difference 
between Sirt6 WT and Sirt6 OE Apcmin/+ mice, which could indicate that overexpression 
of SIRT6 does not provide additional protection against tumor development. It is also 
possible that SIRT6’s tumor suppressor function is dependent on co-factors, which 
could be the rate-limiting factor in increasing SIRT6 activity. Furthermore, we observed 
that the number of polyps in the Sirt6 OE mice varied strongly between each mouse, 
possibly due to the variability in doxycycline water consumption by each mouse. To 
overcome this issue, a constitutive SIRT6 overexpressor might be a more suitable 
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model (Kanfi et al., 2012). Finally, it is plausible that long-term treatment with 
doxycycline could have adverse effects, which could affect adenoma formation in vivo. 
Thus, due to many confounding factors, we cannot conclude at this point that high 
levels of SIRT6 provide additional protection against tumor formation. Further studies 
with either a constitutive Sirt6 overexpressor or with Sirt6 activators would be a 
superior approach. Aditionally, we could reexpress SIRT6 using adenoviral infection in 
our Apcmin/+ mouse model shortly after adenoma formation. Based on the role of SIRT6 
in suppressing aerobic glycolysis and c-MYC mediated cellular growth, we would 
assume that Sirt6 reexpression could prevent tumor growth and would support the 
therapeutic potential of SIRT6 activators, especially in tumors with the actived 
oncogene c-MYC. However, if Sirt6 reexpression is unable to rescue the enhanced 
tumorigenesis phenotype in Sirt6 mutant mice, SIRT6 likely exerts its tumor suppressor 
function through additional mechanisms.  
 
 
Figure 3.14: Polyp number in SIRT6 overexpressing mice 
Mice carrying an inducible SIRT6 OE system (Rosa 26) were crossed with Apcmin/+ 
mice. The number of adenomas were counted macroscopically at day 150 (n=3; Man 
Whitney t-test). 
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Despite our identification of a tumor suppressor function for SIRT6, multiple other 
groups demonstrated that SIRT6 possess tumor-promoting properties (Bauer et al., 
2012; Khongkow et al., 2013b; Liu et al., 2013). It is feasible that SIRT6 has different 
properties based on tumor stage, with protective properties in the initial stages of 
tumorigenesis and tumor enhancing traits in established cancer. Furthermore, it is 
likely that SIRT6’s role in cancer is tissue dependent. Thusfar, no other research group 
has assessed a role for SIRT6 in tumor development as all other studies were done 
using already established cancer cells. The pathways affected in the absence of 
SIRT6, as described in this chapter, are derailed in many cancer types. Thus it is likely 
that deletion of SIRT6 in other tumor models would provide a similar outcome. It would 
be of interest to develop additional mouse tumor models to assess the tumor 
suppressor role for SIRT6 in different tissues and to rule out a tissue specific effect of 
SIRT6.  
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Chapter 4 
 
SIRT6 protects against aneuploidy 
 
 
Abstract 
Identification of novel genes and pathways with functional roles in cancer holds 
out the eventual prospect of improved treatments. We recently identified a major 
function for SIRT6 as a tumor suppressor through the regulation of cellular 
metabolism. In addition to mediating glucose metabolism, SIRT6 plays a crucial 
role in maintaining genomic integrity by enhancing various DNA repair 
pathways. In this study we aspired to identify a second mechanism through 
which SIRT6 protects against tumorigenesis. We found that SIRT6 maintains 
normal chromosome number in mouse embryonic fibroblasts and intestinal 
epithelial cells. Aberrant chromosomal number is a major feature of human 
cancers. In this study we explore two potential pathways that can lead to 
aneuploidy in cells: major satellite repeat instability and elevated reactive 
oxygen species. 
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Introduction 
The acquisition of cancer hallmarks is in large part dependent on genomic instability 
and the accumulation of mutations (Hanahan and Weinberg, 2011). One form of 
chromosomal abnormality, as a result of genomic instability, is the gain or loss of whole 
chromosomes resulting in cells containing an odd chromosome number (= aneuploidy). 
At least one quarter of the genome of cancer cells is affected by chromosome copy 
number alterations (Beroukhim et al., 2010) and gain or loss of specific chromosomes 
is associated with particular cancer types. For example, loss of chromosome 3 is 
observed in 50% of melanomas tested, while an additional copy of this chromosome is 
detected in approximately 22% of multiple myeloma cases (Gordon et al., 2012). It is 
debated whether aneuploidy in cancer cells is a consequence of genome instability or 
a driver of tumorigenesis (Gordon et al., 2012). The consequences of aneuploidy can 
be two-sided. Individuals with trisomy 21 have a significantly increased incidence for 
hematological cancers, but a notable decrease in the occurence of solid tumors 
(Malinge et al., 2009). The maintenance of euploidy requires proper chromosome 
segregation. While a basal rate of spontaneous chromosome missegregation is 
common under tissue culture conditions, disruption of pathways or genes involved in 
this process can result in increased aneuploidy (Gordon et al., 2012). For example, 
centrosome amplification, which often occurs in tumors in vivo, has a strong correlation 
with chromosome instability (Pihan et al., 2003). Additionally, loss of major satellite 
repeats silencing has also been associated with increased aneuploidy. Major satellite 
repeats (MSR), a pericentromeric region comprised of an AT rich sequence of 
approximately 234bp, repeated about 10,000 times in every chromosome and making 
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up 10% of the mouse genome, play an important role in regulating chromosome 
separation during cell division (Guenatri et al., 2004). Furthermore, chromosome 
missegregation due to impaired MSR silencing has been associated with neoplasia 
(Bernard et al., 2001; David et al., 2006; Peters et al., 2001). The expression of MSRs 
is elevated in mouse tumors (Eymery et al., 2009; Ting et al., 2011), and enforced 
expression of this region is sufficient to induce genomic instability (Zhu et al., 2011). 
Alternatively, elevated reactive oxygen species (ROS), which are chemically reactive 
molecules that contain oxygen with one or more unpaired electrons, can induce 
aneuploidy. ROS cause the most frequent DNA damage in living cells and can trigger 
aneuploidy by interfering with some of the pathways involved in mitosis (Wang et al., 
2013). Numerous cellular defense mechanisms are in place to protect against ROS-
induced DNA damage, such as antioxidants and DNA repair systems. Malfunctioning 
ROS defense systems can therefore also drive aneuploidy.  
 
As discussed previously, SIRT6 deficiency results in genomic instability and increased 
sensitivity to DNA damaging agents due to SIRT6’s role in regulating several DNA 
repair pathways (Cardus et al., 2013; Kaidi et al., 2010; Mao et al., 2012; McCord et 
al., 2009; Mostoslavsky et al., 2006; Toiber et al., 2013). SIRT6 was initially postulated 
to play a role in BER (Mostoslavsky et al., 2006). While this finding has not been 
further explored, multiple studies have identified a role for SIRT6 in regulating DNA 
double strand break repair by recruiting a number of DNA repair factors to the 
breakage site (Kaidi et al., 2010; Mao et al., 2012; McCord et al., 2009; Toiber et al., 
2013). We previously reported that SIRT6 acts as a tumor suppressor protein by 
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regulating glucose metabolism; however the genomic instability observed in Sirt6-null 
cells suggests that SIRT6, at least in part, can protect against tumor initiation by 
inhibiting the accumulation of chromosomal aberrations. In this study we aimed to 
identify a second mechanism through which SIRT6 protects against tumorigenesis. 
 
Materials and Methods 
Cell culture 
In our studies we used mouse embryonic fibroblasts (MEFs), which were isolated from 
C57Bl/6 wild type and Sirt6 knockout embryos (E13.5) according to standard 
conditions. MEFs were grown in DMEM supplemented with 15% fetal bovine serum, 
1% L-Glutamine, 1% pen/strep, 1% sodium pyruvate, 1% non-essential amino acids, 
2% HEPES and 115 µl beta-mercaptoethanol. MEFs were grown at low oxygen 
conditions, split 1:3 with each passage and maintained in culture up to passage 8. For 
the aneuploidy study, MEFs were cultured for 4 passages in normoxia prior to inducing 
cell cycle arrest in metaphase with colcemid (Life Technologies). Wild-type and 
Suv39h1/2 KO immortalized MEFs (iMEFs) were grown in the same media as the 
primary MEFs. 
Wild type and Sirt6 KO embryonic stem (ES) cells were used for endogenous co-
immunoprecipitation of SIRT6. ES cells were grown on 0.2% gelatin coated plates in 
MEF media supplemented with LIF (Invitrogen). 
Intestinal epithelial cells (IEC-6) were grown in DMEM supplemented with 10% FBS, 4 
mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 0.1 Unit/ml bovine 
insulin. 
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Metaphase spreads 
Mouse embryonic fibroblasts were treated with colcemid (10 µg/ml) for 4 hours to 
arrest cells in metaphase. MEFs were harvested, washed twice with PBS and 
resuspended in 0.4% KCl. After 15 minutes of incubation at 37°C, 2 ml of freshly 
prepared fixative (methanol:glacial acedic acid – 3:1) was added. The cells were 
pelleted at 1200 rpm for 8 minutes and subsequently subjected to 4 rounds of fixation – 
10 ml of fixative was slowly added to the cell pellet while gently vortexing the tube and 
spun down. Finally the fixed cells were resuspended in a small amount of fixative, 
dropped on slides and mounted with prolong gold containing dapi stain (Invitrogen). 
 
Immunoprecipitation 
HCT116 cells knocked down for Sirt6 (shRNA TripZ vector) (see chapter 5) were 
transfected with the pCDNA3.1 vector containing human FLAG-SIRT6 using 
Lipofectamine LTX reagent (Life Technologies). After 48 hours, cells were gently 
scraped of the dish and washed twice in PBS. The cell pellet was resuspended in cell 
lysis buffer (1% triton x-100, 0.5% NP-40, 150 mM NaCl, 50 mM Tris pH 7.4, 10% 
glycerol, protease inhibitor cocktail (Roche)) and allowed to lyse for 30 minutes on ice. 
Cells were sonicated for 2 x 20 seconds using a Branson Sonifier 450 sonicator at 
2.5% output control and 50% duty cycle. After centrifugation, the supernatant was 
collected and protein concentration was measured using DC assay (Bio-Rad).  
For the immunoprecipitation, 50 µl of protein G agarose beads (Roche) were added to 
2 mg protein lysate diluted in a total volume of 1ml lysis buffer and rotated for 1 hour at 
4°C to preclear. The samples were spun down for 5 minutes at 1000 rpm and the 
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pelleted beads were discarded. The supernatant was subsequently incubated 
overnight in 50 ul of FLAG-M2 agarose beads (Sigma).  The samples were spun down 
5 minutes at 1000 rpm in a refrigerated tabletop centrifuge at 4°C. The supernatant 
was discarded and the beads were washed 3 times in 1 ml lysis buffer. FLAG-SIRT6 
was eluted 2 times using 250 ng/ml of FLAG peptide in PBS + proteinase inhibitors by 
rotating 15 minutes at RT and both elutions were combined. IP reactions were 
fractionated on a 4-20% gradient gel (Bio-Rad) and proteins were subsequently 
visualized with Coomassie stain (BioRad). Mass spectrometry was performed to 
identify proteins co-immunoprecipitated with FLAG-SIRT6. 
For endogenous IPs, mouse embryonic stem cells were grown in a 15 cm dish and 
harvested at 90% confluency. Nuclei were isolated by resuspending the cell pellet in 
hypotonic buffer (10 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT) 
supplemented with 0.5% NP-40 and proteinase inhibitor cocktail (Roche), incubated on 
ice for 10 minutes and spun down for 5 minutes at 500 x g. The pellet was washed 
once in hypotonic buffer and then resuspended in lysis buffer (450 mM NaCl, 20 mM 
HEPES and 0.5% NP-40. After rotation at 4°C for 20 minutes, the samples were 
sonicated using a Branson Sonifier 450. Subsequently, the samples were treated with 
DNase for 25 minutes in a 37°C water bath and spun down at maximal speed at 4°C to 
discard of any cellular debris. At this point, protein concentration was measured (DC 
assay, BioRad) and 1 mg of protein was diluted with 20 mM HEPES + proteinase 
inhibitor cocktail to a final concentration of 115 mM NaCl, 20 mM HEPES and 0.125% 
NP-40. Samples were pre-cleared with protein A agarose beads (Invitrogen) for 1 hour 
on a rotator at 4°C. After removal of the beads with a brief centrifugation, the protein 
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samples were incubated with mouse SIRT6 antibody (Cell Signaling) overnight at 4°C 
on a rotator. Mouse SIRT6 was precipitated with protein A agarose beads, washed 
three times in 115 mM NaCl, 20 mM HEPES, 0.125% NP-40 and proteinase inhibitor 
cocktail. Beads were boiled in 2x Laemmli buffer (100mM Trish-HCl pH 6.8, 2% SDS, 
20% glycerol, 4% beta-mercaptoethanol and a dash of bromophenol blue).  
 
Chromatin immunoprecipitation (ChIP) 
ChIP was performed using standard conditions (see chapter 3). MEFs were cross-
linked using formaldehyde, lysed and sonicated to obtain 200-1000bp DNA fragments. 
For each immunoprecipitation reaction, 10 µg protein was used. The following 
antibodies were utilized for ChIP to MSR: rabbit anti-mSIRT6 (Cell Signaling 
Technologies), rabbit anti-H3K9ac (Abcam), rabbit anti-H3K56ac (Abcam), rabbit anti-
H3K9me3 (Abcam), rabbit anti-H3K56me3 (kind gift of Dr. S Hake), and rabbit anti-
KAP1 (Abcam). 
 
Real-time PCR 
Wild type and Sirt6 KO MEFs were grown to 80% confluency, harvested and lysed in 
TRIzol reagent (Life Technologies). According to manufacturer’s instructions, RNA was 
further isolated by performing phenol:chloroform (pH 4.3) extraction and subsequently 
precipitated with 100% ethanol. The RNA pellet was washed once in 75% ethanol and 
resuspend in RNAse/DNAse free water. 50 µg RNA was treated with 5 µl DNAseI 
(Roche) according to the manufacturer’s instructions, subjected to phenol/chloroform 
extraction and resuspended at a final concentration of 500 ng/µl in DNAse/RNAse free 
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water. Reverse transcription was performed using the high capacity cDNA reverse 
transcription kit (Life Technologies) and quantitave PCR was performed using SYBR 
green select PCR master mix (Life Technologies). Primers for the detection of major 
satellite repeat transcripts: MSR 5’ GACGACTTGAAAAATGACGAAATC, MSR 3’ 
CATATTCCAGGTCCTTCAGTGTGC. 
 
Northern Blot 
Total RNA was extracted from WT and Sirt6 KO MEFs using TRIzol reagent 
(Invitrogen), according to the manufacturer’s instructions.  Precipitated RNA was 
resuspended in 500 ml of RNAse-free H2O and incubated at 56ºC for 10 minutes and 
returned to room temperature. To remove contaminating genomic DNA, RNA was 
incubated with 100 units of RNAse-free DNAse I (Roche) at 37ºC for 30 minutes in the 
presence of 40 units of RNAse inhibitor (Roche).  RNA was precipitated with two 
rounds of phenol (pH 5.2):chloroform extraction was preformed, followed by a final 
extraction using only chloroform.  RNA was then ethanol precipitated in the presence of 
0.3 M sodium acetate pH 5.2 overnight at -20ºC, spun down and washed twice with 
500ml of 70% ethanol. RNA was resuspended in RNAse-free H2O.  RNA integrity was 
confirmed by gel electrophoresis. 
An equal volume of NorthernMax-Gly Sample Loading Dye (Ambion) was added to 5 
mg of total RNA and incubated for 30 minutes at 56ºC. Samples were resolved on a 
1% Bis-Tris-PIPES-EDTA agarose gel at 5 V/cm (as measured between electrodes).  
Resolved RNA was transferred overnight onto a pre-wet Zeta Probe membrane (Bio 
Rad) by upward capillary action using 10X SSC as the solvent. Once transferred, the 
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membrane was briefly rinsed in 2X SSC and UV crosslinked in a Stratalinker 
(Stratagene). The membrane was prehybridized for 1 hour at 68ºC in ULTRAhyb 
Hybridization Buffer (Ambion). During prehybridization, 1 mg of the MSR dsDNA 
template containing the T7 promoter was used to generate a radiolabelled riboprobe 
using the T7 MAXIscript Kit (Ambion) and isotopically labeled UTP, [a-32P] (Perkin 
Elmer), according to manufacturer’s instructions. The labeled probe was purified in a 
MicroSpin G-25 column (GE Healthcare). The prehybridized membrane was incubated 
with the probe overnight at 68ºC and washed for 30 minutes at 68ºC twice in 2X SSC, 
twice in 2X SSC, 0.1% SDS and twice in 0.1X SSC, 0.1%SDS. The membrane was 
imaged by autoradiography.   
 
Immunocytochemistry 
MEFs were grown on chamberslides (BD biosciences) for 24 hours prior to staining. 
Each well was briefly washed with 1x PBS, CSK buffer (100 mM NaCl, 300 mM 
sucrose, 3 mM MgCl2, 10 mM PIPES, at final pH 6.8) and subsequently incubated in 
CSK/0.5% Triton x100 for 5 minutes. After a wash in CSK, cells were fixed in 3% PFA 
in PBS for 10 minutes.  Following 30 minutes of incubation in blocking buffer (1% BSA, 
0.1% Tween-20 in PBS), cells were treated for 1 hour with primary antibody in blocking 
buffer: rabbit anti-KAP1 (Abcam), 1:100; rabbit anti-HP1α (Abcam), 1:50; rabbit anti-
H3K9me3 (Abcam), 1:100; rabbit anti-H3K56me3 (kind gift of Dr. S Hake), 1:200. 
Slides were washed three times in PBST (PBS with 0.2% Tween-20), incubated in 
blocking buffer containing FITC conjugated goat anti-rabbit (Invitrogen, 1:200) for 30 
minutes, and washed again in PBST. Slides were mounted with ProLong Gold antifade 
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mounting media with DAPI (Life Technologies) and imaged with an Olympus BX-51 
scope with an Olympus DP-70 high-resolution digital camera (University of Michigan 
Microscopy & Image Analysis lab). 
 
Immunoblot analysis 
For analysis of immunoprecipitated samples, 25% of the immunoprecipitate was 
fractionated on 4-20% gradient gels (Bio-Rad), transferred to PVDF membranes, and 
probed with the following antibodies in TBST/5% milk at the dilutions indicated: rabbit 
anti-HP1α (Abcam), 1:1000; rabbit anti-HP1β (Abcam), 1:1000; rabbit anti-HP1γ 
(Abcam) 1:1000; mouse anti-SPT16 (Santa Cruz Biotechnology), 1:500; mouse anti-
SSRP1 (Santa Cruz Biotechnology), 1:500; rabbit anti-mouse SIRT6 (Cell Signaling), 
1:1000; rabbit anti-H3 (Abcam), 1:10.000; rabbit anti-HMGB1 (Proteintech), 1:1000.  
 
NAC treatment mice 
Apcmin/+ with specific deletion of Sirt6 in the mouse epithelial cells (Sirt6f/f; V-c) were 
bred and instestines were harvested and processed as previously described (Chapter 
3). Mice treated with the antioxidant N-acetyl cysteine (NAC) were given drinking water 
containing 40 mM NAC (Sigma) starting at two months of age. Water bottles were 
exchanged every 5 days.  
 
ROS levels 
In each well of a 6-well dish 2 x 105 WT or Sirt6 KO MEFs were plated for 3 different 
treatment conditions: untreated, H2O2 or NAC (Sigma). The NAC treated cells were 
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grown in culture media supplemented with 1 mM NAC for 24 hours prior to harvesting. 
Four hours prior to harvesting fresh media was added to the cells. Cells were treated 
with 5 µM DCFDA (dichlorofluorescin diacetate; Invitrogen) for 30 minutes and 
harvested with trypsin. After two washes with PBS, the cells were resuspended in PBS. 
For the treatment groups, the PBS was supplemented with 0.03% H2O2, or 1 mM NAC. 
After an incubation of 15 minutes at room temperature in the dark, the cells were 
analyzed using a FACSCanto II and a 488 nm laser provided by the University of 
Michigan flow cytometry core facility. 
 
Oxidative damage detection 
Oxidative DNA damage was detected using an antibody-based immunoassay (DNA 
damage – AP site-assay kit; Abcam). The assay was performed according to 
manufacturers instructions. Briefly, Sirt6 WT and KO MEFs were plated in 6-well 
dishes in the presence or absence of NAC. After 48 hours, cells were harvested 
through trypsinzation, fixed and incubated over night in ARP-binding solution. After a 
DNA denaturing step, the cells were incubated in a blocking solution and consequently 
stained with avidin-FITC. The samples were analyzed using a FACSCanto II and a 
488nm laser provided by the University of Michigan flow cytometry core facility.  
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Results 
Increased aneuploidy in the absence of SIRT6 
Numerous studies have indicated that SIRT6-deficient cells are more sensitive to DNA 
damaging agents and have an increased number of chromosomal aberrations (Cardus 
et al., 2013; Kaidi et al., 2010; Mao et al., 2012; McCord et al., 2009; Mostoslavsky et 
al., 2006; Toiber et al., 2013). Mostoslavsky et al. identified elevated anomalies such 
as chromosome breaks and detached centromeres. In order to determine if these 
chromosomal abnormalities could explain the increased tumor incidence in SIRT6 
deficiency, we made metaphase spreads from WT and Sirt6 KO MEFs. In contrast to 
previous report, we did not observe chromosomal aberrations such as chromosomal 
breaks and detached centromeres (Figure 4.1A) however we did find increased 
aneuploidy in Sirt6 KO MEFs in comparison to littermate controls. While a certain 
degree of aneuploidy is expected in primary cells due to increased oxidative damage 
as a result of ex vivo tissue culture (Foudah et al., 2009; Liu et al., 2012; Miyai et al., 
2008), the absence of SIRT6 resulted in up to two-fold increase of anueploid cells in 
comparison to littermate controls (Figure 4.1B-C). Furthermore, when Sirt6 was 
knocked down in immortalized rat intestinal epithelial cells (IEC-6) using a constitutive 
knockdown vector (GipZ), we again observed an increase in aneuploidy (Figure 4.1D). 
This data suggests that SIRT6 can protect against chromosome gain or loss in both 
primary and immortalized cells. 
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Figure 4.1: SIRT6-deficient cells show increased aneuploidy 
 (A) Metaphase spread of WT and Sirt6 KO MEFs stained with Dapi. (B) percentage of 
aneuploid metaphase spreads in four sets of WT and Sirt6 KO MEFs (n=50-115 
spreads/cell line). Two sets were tested for aneuploidy by Dr. J. van Deursen and 
Janine Van Ree. (C) Percentage of cells containing the indicated number of 
chromosomes from the MEFs mentioned in (B). (D) Percentage of aneuploid IEC-6 
cells, IEC-6 infected with control GipZ vector and IEC-6 infected with Sirt6 KD GipZ 
vector. Experiments were done in collaboration with M. Skinner. 
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SIRT6 interacts with chromatin silencing factors 
In conjunction with our aneuploidy study, we performed mass spectrometry in 
collaboration with Dr. Elenitoba-Johnson and Dr. Basrur to identify novel SIRT6 
interactors. In this study, we transfected HCT116 cells with pCDNA3.1 FLAG-SIRT6 or 
empty vector and isolated SIRT6 with its interactors via FLAG IP. On a Coomassie 
stain we saw enrichment for SIRT6 and could identify histones, which SIRT6 is known 
to interact with (Figure 4.2A). Furthermore, mass spectrometry revealed a number of 
other known interactors of SIRT6, such as PARP1, which we confirmed by immunoblot 
(Figure 4.2A). In addition to these known SIRT6 binding partners, we identified a series 
of novel SIRT6 interactors that play a role in silencing and/or chromatin remodeling. 
Two such factors are KAP1 (KRAB-associated protein 1) and HP1β/γ (heterochromatin 
protein 1) (Figure 4.2B). KAP1 binding to the chromatin mediates gene silencing by 
suppressing H3K9 acetylation, promoting H3K9 methylation and recruiting HP1 to 
inhibit gene expression (Iyengar and Farnham, 2011; White et al., 2012). Thus KAP1 is 
a scaffold protein that assembles epigenetic factors and interacts with histone methyl 
transfereases and HDACs to remodel chromatin. To verify the mass spectrometry data, 
we performed endogenous SIRT6 IP in mouse WT and Sirt6KO ES cells. We 
confirmed that SIRT6 interacts with KAP1 and the three members of the HP1 protein 
family (HP1α, β and γ) (Figure 4.2C). In addition, SIRT6 binds both members of the 
FACT (facilitates chromatin transcription) complex, SPT16 and SSRP1, which are 
involved in multiple processes such as mRNA elongation, DNA replication and DNA 
repair (Figure 4.2C). Furthermore, we were not able to IP HMGB1,  
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Figure 4.2: SIRT6 interacts with silencing factors 
HCT116 cells containing shSirt6 TripZ vector were transfected with pCDNA3.1 FLAG-
SIRT6 or control vector and subjected to FLAG IP. (A) Coomassie stain of FLAG IP, 
red arrow indicates FLAG-SIRT6 band (top). The presence of SIRT6 and known 
interactor PARP1 were confirmed by immunoblot (below). (B) List of chromatin factors 
that were identified using mass spectrometry. Red factors indicate previously described 
interactors. (C) Endogenous IP of mSIRT6 in mouse ES cells shows interaction of 
SIRT6 with the chromatin factors SPT16, SSRP1, KAP1, HP1α/β/γ and histone H3. No 
iteraction of SIRT6 with HMGB1 was found. Mass spectrometry was performed in 
collaboration with Dr. K. Elenitoba-Johnson and Dr. V. Basrur. 
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which, according to our mass spectrometry data, is a chromatin factor that does not 
interact with SIRT6 (Figure 4.2C). 
 
 
 
Figure 4.3: Hypothesis for SIRT6 mediated aneuploidy 
SIRT6 binds and deacetylates Histone H3 residues at MSR, resulting in their 
methylation. In doing so, SIRT6 recruits the silencing factors KAP1 and HP1 to aid in 
compacting the DNA structure and prevent MSR expression. In the absence of SIRT6, 
histone acetylation at MSR results in high MSR expression and causes aneuploidy. 
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SIRT6 does not regulate histone modifications at MSR   
The majority of aneuploidy occurs due to improper chromosome segregation (Gordon 
et al., 2012). Considering the importance of MSR stability in maintaining euploidy, that 
SIRT6 interacts with numerous silencing factors and the fact that yeast SIR2 has been 
shown to silence heterochromatin (Kaeberlein et al., 1999), we hypothesized that 
SIRT6 maintains proper chromosome number by deacetylating histone H3 at the MSR 
region, enhancing H3 methylation and recruiting the silencing factors KAP1 and HP1 
(Figure 4.3).  
 
To test whether SIRT6 plays a role in regulating pericentromeric heterochromatin, we 
performed a series of ChIP experiments in which we assessed SIRT6 binding to the 
MSR, the level of acetylation and methylation at MSR, and KAP1 interaction with MSR 
in response to Sirt6 deletion. Due to the high abundance of MSR in the mouse genome 
and, consequently, the high risk of sample contamination, we first tested if we could 
observe a change in histone modification in immortalized Suv39h1/2 WT and KO 
MEFs. SUV39H1/2 is a methyltransferase that methylates H3K9 at pericentric 
heterochromatin (Peters et al., 2001). Loss of SUV39H1/2 results in hypomethylation, 
increased MSR expression and increased chromosomal instabilities associated with an 
elevated tumor incidence (Peters et al., 2001). As predicted, loss of SUV39H1/2 
resulted in a decrease in H3K9me3 levels, which coincided with an increase in H3K9ac 
(Figure 4.4A). However, we were unable to observe an interaction of SIRT6 with the 
MSR (Figure 4.4B), nor did we see a change in histone modifications  
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Figure 4.4: SIRT6 does not bind or regulate MSR 
 (A) ChIP of indicated histone marks at MSR in WT and Suv39h1/2 KO iMEFs. (B) 
ChIP for SIRT6 to MSR (n=5). (C) ChIP for histone trimethylation to MSR in WT and 
Sirt6 KO MEFs (n=6). (D) ChIP for H3K9ac (n=2) and H3K56ac (n=4) to MSR in same 
MEFs as (C). (E) ChIP for KAP1 to MSR same MEFs as (C) (n=6). N-value represents 
biological replciates 
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Figure 4.5: SIRT6 does not alter histone trimethylation in MEFs 
Immunocytochemistry of WT and Sirt6 KO MEFs for H3K9me3 (A) and H3K56me3 (B). 
The fluorescence intensity was measured using ImageJ (n= ~30 cells) and represented 
in bar graphs (right). 
 
 
in response to Sirt6 deletion (Figure 4.4C-D). Finally, the interaction of KAP1 at the 
MSR was not disrupted in SIRT6-deficient MEFs. These results indicate that SIRT6 
does not bind and deacetylate its known histone H3 targets at the MSR and it does not 
impact KAP1 recruitment to the MSR. 
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Histone H3 Lysine 9 and 56 methylation are not altered in SIRT6-deficient cells 
To verify these findings, we performed immunocytochemistry for H3K9 and H3K56 
trimethylation, marks for silenced chromatin (Jack et al., 2013; Peters et al., 2002; 
Peters et al., 2001), on WT and Sirt6 KO MEFs.  Heterochromatic regions can be 
visualized by Dapi staini as they appear as small bright foci in the nucleus. H3K9me3 
and H3K56me3 levels were similar in WT and KO MEFs (Figure 4.5A-B). Even more 
so, in both cell lines the histone marks overlapped perfectly with the heterchromatic 
foci suggesting that SIRT6 might not regulate these histone modifications at these 
regions.  
 
MSR expression is not regulated by SIRT6 
Increased expression of MSR is a measure of altered MSR regulation which can 
impact MSR stability. Therefore, we isolated RNA from WT and Sirt6 KO MEFs, and 
from WT and Sirt6 KO ES cells and performed RT- PCR and northern blot for the MSR. 
As a positive control we included WT and Suv39h1/2 KO iMEFs, which, as predicted, 
showed a dramatic increase in MSR expression in the absence of SUV39H1 (Figure 
4.6A-B). Unlike SUV39H1, SIRT6 does not impact MSR expression levels ES cells or 
MEFs. A slight increase was observed in one of the Sirt6 KO ES cell lines, but not in 
the second KO cell line (Figure 4.6B). The ES cells used for these experiments are not 
littermate controls, and thus slight biological variation between these cell lines can be 
expected. 
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Figure 4.6: MSR expression is not regulated by SIRT6 
 (A) Real-time PCR for MSR expression in indicated cell lines. (B) northern blot 
analysis for MSR RNA transcripts using same cell lines as in (A). Experiment in figure 
B was performed by W. Giblin. 
 
 
SIRT6 does not impact KAP/HP1 localization and protein levels 
Finally, we tested by immunocytochemistry whether protein levels or localization of the 
silencing factors HP1 and KAP1 was affected with respect to SIRT6 status. In both WT 
and Sirt6 KO MEFs, HP1α and KAP1 appeared to be associated with the 
heterochromatic foci in these cells (Figure 4.7). Furthermore, we did not observe a 
change in protein levels, as measured by fluorescence intensity, between genotypes 
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(Figure 4.7). We can conclude that, despite SIRT6’s interaction with these factors, 
SIRT6 is not responsible for their protein stability or their interaction with 
pericentromeric MSR. 
 
 
Figure 4.7: SIRT6 does not regulate protein level or localization of silencing 
factors 
Immunocytochemistry of HP1α (A) and KAP1 (B) in WT and Sirt6KO MEFs. 
Fluorescence intensity was measured using ImageJ (n=~30 cells) and represented in 
bar graphs (right). Experiments were done in collaboration with K. Smith. 
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The antioxidant NAC rescues tumorigenesis in absence of SIRT6 
Based on the above data the SIRT6 dependent aneuploidy cannot be explained by 
impaired regulation of MSR. Another possible culprit of aneuploidy is abnormal levels 
of reactive oxygen species (ROS) (Wang et al., 2013). Thus we hypothesized that high 
levels of ROS in SIRT6 could lead to aneuploidy and subsequently an increase in 
tumorigenesis in the absence of SIRT6. To test this hypothesis we treated Apcmin/+ 
mice lacking SIRT6 in the intestinal epithelial cells (chapter 3) with the antioxidant N-
acetyl cysteine (NAC) for two months. At four months, the mice were sacrificed and 
polyp numbers were counted. While we saw an increase in polyp number in the 
absence of SIRT6, treatment with NAC completely rescued this phenotype in SIRT6 
conditional mutant mice (Figure 4.8A-B). Furthermore, the polyps of SIRT6 deficient 
NAC treated mice were of equal grade as their littermate controls (Figure 4.8C). These 
results indicate that treatment with the antioxidant NAC can rescue the increased 
tumorigenesity seen in Apcmin/+; V-c; Sirt6f/f mice.  
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Figure 4.8: NAC treatment rescues increased tumorigenesis in absence of SIRT6 
 (A) increased polyp number observed in Sirt6f/f; V-c; Apcmin/+ mice in comparison to 
their littermate controls (Sebastian et al., 2012). (B) Similar mice as in (A) but subjected 
to NAC treatment. (C) tumor grading of Sirt6f/f; V-c; Apcmin/+ mice and littermate controls 
treated with NAC. Tumor grade was analyzed by Dr. J. Greenson. 
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SIRT6 does not regulate ROS levels or ROS induced DNA damage   
Next we tested if SIRT6 deficient cells showed altered ROS levels. Therefore we took 
WT and Sirt6KO MEFs and measured ROS using the compound DCFDA, a fluorescent 
dye that measures various ROS such as peroxyl, alkoxyl, carbonate and hydroxyl 
radicals (Eruslanov and Kusmartsev, 2010). As a positive control, we treated MEFs 
with hydrogen peroxide to increase ROS levels and pre-treated MEFs with NAC to 
decrease ROS. When analysed by FACS (fluorescent activated cell sorter), we indeed 
observed an increase and decrease in ROS upon H2O2 and NAC treatment 
respectively. However, we did not observe altered ROS levels in the absence of SIRT6 
(Figure 4.9).  
Next we determined oxidative DNA damage in the absence of SIRT6 by using a probe 
that binds specifically to aldehyde groups, which are a result from DNA modifications. 
While treatment with the compound EGCG (epigallocatechin gallate) increased 
oxidative damage when used at high concentrations, and NAC was able to reduce 
oxidative DNA adducts, we again were unable to detect a difference between WT and 
Sirt6 KO MEFs (Figure 4.10). Based on the lack of changes in ROS or oxidative DNA 
damage upon Sirt6 deletion, we can conclude that SIRT6 does not seem to regulate 
intracellular ROS levels and thus changes in ROS is likely not the underlying cause of 
the previously observed aneuploidy.  
 
 
 
	   119	  
 
Figure 4.9: ROS levels are unaltered in SIRT6 null cells 
ROS levels were measured with DCFDA compound in MEFs untreated, or treated with 
NAC or H2O2 (n=3). Data is represented in a bar graph as percentage of cells gated in 
the histogram graphs below. 
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Figure 4.10: SIRT6 does not affect oxidative DNA damage 
Oxidative DNA damage in WT and Sirt6 KO MEFs untreated, or treated with NAC or 
EGCG (n=1). Data is represented in a bar graph as percentage of cells gated in the 
histogram graphs below. 
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Discussion 
The six hallmarks of cancer encompass those traits that cells acquire to become 
carcinogenic. Hannahan and Weinberg, in their most recent review, described the 
concept of enabeling characteristics, mechanisms through which the cancer hallmarks 
can be obtained (Hanahan and Weinberg, 2011). The mutational rate in primary cells is 
generally very low due to the abundant genome maintenance mechanisms that are in 
place. However, the acquisition of a mutation in one of the genome surveillance and 
repair pathways can accelerate the mutational rate, leading to the acquisition of 
additional genomic alterations that provide the cells survival and growth advantage 
(Hanahan and Weinberg, 2011). Considering the role of SIRT6 in guarding genomic 
integrity and the aneuploidy defect that we observe in SIRT6 deficient cells, loss of 
SIRT6 could well be an enabler of tumorigenesis. Therefore we sought to investigate 
the underlying mechanism responsible for SIRT6’s role in mediating euploidy.  
The pericentromeric heterochromatic major satellite repeat region is essential in proper 
chromatid segregation during mitosis. Disruption of MSRs due to improper silencing 
and higher MSR expression can result in aneuploidy and increased cancer incidence 
(Bernard et al., 2001; David et al., 2006; Ekwall et al., 1997; Peters et al., 2001). SIRT1 
was previously shown to interact with the pericentromeric MSRs where it deacetylates 
H1K26. While treatment with the sirtuin inhibitor NAM could enhance MSR expression, 
SIRT1 stable knockout cells did not alter MSR transcript levels, suggesting the 
involvement of other sirtuin proteins (Oberdoerffer et al., 2008). Our results indicate 
that SIRT6, in addition to SIRT1, does not silence MSR. Despite the previous report 
that SIRT6 co-localizes with heterochromatin (Michishita et al., 2005), we were unable 
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to detect an association of SIRT6 with MSR or identify SIRT6 mediated epigenetic 
alterations at these repeats. However, a recent study did identify SIRT6 as a potent 
silencer of LINE-1 (long interspersed nuclear element-1) retrotransposons. 
Mechanistically, SIRT6 binds the 5’ UTR of LINE-1 elements where it raises H3K9me3 
levels and recruits the chromating silencing factors KAP1 and HP1α (Van Meter et al., 
2014). LINE-1 elements are long DNA repeats that actively translocate to different 
regions within the genome with each cell cycle. While no relationship exists between 
LINE-1 elements and aneuploidy, derepressed LINEs are associated with genomic 
alterations such as DNA double strand breaks (Gasior et al., 2006; Gilbert et al., 2002; 
Iskow et al., 2010), and can be found in human lung carcinomas (Iskow et al., 2010). 
Therefore, it is likely that the protection against DNA damage by silencing LINE-1 
elements provides an additional mechanism through which SIRT6 protects against 
tumor formation. 
The aneuploidy phenotype in SIRT6-null cells could not be explained by changes in 
ROS levels either. While it has previously been shown that SIRT6 responds to 
oxidative stress by relocating to DNA damage sites (Mao et al., 2012), SIRT6 does not 
appear to impact ROS levels itself in vitro, nor do SIRT6 deficient cells show more 
oxidative DNA damage. In some respect this seems surprising as SIRT6 deficient cells 
are more glycolytic, and thus should generate less ROS. However, treatment of Sirt6f/f; 
V-c; Apcmin/+ mice with the antioxidant NAC resulted in a rescue of the increased 
tumorigenesis phenotype in the absence of SIRT6, insinuating that NAC protects 
against tumorigenesis in these mice through an alternate mechanism. As aneuploidy is 
predominantly a result of chromosome missegregation, an in depth study of mitosis in 
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SIRT6 deficient cells might reveal the underlying mechanism of SIRT6-mediated ploidy 
changes. 
 
Future directions 
Even though changes in ROS are not the underlying mechanism for the increased 
aneuploidy in the absence of SIRT6, we were able to rescue the increased 
tumorigenesis in our Apcmin/+; V-c; Sirt6f/f mice by treating them with the antioxidant 
NAC. In our study we identified elevated aneuploidy in MEFs and we were able to 
rescue the tumorigenesis in vivo with NAC treatment, though at this point we don’t 
know if treatment of MEFs with NAC can protect against ploidy changes or if the 
adenomas in our Apcmin/+ model show a higher degree of aneuploidy. Nevertheless, the 
tumor suppression of NAC in SIRT6 deficient intestines would be worthwhile exploring 
further. As previously mentioned, Hanahan and Weinberg discussed the existence of 
two emerging hallmarks: genome instability and tumor-promoting inflammation 
(Hanahan and Weinberg, 2011). Virtually every tumor contains some level of immune-
infiltrate, which was historically viewed as an anti-tumor strategy. While this might still 
be the case in some instances, immune cells can also help tumor cells acquire 
additional cancer hallmarks, e.g. by supplying growth or angiogenic factors. Immune 
cells secrete ROS that can result in an increased mutational rate in cancer cells. Thus 
the decrease in tumorigenesis through NAC treatment could be a result of inhibition of 
ROS secreted by the immune cells. In a small pilot experiment, we analyzed intestines 
from our Apcmin/+; V-c; Sirt6f/f and control mice for cytokine levels (Figure 4.11). 
Cytokines are small proteins that are secreted by various cells to regulate the behavior 
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of others. In this experiment we identified a striking increase in interleukin-17 (IL-17) 
levels in SIRT6-deficient tissues. IL-17 can be produced by various immune cells such 
as T-helper cells, natural killer cells (NK cells) and neutrophils, and elicits a pro-
inflammatory response (Lonnberg et al., 2014). Furthermore, high IL-17 levels are 
associated with increased tumor growth (Chang et al., 2014; Cochaud et al., 2013; He 
et al., 2012; Wu et al., 2013; Xiang et al., 2013). While we are not aware how and in 
what cell type IL-17 is produced and what the subsequent role of IL-17 is in this setting, 
it is plausible that SIRT6 deficiency indirectly causes an immune response, resulting in 
increased proliferative potential of the surrounding epithelial cells.  
 
 
Figure 4.11: IL-17 is elevated in SIRT6-deficient colorectal adenomas 
Frozen intestine sections of Apcmin/+; V-c; Sirt6f/f and Apcmin/+ control mice were 
processed and tested for indicated cytokines using the Bio-Plex Multiplex system 
(BioRad). (A) IL-13 levels were elevated in WT versus Apcmin/+ mice (n=3). (B) In the 
absence of SIRT6 in the intestinal epithelial cells, IL-17a and IL-17F cytokine levels 
were significantly higher than in control tissue (n=3). (Dr. S. Mukherjee; n-values 
represents technical replicates) 
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Chapter 5 
 
A study of SIRT6 localization in cancer 
 
 
Abstract 
SIRT6 is a member of the sirtuin family of NAD+-dependent protein deacetylases 
that promote longevity in C. elegans, Drosophilla and yeast. We, and others, 
have shown that SIRT6 deacetylates histone 3 acetylated at lysine 56 (H3K56ac), 
a histone mark that is elevated in many tumor types. Additionally, SIRT6 
deficiency increases susceptibility to tumor development. We assessed the 
expression and localization pattern of SIRT6 in cancer and identified high SIRT6 
protein levels in both nuclear and cytoplasmic fractions of the cell. Our data is 
suggestive of loss of SIRT6-mediated H3K56 deacetylation in cancer cells and of 
a role for SIRT6 in transcriptional regulation of mitochondrial genes. 
Furthermore, examination of the SIRT6 protein sequence revealed a conserved 
nuclear export sequence, implying a tight regulation of SIRT6 localization in the 
cell. Finally we propose SIRT6 immunohistochemistry as a useful marker for 
identifying cancer cells in peritoneal and pleural fluids derived from ovarian 
cancer patients. 
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Introduction 
In chapters 3 and 4 we have provided evidence for SIRT6’s role as a tumor suppressor 
protein. Loss of SIRT6 can drive tumorigenesis by enhancing c-MYC mediated 
ribosomal biogenesis, by supporting a metabolic switch to aerobic glycolysis and 
possibly by increasing chromosomal instability. As an epigenetic regulator, SIRT6 
impacts many transcription factors and their downstream signaling pathways, and thus 
SIRT6 can likely suppress tumorigenesis through other pathways as well. As loss of 
SIRT6 enhances tumor susceptibility, SIRT6 activators or SIRT6 molecules are 
potential therapeutic tools for treatment of malignancies. With this in mind, we analyzed 
SIRT6 expression in various human cancer samples and made an initial assessment of 
SIRT6 function in established cancers. 
 
Materials and Methods 
Cell culture 
Colon cancer cell lines (HCT116, DLD1 and LOVO) were kindly provided by Dr. E. 
Fearon and were grown in high glucose DMEM supplemented with 10% FBS, 1% L-
Glutamine and 1% pen/strep. Ovarian cancer cell lines (OVCA 433, OVCAR5, 
OVCAR8 and HeyA8) were grown in RPMI 1640 containing 10% FBS, 1% L-Glutamine 
and 1% pen/strep. MEFs were isolated as previously described from germline Sirt6KO 
mice and were grown in a low oxygen incubator (3% O2, 5% CO2) in 15% FBS, 1% L-
Glutamine, 1% pen/strep, 1% sodium pyruvate, 1% non-essential amino acids, 2% 
HEPES and 115 µl beta-mercaptoethanol. IEC-6 cells were grown in DMEM 
supplemented with 10% FBS, 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L 
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glucose and 0.1 Unit/ml bovin insulin. Mouse myofibroblast C2C12 cells were grown in 
DMEM containing 10% FBS. All cells were grown at 37°C and 5% CO2. 
 
Immunohistochemistry 
Tissue microarrays of various human carcinomas (colorectal, ovarian, breast, lung and 
pancreatic), melanoma and glioblastoma were obtained from Dr. T. Giordano. 
Cytoblocks of pleural or peritoneal fluids from ovarian cancer patients were provided by 
Dr. M. Roh. Intestines from SIRT6 inducible overexpressing mice on an Apcmin/+ 
background were fixed in 4% formaldehyde over night, processed by the University of 
Michigan histology core.  
IHC was performed by the University of Michigan histology core. Briefly, slides were 
deparaffinized and rehydrated through a series of xylene and alcohol washes. Antigen 
retrieval was performed by first heating the slides for 10 minutes in citrate buffer (10 
mM Citric Acid, 0.05% Tween 20, pH 6.0) and then allowing them to cool down for 10 
minutes at room temperature. Endogenous peroxide was blocked by incubation in 3% 
hydrogen peroxide (H2O2) for 10 minutes. Additional blocking was performed by 
incubating the slides in 5% normal goat serum in PBS for one hour. Tissues were 
incubated with human SIRT6 antibody (Abcam, ab88494 or CST, 2590), mouse SIRT6 
(Novus) or H3K56ac (Epitomics) overnight at 4°C. Signal was visualized using 3,3’-
diaminobenzidine (DAB; Vector Laboratories) and slides were mounted using 
permanent mounting medium (Vector Laboratories). Slides were imaged with an 
Olympus BX-51 scope with an Olympus DP-70 high-resolution digital camera 
(University of Michigan Microscopy & Image Analysis lab). 
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Fractionation 
Nuclear/cytoplasmic fractionation was performed based on the Abcam Histone 
Extraction Protocol with modest alterations. Freshly isolated cells (15 cm dish) were 
incubated for 10 minutes on ice in 500 µl triton extraction buffer (TEB: 0.5% Triton 
x100, 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% NaN3 in PBS). A small 
fraction of samples was saved for whole cell extract (WCE) and the remaining lysed 
cells were spun down at 2000 rpm and 4°C for 10 minutes. The supernatant was saved 
(= cytoplasmic fraction) and the pellet was washed once in 1 ml TEB. The supernatant 
was discarded and the nuclear pellet was resuspended in lysis buffer (1% Triton X-100, 
0.5% NP-40, 150 mM NaCl, 50 mM Tris pH 7.4 and 10% Glycerol). WCE and nuclear 
fractions were sonicated using a Branson Sonifier 450 sonicator at 2.5% output control 
and 50% duty cycle and all samples were spun down at maximum speed in a 
refrigerated table top centrifuge. The supernatants were collected and protein 
concentration was measured using DC protein assay (Bio-Rad).	  
For histone extraction, nuclei were isolated as described above and were rotated over 
night in 0.2N HCl at 4°C. After the acid extraction, samples were centrifuged at 2000 
rpm for 10 minutes. Protein concentration of the supernatants containing histones was 
measured using DC protein assay (Bio-Rad).  
For the isolation of mitochondria, cells were resuspended in 4 ml cell homogenization 
medium (CHM: 25 mM KCl, 5 mM MgCl2, 10 mM Tris-HCl pH 7.4 supplemented with 
NAM, TSA and proteinase inhibitors) and allowed to swell for 2 minutes. For each 
sample, cells were homogenized with 20 strokes in a 7ml dounce with b-pestle. 1 M 
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sucrose was added to each cell homogenate to a final concentration of 0.25 M 
sucrose. Homogenate was inverted for 5 minutes at 4°C and centrifuged for an 
additional 5 minutes at 900xg. Supernantant was further centrifuged at 6200xg in a 
piramoon rotor for 10 minutes to collect mitochondria. Mitochondrial pellets were 
resuspended in lysis buffer and allowed to lyse for 30 minutes on ice. Protein 
concentration was measured as described earlier. 
 
Migration assay 
Cell migration was measured using the CytoSelect 24-well Cell Migration Assay (Cell 
Biolabs) according to the manufacturer’s instructions. In short, 500 µl of growth media 
was added to 12 wells of a 24-well plate. Subsequently, small inserts (8 µm pore size) 
were placed in each well and these insert were filled with 0.5 x 106 cells (in triplicate) in 
serum free media. After 24 hours the cells that migrated through the inserts were 
stained following which the stain was extracted. The extracted stain density was 
measured at OD 560 nm in a plate reader. 
 
Proliferation assay 
Proliferation assay was performed using cell-counting kit-8 (Dojindo Molecular 
Technologies). In quadruplicate, 2.5 x 103 cells were plated per well of a 96-wells plate. 
After 48 hours, 10 µl of CCK-8 solution was added to each well and incubated at 37°C 
for 2 hours. The absorbance was measured at 450nm using a microplate reader.  
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Immunoblot 
For analysis of fractionated cells, histone extracts or SIRT6 knockdown protein 
samples were seperated on 4-20% gradient gels (Bio-Rad), transferred to PVDF 
membranes, and probed with the following antibodies in TBST/5% milk at the dilutions 
indicated: rabbit anti-SIRT6 (Abcam), 1:1000; rabbit anti-SIRT6 (CST), 1:1000; rabbit 
anti-H3 (Abcam), 1:10.000; rabbit anti-LDHA (Santa Cruz biotechnology), 1:2000; 
rabbit anti-H3K56ac (Epitomics), 1:1000; rabbit anti-H4K16ac (Cell Signaling 
Technology), 1:1000; rabbit anti-H3K9ac (Abcam), 1:1000; rabbit anti-Lamin A/C (Cell 
Signaling Technology), 1:2000.  
 
Sirt6 knockdown  
For viral infection of constitutive or inducible knockdown of SIRT6, indicated cancer cell 
lines were infected with lentivirus shSIRT6-GipZ or shSIRT6-TripZ respectively or with 
their respective shControl vectors. shRNA vectors were obtained from Open 
Biosystems and viral particals were made by the University of Michigan vector core 
facility at 100x concentration. Cells were plated in a 6-well dish and after 12 hours 50 µl 
of concentrated virus was added to one well of a 6-well dish containing 1ml of media 
and 4 µg/ml polybrene (Sigma). After 24 hours, media was replaced and cells were 
treated for 48 hours with puromycin (2.5 µg/ml) to select for virally infected cells. 
Following selection, cells were maintained in normal growth media. 
For transient Sirt6 knockdown, cells were transfected with siRNA for SIRT6 or control 
siRNA (Dharmacon) using Lipofectamine LTX transfection reagent (Life Technologies). 
	   131	  
Transfection was performed according to the manufacturer’s instructions. For 
proliferation assay, cells were plated in quadruplicate and each well, containing 100 µl 
pen/strep free media, was transfected with 0.25 µl siRNA and 0.25 µl Lipofectamine 
LTX in 50 µl Opti-MEM (Life Technologies). After 24 hours media was refreshed and 
48 hours post transfection cellular proliferation was measured. To assess efficient 
SIRT6 knockdown, cells were plated in 6-well dish and to each well 500 µl Opti-MEM 
containing 5 µl siRNA and 5 µl Lipofectamine LTX was added. After 48 hours 
knockdown was verified through western blot analysis. 
  
Transfection 
For transient transfection of SIRT6 mutants, WT hSIRT6, mNES SIRT6 and mNLS 
SIRT6 were transfected into HCT116 SIRT6 KD-GipZ using the transfection reagent 
Lipofectamine LTX. HCT116 cells were plated into 15 cm dishes and after 24 hours 
(~60% confluency), media was replaced and Opti-MEM containing plasmid and 
transfection reagent were gently added. Cells were harvested after 48 hours and 
fractionated as described above. 
 
Mutagenesis 
The identified consensus sequences in the SIRT6 protein sequence (Figure 5.A) were 
each mutated in two steps: NES Leucine 209 (1) and Leucine 213 (2) were replaced by 
two alanine residues, NLS lysine/arginine 230/231 (1) and 346/347 (2) were mutated to 
two alanine residues (see Table 5.1). As a template Flag-tagged human SIRT6 in 
pCDNA3.1, obtained from Addgene (plasmid 13817), was used. The DNA polymerase 
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PFU Ultra II fusion HS (Agilent) was used for the mutagenesis as recommended by the 
manufacturer. PCR products were verified by gelelctrophoresis for correct size, then 
treated with DPN-1 for 1 hour at 37°C to digest original DNA template, and DH5α 
competent cells were transformed with the generated PCR products by mixing 50 µl 
DH5α with 1 µl PCR product, incubating on ice for 30 minutes, heat shock 45 seconds 
at 42°C, recovering DH5α 45 minutes at 37°C in LB media (Miller’s LB broth, Sigma) 
and plating the transformed bacteria onto LB agar plates containing carbenicillin (500 
µg/ml). After 18 hours, colonies were picked, expanded into a large culture and 
plasmids were isolated with Qiagen maxiprep kit. Mutations were confirmed by the 
University of Michigan sequencing core using pCDNA3.1 specific sequencing primers 
(Table 5.1). The generated plasmids were used as a template to generate the second 
mutation and the above-described procedure was repeated. 
 
Table 5.1: Primer sequences Sirt6 mutagenesis 
 Forward (5’) Reverse (3’) 
mNES step 1 
(L209A) 
GCCAGCAGGAACGCCGACGCGTCCATCACG
CTGGGTACA 
TGTACCCAGCGTGATGGACGCGTCGGCGTT
CCTGCTGGC 
 
mNES step 2 
(L213A) 
GCCGACGCGTCCATCACGGCGGGTACATCG
CTGCAGATC 
 
GATCTGCAGCGATGTACCCGCCGTGATGGA
CGCGTCGGC 
 
mNLS step 1 
(KR230/1AA) 
CTGCCGCTGGCTACCGCGGCCCGGGGAGGC
CGCCTG 
 
CAGGCGGCCTCCCCGGGCCGCGGTAGCCA
GCGGCAG 
 
mNLS step 2 
(KR246/7AA) 
CCCCACAGACCCCCCGCAGCGGTGAAGGCC
AAGGCG 
 
CGCCTTGGCCTTCACCGCTGCGGGGGGTC
TGTGGGG 
 
pCDNA3.1 seq TAATACGACTCACTATAGGG 
 
TAGAAGGCACAGTCGAGG 
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Results 
SIRT6 protein levels are elevated in human carcinomas in vivo 
We recently identified a role for SIRT6 as a potent tumor suppressor in part by 
suppressing aerobic glycolysis and c-myc mediated cell growth (Sebastian et al., 
2012). In addition, our studies suggest that SIRT6 could protect against tumorigenesis 
by promoting euploidy, though the underlying mechanism remains to be elucidated 
(chapter 4). Based on SIRT6’s protective role in tumor formation, we wanted to assess 
SIRT6 expression levels in human cancer tissues, hypothesizing that SIRT6 levels 
would be strongly reduced in established malignancies. Dr. T. Giordano (University of 
Michigan) kindly provided us with tissue microarrays containing tissue samples from 
various normal and malignant tumors. First we assessed SIRT6 staining intensity in 
normal colon tissue, adenomas and carcinoma (Figure 5.1). In normal tissue, SIRT6  
is localized to the nucleus and has a higher staining intensity at the top of the vilii 
versus the base of the crypts. In adenomas, SIRT6 remains nuclear but is less 
abundant than in normal tissue, which is consistent with our hypothesis. However, 
SIRT6 protein levels in colorectal carcinomas are strongly elevated and SIRT6 appears 
to be localized in both the nuclear and cytoplasmic region of the cell (Figure 5.1A). We 
quantified these results by comparing SIRT6 staining intensity in carcinoma samples 
with normal tissue and found that approximately 38% of colon cancers showed similar 
SIRT6 expression to normal colon tissue, while in the remaining samples SIRT6 levels 
were elevated (Figure 5.1B). In addition to the high SIRT6 levels observed in colon 
cancer, SIRT6 appears to be highly abundant in the cytoplasm. To determine if this 
finding was consistent in other 
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Figure 5.1: SIRT6 protein levels in colon tissue 
(A) Human normal colon, adenomas and colorectal carcinomas stained for human 
SIRT6. (B) Staining intensity for SIRT6 with one plus sign equals SIRT6 levels in 
normal colon tissue. 
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tumor types, we assessed SIRT6 protein levels and localization in other carcinomas, 
melanoma and glioblastoma (Figure 5.2). Strikingly, although SIRT6 levels did not 
appear to change in cancerous tissue compared to normal brain tissue or melanocytes, 
our previous finding did hold up for other carcinomas such as breast and ovarian 
cancer (Figure 5.2A). Furthermore, while almost every tissues sample analyzed was 
positive for SIRT6 (Figure 5.2B – brackets), SIRT6 cytoplasmic localization was 
generally associated with carcinomas and is rarely visible in melanomas and 
glioblastomas (Figure 5.2B).   
 
SIRT6 is elevated and relocalized in human carcinoma cell lines 
To verify the above findings, we assessed SIRT6 levels and localization in human 
ovarian (HeyA8, OVCA 433, OVCAR5 and OVCAR8) and colon  
cancer cell lines (HCT116, DLD1 and LOVO) by immunoblot. Nuclear/cytoplasmic 
fractionation of these cells revealed a high abuncance of SIRT6 in both compartments 
of the cell. We used an inducible Sirt6 knockdown vector (TripZ) to confirm the 
specificity of our antibody, and lactate dehydrogenase A and lamin A/C were used as 
cytoplasmic and nuclear loading controls respectively. To test if SIRT6 cytoplasmic 
localization is tumor specific, we fractionated various non-cancerous cell lines: 
myoblasts (C2C12), primary MEFs, human dermal fibroblasts, 3T3 immortalized MEFs 
(Figure 5.3B-E), and intestinal epithelial cells (IEC-6; Figure 5.5B). While SIRT6 levels 
were dramatically lower in these cell lines in comparison to the carcinoma cell lines 
(Figure 5.3A vs D), we did observe cytoplasmic localized SIRT6, suggesting that 
SIRT6 has functional importance in the cytoplasm.  
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Figure 5.2: SIRT6 localization in human malignancies 
(A) Expression and localization of human SIRT6 was assessed in the tumor types 
indicated using immunohistochemistry. (B) The majority of ovarian, colon and breast 
carcinomas contain a significant fraction of cytoplasmic SIRT6, in contrast to 
melanomas and high-grade brain tumors (HGBT). The numbers between brackets 
indicate the number of samples positive for SIRT6 staining out of the number of tissues 
analyzed. 
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SIRT6 mRNA expression not altered in carcinomas 
To determine if SIRT6 expression was altered in carcinomas, we analyzed SIRT6 
mRNA levels using Affymetrix-based data previously generated in the laboratories of 
Dr. S. Gruber (colon cancer) and Dr. K. Cho (ovarian cancer). SIRT6 expression in 4 
normal colon samples was compared to its expression in 227 colorectal cancers, and 
only a modest (not significant) increase in SIRT6 RNA levels was observed in the colon 
tumors (Figure 5.4A). Likewise, SIRT6 expression was assessed in ovarian adenoma, 
ovarian cancer and normal ovarian surface epithelial cells (Figure 5.4B). Overall, no 
change in SIRT6 mRNA levels was observed when comparing normal ovarian cells to 
benign or malignant tumor cells. Thus the elevated SIRT6 protein levels are likely due 
to increased SIRT6 protein stability or a decrease in proteasomal degradation. Recent 
work has identified the ubiquitin-specific peptidase USP10 as a novel SIRT6 interactor 
in colon cancer cells (HCT116). Through its interaction with USP10, SIRT6 is protected 
against ubiquitination and subsequent degradation (Lin et al., 2013). Future studies 
should verify the correlation between SIRT6 and USP10 protein levels in various 
carcinoma cell lines and tissues. 
 
	   138	  
 
Figure 5.3: SIRT6 localization in cell lines 
SIRT6 levels were assessed in subcellular fractions from (A-top) four ovarian and (A-
bottom) three colon carcinoma cell lines, (B) mouse myoblast cells (C2C12), (C) WT 
and SIRT6 KO MEFs, (D) human dermal fibroblasts (HDF), and (E) 3T3 immortalized 
WT and SIRT6 KO MEFs. Equal amounts of protein were loaded in each lane (50 µg). 
Fractions were probed for SIRT6 or LDHA and LMNA as controls for cytoplasmic and 
nuclear fractionation, respectively. Both normal and malignant cell lines have 
detectable levels of SIRT6 in the cytoplasm. 
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Figure 5.4: SIRT6 mRNA expression in carcinomas 
SIRT6 mRNA expression levels were assessed in (A) colon cancer tissue and (B) 
ovarian cell lines based on affimetrix data generated by Dr. S. Gruber and Dr. K. Cho 
respectively. (1) Spontaneously immortalized cystadenomas, (2) Ovarian carcinomas, 
(3) ovarian surface epithelial cells. 
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Loss of SIRT6 deacetylase activity in adenoma lesion 
We, and others, have identified SIRT6 as a H3K56 deacetylase (Michishita et al., 2009; 
Yang et al., 2009). Because elevated H3K56ac is found in various tumor types (Das et 
al., 2009), we predicted that SIRT6 levels would either be decreased or that SIRT6 
deacetylase activity would be inactivated in cancer. To assess H3K56ac levels in 
cancer cells with respect to SIRT6 status, we isolated histones from HCT116 cells 
infected with an inducible shSirt6 TripZ vector (or scrambled shRNA). As a negative 
control we included H4K16ac, which is not targeted by SIRT6. We did not observe an 
increase in H3K56ac or H3K9ac levels with SIRT6 KD (Figure 5.5A). In fact, it 
appeared that global histone acetylation was slightly decreased in the SIRT6 depleted 
cells. Likewise, Sirt6 knockdown in IEC-6 did not result in augmented H3K56ac (Figure 
5.5B). These results indicate that SIRT6 either loses its ability to deacetylate some or 
all histone targets, or that the remaining amount of SIRT6 after SIRT6 KD is sufficient 
to maintain histone acetylation status. To answer this question, we assessed H3K56ac 
and SIRT6 levels in normal intestines and adenomas of an inducible Sirt6 
overexpressing mouse with an Apcmin/+ background. By using an inducible SIRT6 
overexpressor, we would circumvent the decrease in SIRT6 protein levels, which we 
previously observed in adenomas. In normal tissue, SIRT6 was strictly nuclear and 
coincided with the absence of H3K56ac (Figure 5.5C). However, in pre-cancerous 
epithelial cells, SIRT6 levels were elevated and relocalized to the cytoplasm. 
Furthermore, cytoplasmic localization of SIRT6 corresponded with higher levels of 
H3K56ac. These results suggest that in normal tissue SIRT6 is a potent H3K56 
deacetylase, a function that may be lost in pre-malignant lesions. 
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Figure 5.5: SIRT6 loses global deacetylation function upon cellular 
transformation 
(A) Western blot analysis of isolated histones from HCT116 TripZ or Sirt6 KD for 
histone acetylation. (B) Nuclear/cytoplasmic fractionation of IEC-6 cells infected with 
Sirt6 shRNA vector or control. Ponceau staining serves as loading control (A-B). (C) 
IHC of normal intestine and adenoma in Sirt6 OE Apcmin/+ for mSIRT6 and H3K56ac. 
Sections were imaged with Olympus BX-51 scope at 40X magnification. 
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SIRT6 actively shuttles to the cytoplasm 
The cytoplasmic localization of SIRT6 suggests that SIRT6 is actively transported in 
and out of the nucleus. Transport across the nuclear envelope requires interaction with 
karyopherins (importins and exportins) that bind their target protein at specific amino 
acid sequences. These specific sequences are called nuclear localization signal (NLS) 
and nuclear export sequence (NES). A close look at the SIRT6 protein sequence 
revealed one NES and two NLS conserved between mouse and human (Figure 5.6A). 
We mutated both leucine residues in the NES and the first lysine and arginine residues 
of both NLSs of SIRT6. We performed transient transfection of HCT116 with WT, 
mutant NES (mNES) or mutant NLS (mNLS) followed by nuclear/cytoplasmic 
fractionation (Figure 5.6B). Strikingly, mutation of NES resulted in strictly nuclear 
SIRT6. Furthermore, mNES is present at a much lower concentration in the nucleus 
than WT SIRT6. While this may be attributed to lower transfection efficiency, it is also 
possible that strictly nuclear localized SIRT6 is less stable than WT. mNLS did not alter 
SIRT6 cellular distribution. In the human SIRT6 protein sequence a third NLS can be 
found that is absent in mouse SIRT6. It is also possible that all three NLSs need to be 
mutated to restrict SIRT6 to the cytoplasm.  
In an attempt to identify a potential role for SIRT6 in the cytoplasm, we assessed 
whether SIRT6, like some other sirtuin proteins, is localized to the mitochondria. We 
isolated mitochondria from two colon cancer cell lines (HCT116 and DLD1) and found 
SIRT6 to be present in the mitochondria (Figure 5.6C). This was further confirmed in 
our previously performed interaction screen (Chapter 4) in which we identified  
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Figure 5.6: Conserved nuclear export sequence and nuclear localization signals 
in SIRT6 
(A) Two nuclear localization signals (NLS) and one nuclear export sequence (NES) are 
conserved in the C-termini of the mouse and human SIRT6 sequences. (B) 
Mutagenesis of NES, but not NLS, results in strictly nuclear SIRT6 when transfected 
into HCT116. (C) SIRT6 may be localized to the mitochondria (50 µg protein/lane) and 
(D) interacts with a number of mitochondrial factors. E1α, mitochondrial marker; LDHA, 
cytoplasmic marker; LMNAC, nuclear marker. 
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numerous mitochondrial factors as SIRT6 interactors (Figure 5.6D). Overall, these 
results indicate that SIRT6 might have functions outside the nucleus. 
 
SIRT6 does not regulate cancer cell growth or migration 
The high levels of SIRT6 in various carcinoma tissues and cell lines raise the question 
whether SIRT6 provides the tumor cells with a growth advantage. Therefore, we 
generated two constitutive Sirt6 knockdown ovarian cancer cell lines (Figure 5.7B) and 
found that the absence of SIRT6 resulted in increased proliferation (Figure 5.7A). To 
verify our findings, we repeated this experiment using an inducible Sirt6KD vector 
(TripZ). Unlike the constitutive Sirt6 knockdown, doxycycline induced knockdown 
resulted in decreased proliferation. As Sirt6-null MEFs are sensitive to DNA damaging 
agents and are genomically unstable, the proliferation results might be due to side 
effects of doxycycline treatment rather than a direct cause of SIRT6 ablation. Thus we 
reassessed proliferative potential of three carcinoma cell lines by using transient SIRT6 
knockdown (Figure 5.7F). HCT116 and OVCAR8 showed a mild decrease in 
proliferation in the absence of SIRT6, while no change in cell growth was observed in 
HeyA8 cells (Figure 5.7E). Due to the variaton of this data, we cannot conclude at this 
point whether SIRT6 impacts growth of carcinoma cells. 
In addition to proliferation, invasive potential is also an important trait of cancer cells. 
Thus we analyzed the migration ability of two ovarian cancer cell lines using both the 
constitutive and the inducible knockdown systems. While a mild increase in migration 
was observed in the constitutive knockdown cell lines (Figure 5.8A), these results were 
not reproducible in doxycycline inducible knockdowns (Figure 5.8B).   
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Figure 5.7: Assessment of SIRT6-dependent cellular proliferation  
(A) Cellular proliferation in OVCA 433 and OVCAR8 cell lines infected with shSIRT6 
and shControl in GipZ vector. (B) shSIRT6-GipZ efficiently knockdowns SIRT6 in 
indicated cell lines. (C) Cellular proliferation of same cells as in (A) using the inducible 
TripZ SIRT6 KD vector. (D) shSIRT6-TripZ efficiently knocked down SIRT6 in OVCA 
433 cells. (E) Proliferation assay of indicated cell lines using transient siRNA 
knockdown. (F) SIRT6 proteins levels upon siSIRT6 treatment. * p < 0.05, *** p < 0.001 
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Figure 5.8: SIRT6-mediated tumor cell migration  
Migration of OVCAR8 and OVCA433 cell lines with respect to SIRT6 status using (A) 
constitutive (n = 2) or (B) doxycycline (Dox) inducible knockdown system. Values were 
normalized to control vector (A) or untreated sample (B). 
 
 
SIRT6 as a diagnostic tool 
While we were unable to identify a role for SIRT6 in carcinoma cells or assess how 
SIRT6 cellular localization is regulated, the high SIRT6 protein levels and localization 
might be useful from a diagnostic perspective. In collaboration with Dr. M. Roh, we 
stained cytoblocks made of pleural or peritoneal fluids, obtained from ovarian cancer 
patients, for SIRT6 using two independent SIRT6 antibodies (Figure 5.9). Overall, both 
antibodies clearly visualized the tumor cells with elevated and cytoplasmic staining. 
When comparing both antibodies, the Abcam antibody showed a higher staining 
intensity in all cell types and identified cytoplasmic SIRT6 in macrophages. SIRT6-CST 
(SIRT6 antibody from Cell Signaling Technology) staining, on the other hand, only 
showed postive cytoplasmic staining in tumor cells and was largely negative in normal 
cells. No distinction could be made in SIRT6 staining pattern between low versus high-
grade adenocarcinomas. 
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Figure 5.9: Detection of ovarian cancer in pleural fluids/ascites 
Cytoblocks from pleural or peritoneal fluids were analyzed for the presence of ovarian 
cancer cells using SIRT6 staining. Two commercial SIRT6 antibodies were compared 
for specificity. CST, Cell Signaling Technologies.  
 
Discussion 
A number of recent studies have provided compelling evidence for a role of SIRT6 as a 
tumor suppressor protein by regulating numerous pathways such as apoptosis, cell 
growth and metabolism (discussed in detail in chapter 3) (Han et al., 2014; Min et al., 
2012; Sebastian et al., 2012; Van Meter et al., 2011). Others have reported tumor-
promoting properties for SIRT6 (Figure 5.10). Elevated SIRT6 levels are associated 
with chemotherapeutic drug resistance in MCF-7 breast cancer cells (Khongkow et al., 
2013a). Deacetylation of the tumor suppressor proteins FOXO3A and p53 by SIRT6, 
resulting in reduced cell cycle arrest and apoptosis in response to chemotherapeutic 
treatment, has been proposed to explain this effect. However, importantly there 
currently is no direct evidence in vitro that SIRT6 can deacetylate these proteins. In 
addition, Khongkow and colleagues reported that high nuclear levels of SIRT6 
correlated with a poor prognosis in breast cancer patients (Khongkow et al., 2013a). 
Furthermore, high SIRT6 levels are associated with undifferentiated squamous cell 
carcinoma (SCC) (Lefort et al., 2013). The tumor suppressor and tumor promoting 
functions of SIRT6 are likely to result from different underlying functions of this protein.  
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Figure 5.10: Dual roles for SIRT6 in cancer 
SIRT6 has been reported to have both tumor suppressor and oncogenic properties. 
Low levels of SIRT6 have been described in colon cancer (CC), hepatocellular 
carcinoma (HCC), pancreatic cancer (PaC), head and neck squamous cell carcinoma 
(HNSCC) and non-small cell lung cancer (NSCLC), and correlates with a shortened 
time to relapse. By contrast, high SIRT6 levels have been reported in breast cancer 
(BC), PaC and prostate cancer (PrC), and is associated with drug resistance and poor 
prognosis. Ac, acetyl group; TNF, tumor necrosis factor; IL-8, interleukin-8. 
 
In conjunction with these studies, we found SIRT6 protein, but not mRNA, levels in 
human carcinoma tissues and cell lines to be significantly elevated. Furthermore, 
SIRT6, a previously described nuclear protein (Liszt et al., 2005; Michishita et al., 
2005; Mostoslavsky et al., 2006; Xiao et al., 2010), is highly abundant in the 
cytoplasmic fraction of the normal and cancer cells analyzed. Khongkow et al. also 
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identified cytoplasmic localization of SIRT6 in breast cancer cells and reported that the 
cytoplasmic fraction of SIRT6, in contrast to nuclear SIRT6, correlated with a better 
clinical outcome in breast cancer (Khongkow et al., 2013b). The presence of SIRT6 
outside the nucleus in both normal and cancerous cells implies that SIRT6 targets non-
nuclear proteins as well. However, we were not able to detect cytoplasmic localized 
SIRT6 in normal cells by immunohistochemistry. While this could be explained by 
technical variability, it is also likely that cells grown in culture are subjected to a mild 
form of stress. Jedrusik-Bode and colleagues reported that cellular stress causes 
SIRT6 to relocalize to the cytoplasm where it is essential for rapid stress granule 
formation and disassembly (Jedrusik-Bode et al., 2013). Currently other cytoplasmic 
functions for SIRT6 are unknown. 
 
Further cellular subfractionation revealed the presence of SIRT6 in the mitochondria 
(Figure 5.6C). In support of this, we identified a number of mitochondrial factors in a 
SIRT6 interaction screen (Figure 5.6D). Among these the mitochondrial transcription 
factor TFAM, the mitochondrial transporters PHC and SLC20A, the catalytic subunit of 
mitochondrial DNA polymerase POLG, HSPD1, which is essential for folding and 
assembly of newly imported proteins in the mitochondria, and ATAD3A, a 
mitochondrial protein that stabilizes nucleoids (mitochondrial DNA protein complexes). 
While SIRT6’s interaction with these mitochondrial proteins needs to be confirmed, 
SIRT6’s interaction with the transporters PHC and SLC20A suggests that SIRT6 may 
be actively transported into the mitochondria, while SIRT6’s binding to TFAM implies 
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that SIRT6 could act as a transcriptional regulator, similar to its function in the nucleus. 
Future studies are needed to test this hypothesis. 
Examination of the SIRT6 protein sequence revealed the presence of three conserved 
localization sequences: one NES and two NLSs. These sequences indicate that SIRT6 
cellular localization is tightly regulated. Indeed, mutating the NES allowed us to confine 
SIRT6 to the nucleus (Figure 5.6B). Mutagenesis of the two NLSs did not result in 
SIRT6 relocalization. However, deletion of the N- and C-termini of SIRT6 does drive 
SIRT6 out of the nucleus (Tennen et al., 2010) and thus other or additional sequences 
are likely responsible for nuclear localization of SIRT6.  
 
The high protein levels of SIRT6 in carcinoma cells, possibly due to enhanced protein 
stability or decreased protein degradation, would seem to oppose the previously 
described tumor suppressor function of SIRT6. H3K56ac, a target of SIRT6, is 
associated with DNA instability and cancer (Das et al., 2009). Knockdown of SIRT6 in 
HCT116 cells did not result in increased H3K9 or H3K56 acetylation (Figure 5.5A). 
Strikingly, SIRT6 knockdown did not alter H3K56ac levels in IEC-6 cells either (Figure 
5.5B). We, and others, have previously shown that SIRT6 deacetylates H3K56 using 
germline Sirt6KO MEFs (Michishita et al., 2009; Yang et al., 2009). Knockdown of Sirt6 
with shRNA is about 90% effective and thus it is possible that the small fraction of 
remaining SIRT6 is sufficient to regulate H3K56ac. However, in vivo overexpression of 
SIRT6 resulted in complete loss of H3K56 acetylation in normal intestinal epithelial 
cells. Notably, in polyps, H3K56ac reappeared, which coincided with SIRT6 
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relocalization to the cytoplasm (Figure 5.5C). These results suggest that SIRT6 
relocalization to the cytoplasm is a means to attenuate nuclear SIRT6 function. 
 
Finally, in an effort to identify functional properties of SIRT6 in cancer, we measured 
the proliferative and migratory capacity of cancer cells with respect to SIRT6 status 
using various Sirt6 knockdown systems. When knocking down Sirt6 constitutively, 
cancer cells grew and migrated faster, while inducible Sirt6 knockdown with 
doxycycline had the opposite effect on cellular growth and did not impact cell migration 
(Figures 5.7-5.8). Furthermore, the change in cellular growth was variable between 
cancer cell lines when using transient siRNA transfection. We previously identified 
increased aneuploidy upon constitutive knockdown of Sirt6 in IEC-6. Thus long-term 
SIRT6 ablation could result in genomic instability and possible accumulation of 
mutations that provide cancer cells with additional cancer traits. Likewise, SIRT6 
deficient cells are sensitive to genotoxins and thus SIRT6 depleted cancer cells might 
be vulnerable to doxycycline treatment resulting in decreased growth.  
 
While we cannot provide mechanistic insight in SIRT6 function in cancer cells, our 
results suggest that SIRT6 relocalization results in loss of SIRT6’s H3K56 
deacetylation function. In this regard, treatment with SIRT6 activators might be a 
usefull therapeutic tool. The distinct staining pattern of SIRT6 does provide a valuable 
diagnostic tool as we can clearly identify ovarian carcinoma cells in ascites and pleural 
lavages from ovarian cancer patients by performing IHC for SIRT6.  
  
	   153	  
Future directions 
In this study we identified SIRT6 relocalization to the cytoplasmic fraction of carcinoma 
cells. SIRT6 cellular localization is likely tightly regulated as we were able to confine 
SIRT6 to the nuclear fraction by mutating the NES. A more indepth study of SIRT6 
shuttling across the nuclear membrane will provide the means to identify the 
importance of nuclear versus cytoplasmic SIRT6 in normal and cancerous cells. Except 
for SIRT6’s role in mediating stress granule formation (Jedrusik-Bode et al., 2013), no 
cytoplasmic functions for SIRT6 have been described. The initial observation that 
SIRT6 interacts with a number of mitochondrial proteins could imply that SIRT6 plays a 
role in regulating mitochondrial gene expression and possibly maintaining the integrity 
of mitochondrial DNA (mtDNA). Mice heterozygous for TFAM have a 30-50% reduction 
of mtDNA (Larsson et al., 1998) and changes in mtDNA content are associated with 
tumorigenesis (Lan et al., 2008; Lee et al., 2005). Therefore, it is feasible that SIRT6 
could maintain mitochondrial integrity and suppress tumor formation by regulating 
TFAM. However, further studies are necessary to test this a possible role for SIRT6 in 
the mitochondria.  
In addition to exploring a role for SIRT6 in various cellular compartments, a better 
understanding of how SIRT6 protein levels are regulated in cancer cells is essential 
when considering SIRT6 as a potential therapeutic target. We did not observe a 
change in SIRT6 transcripts, suggesting increased SIRT6 stability or a decrease in 
SIRT6 proteasomal degradation. Ubiquitination of SIRT6 by CHIP enhances SIRT6 
stability (Ronnebaum et al., 2013). Changes in PTMs on SIRT6 might be a means 
through which SIRT6 is stabilized in cancer cells. 
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Chapter 6 
Concluding remarks 
 
A cancer cell is generated through the accumulation of multiple mutations that provide 
the initial cell the ability to surpass the many defense mechanisms in place to protect 
the organism from malignancies, such as DNA repair systems, antioxidants, cell cycle 
checkpoints and immune response. Hanahan and Weinberg described the 6 halmarks, 
and the four enabling and emerging characteristics of cancer (Hanahan and Weinberg, 
2011). In my thesis work we have identified the histone deacetylase SIRT6 as a potent 
tumor suppressor protein, possibly by inhibiting several of these cancer traits. First 
SIRT6 suppresses aerobic glycolysis, the preferred method of energy generation in 
cancer cells (Hallmark: deregulating cellular energetics). Secondly, SIRT6 inhibits 
ribosomal biogenesis and subsequent cell growth through c-MYC (Hallmark: sustaining 
proliferative signaling). In addition to these two traits, we have suggestive data that 
SIRT6 can protect against tumor formation through two additional mechanisms. SIRT6 
deficient cells have a higher percentage of aneuploidy, possibly through SIRT6’s role in 
DNA repair (Hallmark: genome instability and mutation). Furthermore, enterocyte 
specific SIRT6-deficient mice in an Apcmin/+ background have elevated levels of the 
cytokine Il-17, a cytokine that can promote tumor growth by inducing an inflammatory 
response (Hallmark: tumor-promoting inflammation).  
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In addition, we have identified various novel cellular activities of SIRT6 that contribute 
to the current understanding of SIRT6 biology. In addition to H3K9ac, we found that 
SIRT6 deacetylates histone H3 acetylated at K18, 23 and 56. The latter is specifically 
target by SIRT6 at the promoter sites of ribosomal genes normally transcribed by c-
MYC. Additionally, we identified an interaction of SIRT6 with the silencing factors KAP1 
and HP1, and the members of the FACT complex, possibly to regulate gene 
transcription. Furthermore, in vivo treatment with the antioxidant NAC rescues the 
increased tumor incidence seen in the absence of SIRT6. In cancer, we observed that 
SIRT6 protein levels, but not mRNA, are elevated in numerous carcinoma cell lines 
and tissues. Here SIRT6 is localized in both the nuclear and cytoplasmic fraction of the 
cell, and it appears to be actively transported out of the nucleus through a conserved 
nuclear export sequence. Finally, we have generated suggestive evidence that SIRT6 
is present in the mitochondrial compartment of the cell where it interacts with several 
mitochondrial proteins.  
 
The work in this dissertation has given further insight in the diverse roles of SIRT6. 
Although many questions about SIRT6 function under physiological and pathological 
conditions remain to be answered, we believe that SIRT6 has strong therapeutic 
potential for the treatment of cancer or other age-related conditions.  
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